<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report : October 16, 1996
(Date of earliest event reported)
ORNDA HEALTHCORP
-------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 1-11591 75-1776092
- --------------- ---------------- -------------------
(State or other (Commission File (I.R.S. Employer
jurisdiction of Number) Identification No.)
incorporation)
3401 West End Avenue, Suite 700, Nashville, Tennessee 37203
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(615) 383-8599
----------------------------------
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
Item 1. CHANGES IN CONTROL OF REGISTRANT.
(b) On October 16, 1996, Tenet Healthcare Corporation ("Tenet"),
OHC Acquisition Co., a wholly owned subsidiary of Tenet ("Sub"), and OrNda
Healthcorp (the "Corporation") entered into an Agreement and Plan of Merger (the
"Merger Agreement") providing, subject to the terms and conditions set forth
therein, for the merger of Sub with and into the Corporation (the "Merger").
Pursuant to the terms of the Merger Agreement, stockholders of the Corporation
will receive in the Merger 1.35 shares of common stock of Tenet in exchange for
each share of common stock of the Corporation. The shares of Tenet common
stock to be issued in the Merger will be registered under the Securities Act
of 1933, as amended.
On October 17, 1996, the Corporation entered into a Stock Option
Agreement (the "OrNda Stock Option Agreement") with Tenet whereby the
Corporation has granted to Tenet an option to purchase up to 11,608,358 shares
of the Corporation's common stock at a price of $29.869 per share, exercisable
only upon the occurrence of certain events. Also on October 17, 1996, Tenet
entered into a Stock Option Agreement (together with the OrNda Stock Option
Agreement, the "Stock Option Agreements") with the Corporation whereby Tenet has
granted to the Corporation an option to purchase up to 28,388,098 shares of
Tenet's common stock at a price of $22.125 per share, exercisable only upon the
occurrence of certain events.
In addition, on October 17, 1996, Tenet and certain stockholders of
the Corporation entered into certain Stockholder Voting Agreements (the
"Stockholder Voting Agreements") providing, subject to the terms and conditions
set forth therein, that such stockholders will vote the shares of stock of the
Corporation held by them in favor of the Merger.
Consummation of the merger is subject to the approval of the
Corporation's and Tenet's stockholders, regulatory approvals, and the
satisfaction or waiver of various other conditions as more fully described in
the Merger Agreement.
Copies of the Merger Agreement, the Stockholder Voting Agreements, the
Stock Option Agreements and the related press release are attached as exhibits
hereto and are incorporated herein by reference.
<PAGE>
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
2.1 Agreement and Plan of Merger, dated as of October 16, 1996, among
Tenet Healthcare Corporation, OHC Acquisition Co. and OrNda
Healthcorp
10.1 Stock Option Agreement, dated October 17, 1996, between OrNda
Healthcorp, as Grantee, and Tenet Healthcare Corporation, as
Issuer.
10.2 Stock Option Agreement, dated October 17, 1996, between OrNda
Healthcorp, as Issuer, and Tenet Healthcare Corporation, as
Grantee.
99.1 Stockholder Voting Agreement, dated as of October 17, 1996, between
Tenet Healthcare Corporation and Charles N. Martin, Jr.
99.2 Stockholder Voting Agreement, dated as of October 17, 1996, between
Tenet Healthcare Corporation and Joseph Littlejohn & Levy Fund,
L.P.
99.3 Press Release, dated October 17, 1996, regarding the Merger.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ORNDA HEALTHCORP
(Registrant)
By: /s/ Ronald P. Soltman
----------------------
Name: Ronald P. Soltman
Title: Senior Vice President
Date: October 30, 1996
<PAGE>
EXHIBIT INDEX
Exhibit
Number Exhibit
- ------ -------
2.1 Agreement and Plan of Merger, dated as of
October 16, 1996, among Tenet Healthcare
Corporation, OHC Acquisition Co. and
OrNda Healthcorp
10.1 Stock Option Agreement, dated
October 17, 1996, between OrNda
Healthcorp, as Grantee, and
Tenet Healthcare Corporation,
as Issuer
10.2 Stock Option Agreement, dated
October 17, 1996, between OrNda
Healthcorp, as Issuer, and Tenet
Healthcare Corporation, as Grantee
99.1 Stockholder Voting Agreement, dated as of
October 17, 1996, between Tenet
Healthcare Corporation and
Charles N. Martin, Jr.
99.2 Stockholder Voting Agreement, dated as of
October 17, 1996, between Tenet
Healthcare Corporation and
Joseph Littlejohn & Levy Fund, L.P.
99.3 Press Release, dated October 17, 1996,
regarding the Merger
<PAGE>
Exhibit 2.1
-----------------------------------------------------
AGREEMENT AND PLAN OF MERGER
By and Among
Tenet Healthcare Corporation
OHC Acquisition Co.
and
OrNda Healthcorp.
Dated as of October 16, 1996
-----------------------------------------------------
<PAGE>
TABLE OF CONTENTS
ARTICLE I
THE MERGER............................................................... 1
Section 1.1 The Merger................................. 1
Section 1.2 Effective Time of the Merger. ............. 2
ARTICLE II
THE SURVIVING CORPORATION................................................ 2
Section 2.1 Certificate of Incorporation............... 2
Section 2.2 By-Laws.................................... 2
Section 2.3 Directors and Officers of Surviving
Corporation................................ 2
ARTICLE III
CONVERSION OF SHARES..................................................... 3
Section 3.1 Exchange Ratio............................. 3
Section 3.2 Exchange of Certificates Representing
Shares..................................... 3
Section 3.3 Dividends; Transfer Taxes.................. 5
Section 3.4 No Fractional Securities................... 5
Section 3.5 Closing of Company Transfer Books.......... 6
Section 3.6 Closing.................................... 6
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PARENT................................. 6
Section 4.1 Organization............................... 6
Section 4.2 Capitalization............................. 7
Section 4.3 Subsidiaries............................... 8
Section 4.4 Authority Relative to this Agreement....... 10
Section 4.5 Consents and Approvals; No Violations...... 10
Section 4.6 Reports and Financial Statements........... 11
Section 4.7 Absence of Certain Changes or Events....... 12
Section 4.8 Litigation................................. 12
i
<PAGE>
PAGE
Section 4.9 Information in Disclosure Documents and
Registration Statement..................... 12
Section 4.10 Absence of Undisclosed Liabilities......... 13
Section 4.11 No Default................................. 13
Section 4.12 Taxes. .................................... 14
Section 4.13 Title to Properties; Encumbrances.......... 15
Section 4.14 Compliance with Applicable Law............. 15
Section 4.15 Medicare Participation/
Accreditation.............................. 16
Section 4.16 Labor Matters.............................. 17
Section 4.17 Employee Benefit Plans; ERISA............. 17
Section 4.18 Vote Required.............................. 20
Section 4.19 Opinion of Financial Advisor. ............. 20
Section 4.20 Certain Actions Under Nevada Law........... 20
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF COMPANY................................ 21
Section 5.1 Organization............................... 21
Section 5.2 Capitalization............................. 21
Section 5.3 Subsidiaries............................... 22
Section 5.4 Authority Relative to this Agreement....... 23
Section 5.5 Consents and Approvals; No Violations...... 24
Section 5.6 Reports and Financial Statements........... 25
Section 5.7 Absence of Certain Changes or Events....... 25
Section 5.8 Litigation................................. 26
Section 5.9 Information in Disclosure Documents and
Registration Statement..................... 26
Section 5.10 Absence of Undisclosed Liabilities......... 26
Section 5.11 No Default................................. 27
Section 5.12 Taxes...................................... 27
ii
<PAGE>
PAGE
Section 5.13 Title to Properties; Encumbrances.......... 27
Section 5.14 Compliance with Applicable Law............. 28
Section 5.15 Medicare Participation/
Accreditation.............................. 28
Section 5.16 Labor Matters.............................. 29
Section 5.17 Employee Benefit Plans; ERISA. ............ 29
Section 5.18 Vote Required.............................. 32
Section 5.19 Opinion of Financial Advisor............... 32
Section 5.20 Takeover Status............................ 33
ARTICLE VI
CONDUCT OF BUSINESS PENDING THE MERGER................................... 33
Section 6.1 Conduct of Business by Company Pending the
Merger..................................... 33
Section 6.2 Conduct of Business by Parent Pending
the Merger................................. 35
Section 6.3 Conduct of Business of Sub................. 37
Section 6.4 Certain Tax Matters........................ 37
ARTICLE VII
ADDITIONAL AGREEMENTS.................................................... 37
Section 7.1 Access and Information..................... 37
Section 7.2 Acquisition Proposals...................... 38
Section 7.3 Registration Statement; Listing
Application................................ 39
Section 7.4 Proxy Statements; Stockholder Approvals.... 39
Section 7.5 Compliance with the Securities Act......... 41
Section 7.6 Antitrust Laws............................. 41
Section 7.7 Voting Agreements.......................... 42
Section 7.8 Employee Stock Options..................... 42
Section 7.9 Public Announcements....................... 43
Section 7.10 Continuance of Existing Indemnification
Rights..................................... 43
Section 7.11 Expenses................................... 44
Section 7.12 Additional Agreements...................... 44
Section 7.13 Directors of Parent........................ 45
iii
<PAGE>
Section 7.14 Certain Benefits........................... 45
Section 7.15 Registration Statement for Securities Act
Affiliates................................. 45
Section 7.16 Publication of Post Merger Financial
Results.................................... 45
ARTICLE VIII
CONDITIONS TO CONSUMMATION OF THE MERGER................................. 45
Section 8.1 Conditions to Each Party's Obligation to
Effect the Merger.......................... 45
Section 8.2 Conditions to Obligation of Company to
Effect the Merger.......................... 46
Section 8.3 Conditions to Obligations of Parent and
Sub to Effect the Merger................... 49
ARTICLE IX
TERMINATION, AMENDMENT AND WAIVER........................................ 52
Section 9.1 Termination................................ 52
Section 9.2 This Section Intentionally Left Blank...... 55
Section 9.3 Effect of Termination...................... 55
Section 9.4 Amendment.................................. 57
Section 9.5 Waiver..................................... 58
ARTICLE X
GENERAL PROVISIONS....................................................... 58
Section 10.1 Survival of Representations, Warranties
and Agreements............................. 58
Section 10.2 Brokers.................................... 58
Section 10.3 Notices.................................... 59
Section 10.4 Descriptive Headings....................... 60
Section 10.5 Entire Agreement; Assignment............... 60
Section 10.6 Severability............................... 61
Section 10.7 Governing Law.............................. 61
Section 10.8 Specific Performance....................... 61
iv
<PAGE>
PAGE
Section 10.9 Counterparts............................... 61
v
<PAGE>
EXHIBITS
Exhibit A-1 Form of Stockholder Voting Agreement
Exhibit A-2 Form of Stockholder Voting Agreement
Exhibit B Form of Registration Rights Agreement
Exhibit C Certain Benefits
Exhibit D Intentionally Omitted
Exhibit E Form of Affiliate Letter
Exhibit F-1 Form of Stock Option Agreement
Exhibit F-2 Form of Stock Option Agreement
vi
<PAGE>
AGREEMENT AND PLAN OF MERGER
This AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of
October 16, 1996, is made by and among Tenet Healthcare Corporation, a Nevada
corporation ("Parent"), OHC Acquisition Co., a Delaware corporation and a wholly
owned subsidiary of Parent ("Sub"), and OrNda Healthcorp, a Delaware corporation
("Company").
WHEREAS, The Boards of Directors of Parent, Sub and Company deem it
advisable and in the best interests of their respective stockholders that Sub
merge with and into Company, and such Boards of Directors have approved the
merger (the "Merger") of Sub with and into Company upon the terms and subject to
the conditions set forth herein; and
WHEREAS, for Federal income tax purposes, it is intended that the
Merger shall qualify as a reorganization within the meaning of section 368(a) of
the Internal Revenue Code of 1986, as amended (the "Code"); and
WHEREAS, for accounting and financial reporting purposes, it is
intended that the Merger shall be treated as a pooling of interests;
NOW, THEREFORE, in consideration of the foregoing and the respective
representations, warranties, covenants and agreements set forth herein and in
the Stockholder Voting Agreements (as defined herein), the parties hereto agree
as follows:
ARTICLE I
THE MERGER
Section 1.1 THE MERGER. Upon the terms and subject to the
conditions hereof, at the Effective Time (as defined in Section 1.2 hereof), Sub
shall be merged with and into Company and the separate corporate existence of
Sub shall thereupon cease, and the Company shall be the surviving corporation in
the Merger (the "Surviving Corporation"). The Merger shall have the effects set
forth in Section 259 of the General Corporation Law of the State of Delaware
(the "GCL").
<PAGE>
Section 1.2 EFFECTIVE TIME OF THE MERGER. The Merger shall
become effective when a properly executed Certificate of Merger is duly filed
with the Secretary of State of the State of Delaware, which filing shall be made
as soon as practicable after satisfaction or, to the extent permitted hereunder,
waiver of all of the conditions to each party's obligation to consummate the
Merger contained in Article VIII. When used in this Agreement, the term
"Effective Time" shall mean the date and time at which such Certificate of
Merger is so filed.
ARTICLE II
THE SURVIVING CORPORATION
Section 2.1 CERTIFICATE OF INCORPORATION. The Certificate
of Incorporation of Sub in effect at the Effective Time shall be the Certificate
of Incorporation of the Surviving Corporation.
Section 2.2 BY-LAWS. Subject to Section 7.10 hereof, the
By-Laws of Sub as in effect at the Effective Time shall be the By-Laws of the
Surviving Corporation.
Section 2.3 DIRECTORS AND OFFICERS OF SURVIVING CORPORATION.
(a) The directors of Sub at the Effective Time shall be the
initial directors of the Surviving Corporation and shall hold office from the
Effective Time until their respective successors are duly elected or appointed
and qualify in the manner provided in the Certificate of Incorporation and
By-Laws of the Surviving Corporation or as otherwise provided by law.
(b) The officers of Sub at the Effective Time shall be the
initial officers of the Surviving Corporation and shall hold office from the
Effective Time until their respective successors are duly elected or appointed
and qualify in the manner provided in the Certificate of Incorporation and
By-Laws of the Surviving Corporation, or as otherwise provided by law.
2
<PAGE>
ARTICLE III
CONVERSION OF SHARES
Section 3.1 EXCHANGE RATIO. At the Effective Time, by
virtue of the Merger and without any action on the part of the holder thereof:
(a) Each of the shares of the Company's Common Stock, par
value $.01 per share (the "Shares") issued and outstanding immediately prior to
the Effective Time (other than Shares held in the treasury of the Company or by
Parent or any subsidiary of Parent or the Company) shall be converted into the
right to receive (i) 1.35 (the "Exchange Ratio") shares of Parent Common Stock,
par value $.075 per share (the "Parent Common Stock"; and upon such conversion,
the "Parent Shares"), issuable upon the surrender of the certificate formerly
representing such Share, and (ii) one associated preferred stock purchase right
(a "Parent Right") issued in accordance with the Rights Agreement, dated as of
December 7, 1988, as amended from time to time, between Parent and Bank of
America NTS as successor to Bankers Trust Company (references to Parent Shares
issuable in the Merger shall be deemed to include the associated Parent Rights);
(b) Each Share held in the treasury of Company, if any, and
each Share held by Parent or any subsidiary of Parent or Company immediately
prior to the Effective Time shall be cancelled and retired and cease to exist;
(c) Each share of Common Stock of the Sub, par value $.01
per share (the "Sub Common Stock"), issued and outstanding immediately prior to
the Effective Time shall be converted into and become a fully paid and
nonassessable share of Common Stock of the Surviving Corporation.
Section 3.2 EXCHANGE OF CERTIFICATES REPRESENTING SHARES.
(a) As of the Effective Time, Parent shall deposit, or shall
cause to be deposited, with an exchange agent selected by Parent and reasonably
satisfactory to the Company (the "Exchange Agent"), for the
3
<PAGE>
benefit of the holders of Shares, for exchange in accordance with this Article
III, (i) certificates representing the number of Parent Shares issuable in the
Merger, to be issued in respect of all Shares outstanding immediately prior to
the Effective Time and which are to be exchanged pursuant to the Merger
(exclusive of shares to be cancelled pursuant to Section 3.1(b)), and (ii) cash
to be paid in lieu of the issuance of fractional shares as provided in Section
3.4 hereof (such cash and certificates for Parent Shares being hereinafter
referred to collectively as the "Exchange Fund").
(b) Promptly after the Effective Time, Parent shall cause
the Exchange Agent to mail (or deliver at its principal office) to each holder
of record of a certificate or certificates representing Shares (i) a letter of
transmittal which shall specify that delivery shall be effected, and risk of
loss and title to the certificates for Shares shall pass, only upon delivery of
the certificates for Shares to the Exchange Agent and shall be in such form and
have such other provisions, including appropriate provisions with respect to
back-up withholding, as Parent may reasonably specify, and (ii) instructions for
use in effecting the surrender of the certificates for Shares. Upon surrender
of a certificate for Shares for cancellation to the Exchange Agent, together
with such letter of transmittal, duly executed and completed in accordance with
the instructions thereto, the holder thereof shall be entitled to receive in
exchange therefor that portion of the Exchange Fund which such holder has the
right to receive pursuant to the provisions of this Article III, after giving
effect to any required withholding tax, and the certificate for Shares so
surrendered shall forthwith be cancelled. No interest will be paid or accrued
on the cash to be paid which is in the Exchange Fund as part of the Exchange
Ratio. In the event of any transfer of ownership of Shares which has not been
registered in the transfer records of the Company, certificates representing the
proper number of Parent Shares, if any, together with a check in an amount
equal to the proper amount of the cash component, if any, of the Exchange Fund,
will be issued to the transferee of the certificate representing the transferred
Shares presented to the Exchange Agent, accompanied by all documents required to
evidence and effect the prior transfer thereof and to evidence that
4
<PAGE>
any applicable stock transfer taxes associated with such transfer were paid.
Section 3.3 DIVIDENDS; TRANSFER TAXES. No dividends that
are declared on Parent Shares will be paid to persons entitled to receive
certificates representing Parent Shares until such persons surrender their
certificates representing Shares. Upon such surrender, there shall be paid to
the person in whose name the certificates representing such Parent Shares shall
be issued, any dividends which shall have become payable with respect to such
Parent Shares between the Effective Time and the time of such surrender. In no
event shall the person entitled to receive such dividends be entitled to receive
interest on such dividends. If any certificates for any Parent Shares are to be
issued in a name other than that in which the certificate representing Shares
surrendered in exchange therefor is registered, it shall be a condition of such
exchange that the person requesting such exchange shall pay to the Exchange
Agent any transfer or other taxes required by reason of the issuance of
certificates for such Parent Shares in a name other than that of the registered
holder of the certificate surrendered or shall establish to the satisfaction of
the Exchange Agent that such tax has been paid or is not applicable.
Notwithstanding the foregoing, (i) neither the Exchange Agent nor any party
hereto shall be liable to a holder of Shares for any Parent Shares or dividends
thereon or, in accordance with Section 3.4 hereof, proceeds of the sale of
fractional interests, delivered to a public official pursuant to applicable
escheat laws and (ii) any Parent Shares held by the Exchange Agent prior to
surrender of certificates representing Shares shall not be deemed issued.
Section 3.4 NO FRACTIONAL SECURITIES. No certificates or
scrip representing fractional Parent Shares shall be issued upon the surrender
for exchange of certificates representing Shares pursuant to this Article III
and no dividend, stock split or other change in the capital structure of Company
shall relate to any fractional security, and such fractional interests shall not
entitle the owner thereof to vote or to any rights of a security holder. In
lieu of any such fractional securities, each holder of Shares who would
otherwise have been entitled to a fraction of a Parent Share upon surrender of
stock certificates for exchange pursuant to
5
<PAGE>
this Article III will be paid cash upon such surrender in an amount equal to the
product of such fraction multiplied by the closing sale price of one share of
Parent Common Stock on the New York Stock Exchange on the day of the Effective
Time, or, if shares of Parent Common Stock are not so traded on such day, the
closing sale price of one such share on the next preceding day on which such
share was traded on the New York Stock Exchange. For this purpose, Shares of
any holder represented by two or more certificates may be aggregated, and in no
event shall any holder be paid an amount in respect of more than one Parent
Share.
Section 3.5 CLOSING OF COMPANY TRANSFER BOOKS. At the
Effective Time, the stock transfer books of Company shall be closed and no
transfer of Shares shall thereafter be made. If, after the Effective Time,
certificates representing Shares are presented to the Surviving Corporation,
they shall be cancelled and exchanged for certificates representing Parent
Shares.
Section 3.6 CLOSING. The Closing of the transaction
contemplated by this Agreement (the "Closing") shall take place at the offices
of Skadden, Arps, Slate, Meagher & Flom, 300 South Grand Avenue, Suite 3400, Los
Angeles, California, at 10:00 a.m., local time, on the later of (a) the date of
the stockholders' meetings referred to in Section 7.4 hereof or (b) the day on
which all of the conditions set forth in Article VIII hereof are satisfied or
waived, or at such other date, time and place as Parent and Company shall agree.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PARENT
Except as otherwise disclosed to Company in a letter delivered to it
prior to the execution hereof (which letter shall contain appropriate references
to identify the representations and warranties herein to which the information
in such letter relates) (the "Parent Disclosure Letter"), Parent represents and
warrants to Company as follows:
Section 4.1 ORGANIZATION. Each of Parent and Sub is a
corporation duly organized, validly existing and in good standing under the laws
of the state of its
6
<PAGE>
incorporation and has the corporate power to carry on its business as it is now
being conducted or presently proposed to be conducted. Each of Parent and Sub
is duly qualified as a foreign corporation to do business, and is in good
standing, in each jurisdiction where the character of its properties owned or
held under lease or the nature of its activities make such qualification
necessary, except where the failure to be so qualified would not individually or
in the aggregate have a material adverse effect on the business, assets,
liabilities, results of operations or financial condition of Parent and its
subsidiaries, taken as a whole (a "Parent Material Adverse Effect").
Section 4.2 CAPITALIZATION. The authorized capital stock of
Parent consists of 450,000,000 shares of Parent Common Stock, and 2,500,000
shares of Parent Preferred Stock, par value $.15 per share (the "Parent
Preferred Stock"). As of August 31, 1996, (i) 216,556,908 shares of Parent
Common Stock were issued and outstanding, (ii) employee and non-employee
director stock options to acquire 20,076,236 shares of Parent Common Stock (the
"Parent Employee Stock Options") were outstanding under all stock option plans
of Parent, (iii) 500,000 shares of Parent Common Stock were reserved for
issuance in connection with Parent's Deferred Compensation Plan Trust (and
250,000 additional shares were approved by the Board of Directors of Parent on
September 25, 1996), (iv) 1,000,000 shares of Parent Common Stock were reserved
for issuance in connection with Parent's 1994 SERP Trust (and 1,500,000
additional shares were approved by the Board of Directors of Parent on September
25, 1996), (v) 225,000 shares of Parent Series A Junior Participating Preferred
Stock, par value $.15 per share, (the "Series A Preferred Stock") were reserved
for issuance upon the exercise of Parent Rights held by holders of the Parent
Common Stock which, when exercisable, enable the holders thereof to purchase one
two-thousandths of a share of Series A Preferred Stock, and (vi) 1,889,394
shares of Parent Common Stock were reserved for issuance in connection with
Parent's Employee Stock Purchase Plan. In addition, on September 25, 1996, the
Board approved the reservation of 60,000 shares of Parent Common Stock to fund a
trust securing the retirement benefits of two employees of an acquired hospital.
As of August 31, 1996, Parent had 1,176,091 treasury shares and no shares of
Parent Common Stock were held by Parent's
7
<PAGE>
subsidiaries. All of the issued and outstanding shares of Parent Common Stock
and Parent Preferred Stock are validly issued, fully paid and nonassessable and
free of preemptive rights. All of the shares of Parent Common Stock issuable in
exchange for Shares at the Effective Time in accordance with this Agreement will
be, when so issued, duly authorized, validly issued, fully paid and
nonassessable and free of preemptive rights. The authorized capital stock of
Sub consists of 1,000 shares of Sub Common Stock, all of which shares are
validly issued and outstanding, fully paid and nonassessable and are owned by
Parent. Except as set forth above, as of the date of this Agreement there are
no shares of capital stock of Parent issued or outstanding or any options,
warrants, subscriptions, calls, rights, convertible securities or other
agreements or commitments obligating Parent to issue, transfer, sell, redeem,
repurchase or otherwise acquire any shares of its capital stock or securities,
or the capital stock or securities of Sub. Except as provided in this
Agreement, after the Effective Time, Parent will have no obligation to issue,
transfer or sell any shares of its capital stock pursuant to any employee
benefit plan or otherwise.
Section 4.3 SUBSIDIARIES. Parent does not directly or
indirectly own any interest in any other corporation, partnership, joint venture
or other business association or entity, foreign or domestic. (Such
corporations, partnerships, joint ventures or other business entities of which
Parent owns, directly or indirectly, greater than fifty percent of the shares of
capital stock or other equity interests (including partnership interests)
entitled (without regard to the occurrence of any contingency) to cast at least
a majority of the votes that may be cast by all shares or equity interests
having ordinary voting power for the election of directors or other governing
body of such entity are hereinafter referred to as the "Parent Subsidiaries".)
(a) Each Parent Subsidiary that is a corporation is a
corporation duly organized, validly existing and in good standing under the laws
of its jurisdiction of incorporation. Each Parent Subsidiary that is a
partnership or a limited liability company is duly formed and validly existing
under the laws of its jurisdiction of formation.
8
<PAGE>
(b) Each Parent Subsidiary has the corporate power or the
partnership power, as the case may be, to carry on its business as it is now
being conducted or presently proposed to be conducted.
(c) Each Parent Subsidiary that is a corporation is duly
qualified as a foreign corporation to do business, and is in good standing, in
each jurisdiction where the character of its properties owned or held under
lease or the nature of its activities makes such qualification necessary, except
where the failure to be so qualified would not individually or in the aggregate
have a Parent Material Adverse Effect. Each Parent Subsidiary that is a
partnership is duly qualified as a foreign partnership authorized to do
business, and is in good standing, in each jurisdiction where the character of
its properties owned or held under lease or the nature of its activities makes
such qualification necessary, except where the failure to be so qualified would
not individually or in the aggregate have a Parent Material Adverse Effect.
(d) All of the outstanding shares of capital stock of the
Parent Subsidiaries that are corporations are validly issued, fully paid and
nonassessable.
(e) All of the outstanding shares of capital stock of, or
other ownership interests in, each of the Parent Subsidiaries owned by Parent or
a Parent Subsidiary are owned by Parent or by a Parent Subsidiary free and clear
of any liens, claims, charges or encumbrances. Except as set forth in Section
4.2 hereof, there are not now, and at the Effective Time there will not be, any
outstanding options, warrants, subscriptions, calls, rights, convertible
securities or other agreements or commitments obligating Parent or any Parent
Subsidiary to issue, transfer or sell any securities of Parent or any Parent
Subsidiary.
(f) There are not now, and at the Effective Time there will
not be, any voting trusts, standstill, stockholder or other agreements or
understandings to which Parent or any of the Parent Subsidiaries is a party or
is bound with respect to the voting of the capital stock of Parent or any of the
Parent Subsidiaries.
9
<PAGE>
(g) Sub is a newly incorporated company formed solely for
purposes of the transactions contemplated by this Agreement and has engaged in
no activity other than as provided in, or contemplated by, this Agreement.
Section 4.4 AUTHORITY RELATIVE TO THIS AGREEMENT. Each of
Parent and Sub has the corporate power and authority to enter into this
Agreement, the Stock Option Agreements between Parent and Company dated as of
October 17, 1996 (the "Stock Option Agreements"), the Registration Rights
Agreements between Parent and the stockholders listed therein (the "Registration
Rights Agreements") and the Stockholder Voting Agreements between Parent and the
Stockholders listed therein dated as of October 17, 1996 (the "Stockholder
Voting Agreements" and, together with this Agreement, the Stock Option
Agreements and the Registration Rights Agreements, the "Transaction Documents")
and to carry out its obligations hereunder and thereunder and to consummate the
transactions contemplated hereby and thereby. The execution and delivery of
this Agreement and each of the Stock Option Agreements by each of Parent and Sub
and the consummation by each of Parent and Sub of the transactions contemplated
hereby have been duly authorized by the Board of Directors of each of Parent and
Sub and by Parent as the sole stockholder of Sub, and, except for the approval
of Parent's stockholders to be sought at the stockholders' meeting contemplated
by Section 7.4(b) hereof, no other corporate action or proceedings on the part
of either Parent or Sub are necessary to authorize this Agreement or the
transactions contemplated hereby. This Agreement has been duly and validly
executed and delivered by each of Parent and Sub and constitutes a valid and
binding agreement of each of Parent and Sub, enforceable against each of Parent
and Sub in accordance with its terms, subject to bankruptcy, insolvency,
reorganization, moratorium or similar laws now or hereafter in effect relating
to creditors' rights generally or to general principles of equity.
Section 4.5 CONSENTS AND APPROVALS; NO VIOLATIONS. Except
for applicable requirements of the Hart-Scott-Rodino Antitrust Improvements Act
of 1976 (the "HSR Act"), the Securities Act of 1933, as amended (the "Securities
Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
state or foreign laws
10
<PAGE>
relating to takeovers, if applicable, state securities or blue sky laws, certain
state and local regulatory filings relating to health care licensing and similar
matters, and the filing of an appropriate certificate of merger (the
"Certificate of Merger") in such form as required by, and executed in accordance
with the relevant provisions of, the GCL, no filing with, and no permit,
authorization, consent or approval of, any public body or authority is necessary
for the consummation by Parent or Sub of the transactions contemplated by the
Transaction Documents, except for such filings, permits, authorizations,
consents or approvals the failure of which to be made or obtained would not
individually or in the aggregate have a Parent Material Adverse Effect. Neither
the execution and delivery of this Agreement by Parent or Sub nor the
consummation by Parent or Sub of the transactions contemplated hereby, nor
compliance by Parent or Sub with any of the provisions hereof, will (a) conflict
with or result in any breach of any provisions of the charter documents or
By-Laws of Parent or Sub, (b) result in a violation or breach of, or constitute
(with or without due notice or lapse of time or both) a default (or give rise to
any right of termination, cancellation or acceleration) under, any of the terms,
conditions or provisions of any note, bond, mortgage, indenture, license,
contract, agreement or other instrument or obligation to which Parent or any of
the Parent Subsidiaries is a party or by which any of them or any of their
properties or assets may be bound, or (c) violate any order, writ, injunction,
decree, statute, rule or regulation applicable to Parent, any of the Parent
Subsidiaries or any of their properties or assets, except in the case of clauses
(b) and (c) for violations, breaches or defaults which would not individually or
in the aggregate have a Parent Material Adverse Effect.
Section 4.6 REPORTS AND FINANCIAL STATEMENTS. Parent has
timely filed all reports required to be filed with the Securities and Exchange
Commission (the "SEC") pursuant to the Exchange Act since January 1, 1993
(collectively, the "Parent SEC Reports"). None of such Parent SEC Reports, as
of their respective dates, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they were
made, not misleading. Each of the balance sheets (including the related notes)
11
<PAGE>
included in the Parent SEC Reports fairly presents the consolidated financial
position of Parent and its subsidiaries as of the respective dates thereof, and
the other related statements (including the related notes) included therein
fairly present the results of operations and the changes in financial position
of Parent and its subsidiaries for the respective periods or as of the
respective dates set forth therein, all in conformity with generally accepted
accounting principles ("GAAP") consistently applied during the periods involved,
except as otherwise noted therein.
Section 4.7 ABSENCE OF CERTAIN CHANGES OR EVENTS. Except as
set forth in the Parent SEC Reports, since May 31, 1996, neither Parent nor any
of the Parent Subsidiaries has: (a) taken any of the actions set forth in
Sections 6.2(b) or 6.2(c) hereof; (b) suffered any material adverse change in
the business, financial condition, results of operations, properties, assets or
liabilities of Parent and the Parent Subsidiaries taken as a whole (other than
any change relating to the United States economy in general or to the United
States investor owned hospital business in general); or (c) subsequent to the
date hereof, except as permitted by Section 6.2 hereof, conducted its business
and operations other than in the ordinary course of business and consistent with
past practices.
Section 4.8 LITIGATION. Except for litigation disclosed in
(i) the notes to the financial statements included in Parent's Annual Report to
Stockholders for the year ended May 31, 1996 or (ii) the Parent SEC Reports,
there is no suit, action or proceeding pending or, to the best of Parent's
knowledge, threatened against or affecting Parent or any of the Parent
Subsidiaries, the outcome of which, in the reasonable judgment of Parent, is
likely individually or in the aggregate to have a Parent Material Adverse
Effect; nor is there any judgment, decree, injunction, citation, settlement
agreement, rule or order of any court, governmental department, commission,
agency, instrumentality or arbitrator outstanding against Parent or any of the
Parent Subsidiaries having, or which, insofar as can reasonably be foreseen, in
the future may have, any such effect.
Section 4.9 INFORMATION IN DISCLOSURE DOCUMENTS AND
Registration Statement. None of the infor-
12
<PAGE>
mation to be supplied by Parent for inclusion or incorporation by reference in
(a) the Registration Statement to be filed with the SEC by Parent on Form S-4
under the Securities Act for the purpose of registering the offering of the
Parent Shares to be issued in the Merger or any registration statement relating
to other securities to be issued in connection with the Merger (in each case,
the "Registration Statement") or (b) the joint proxy statement to be distributed
in connection with Parent's and Company's meeting of stockholders to vote upon
this Agreement (the "Proxy Statement") will, in the case of the Registration
Statement, at the time it becomes effective and at the Effective Time, or, in
the case of the Proxy Statement or any amendments thereof or supplements
thereto, at the time of the mailing of the Proxy Statement and any amendments or
supplements thereto and at the time of the meetings of stockholders to be held
in connection with the Merger, contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they are made, not misleading. The Registration Statement and the Proxy
Statement will comply as to form in all material respects with the provisions of
the Securities Act or the Exchange Act, as the case may be, and the rules and
regulations promulgated thereunder.
Section 4.10 ABSENCE OF UNDISCLOSED LIABILITIES. Except for
liabilities or obligations which (i) are accrued or reserved against in Parent's
financial statements (or reflected in the notes thereto) included in the Parent
SEC Reports, or (ii) were incurred after May 31, 1996 in the ordinary course of
business and consistent with past practices, neither Parent nor any Parent
Subsidiary has any liabilities or obligations (whether absolute, accrued,
contingent or otherwise) of a nature required by GAAP to be reflected in a
corporate balance sheet or the notes thereto.
Section 4.11 NO DEFAULT. Neither Parent nor any of the
Parent Subsidiaries is in default or violation (and no event has occurred which
with notice or the lapse of time or both would constitute a default or
violation) of any term, condition or provision of (a) its Articles of
Incorporation or By-Laws, (b) any note, bond, mortgage, indenture, license,
agreement, contract, lease, commitment or other obligation to which Parent or
any of
13
<PAGE>
the Parent Subsidiaries is a party or by which they or any of their properties
or assets may be bound, or (c) any order, writ, injunction, decree, statute,
rule or regulation applicable to Parent or any of the Parent Subsidiaries,
except in the case of clauses (b) and (c) above for defaults or violations which
would not individually or in the aggregate have a Parent Material Adverse
Effect.
Section 4.12 TAXES.
(a) Parent and the Parent Subsidiaries have duly filed all
material Tax Returns required to be filed by Parent or the Parent Subsidiaries
and have paid the Taxes shown to be due thereon. The most recent financial
statements contained in the Parent SEC Reports provide an adequate accrual for
the payment of Taxes for the periods covered by such Parent SEC Reports. No
material deficiencies for Taxes have been assessed or asserted by a "30-Day
Letter" or a notice of deficiency as defined in section 6212 of the Code (or
similar notice under state, local, or foreign law) which would have a Parent
Material Adverse Effect and for which adequate reserves have not been
established in the most recent financial statements contained in the most recent
Parent SEC Reports as of the date hereof.
(b) For purposes of this Agreement:
(i) "AUDIT" shall mean any audit, assessment of
Taxes, other examination by any Taxing Authority, proceeding
or appeal of such proceeding relating to Taxes.
(ii) "TAXES" shall mean all Federal, state, local and
foreign taxes, and other assessments of a similar nature
(whether imposed directly or through withholding), including
any interest, additions to tax, or penalties applicable
thereto.
(iii) "TAXING AUTHORITY" shall mean the Internal
Revenue Service and any other domestic or foreign governmental
authority responsible for the administration of any Taxes.
14
<PAGE>
(iv) "TAX RETURNS" shall mean all Federal, state,
local and foreign tax returns, declarations, statements,
reports, schedules, forms and information returns and any
amended Tax Return relating to Taxes.
Section 4.13 TITLE TO PROPERTIES; ENCUMBRANCES.
Except as otherwise provided in this Section 4.13, each of Parent
and the Parent Subsidiaries has good, valid and marketable title to, or a valid
leasehold interest in, all of its properties and assets (real, personal and
mixed, tangible and intangible), including, without limitation, all the
properties and assets reflected in the consolidated balance sheet of Parent and
the Parent Subsidiaries as of May 31, 1996 included in Parent's Annual Report on
Form l0-K for the period ended on such date (except for properties and assets
disposed of in the ordinary course of business and consistent with past
practices since May 31, 1996). None of such properties or assets are subject to
any liability, obligation, claim, lien, mortgage, pledge, security interest,
conditional sale agreement, charge or encumbrance of any kind (whether absolute,
accrued, contingent or otherwise), except for (i) minor imperfections of title
and encumbrance, if any, which are not substantial in amount, do not materially
detract from the value of the property or assets subject thereto, and do not
impair the operations of Parent and the Parent Subsidiaries, (ii) liens for
Taxes that are not yet due or that are being contested in good faith by
appropriate proceedings and for which adequate reserves have been established in
accordance with GAAP, and (iii) mortgages on real property in an aggregate
amount not greater than $100,000,000.
Section 4.14 COMPLIANCE WITH APPLICABLE LAW. Each of Parent
and the Parent Subsidiaries is in compliance with all applicable laws (whether
statutory or otherwise), rules, regulations, orders, ordinances, judgments or
decrees of all governmental authorities (federal, state, local, foreign or
otherwise) (collectively, the "Laws"), except where the failure to be in such
compliance would not individually or in the aggregate have a Parent Material
Adverse Effect.
15
<PAGE>
Section 4.15 MEDICARE PARTICIPATION/ACCREDITATION.
(a) All hospitals or significant health care facilities
owned or operated as continuing operations by Parent or any Parent Subsidiary
(each, a "Parent Facility") are certified for participation or enrollment in the
Medicare and Medicaid programs, have a current and valid provider contract with
the Medicare and Medicaid programs, are in substantial compliance with the
conditions of participation of such programs and have received all approvals or
qualifications necessary for capital reimbursement of Parent's assets except
where the failure to be so certified, to have such contracts, to be in such
compliance or to have such approvals or qualifications would not individually or
in the aggregate have a Parent Material Adverse Effect. Neither Parent nor any
of the Parent Subsidiaries has received notice from the regulatory authorities
which enforce the statutory or regulatory provisions in respect of either the
Medicare or the Medicaid program of any pending or threatened investigations,
and neither Parent nor any of the Parent Subsidiaries has any reason to believe
that any such investigations or surveys are pending, threatened or imminent
which may individually or in the aggregate have a Parent Material Adverse
Effect. Each Parent Facility eligible for such accreditation is accredited by
the Joint Commission on Accreditation of Healthcare Organizations, the
Commission on Accreditation of Rehabilitation or other appropriate accreditation
agency.
(b) Each Parent Facility is licensed by the proper state
department of health to conduct its business in substantially the manner
conducted by such Parent Facility and is authorized to operate the number of
beds utilized therein. The Parent Facilities are presently in substantial
compliance with all of the terms, conditions and provisions of such licenses.
Parent has heretofore made available to Company correct and complete copies of
all such licenses. The facilities, equipment, staffing and operations of the
Parent Facilities satisfy the applicable state hospital licensing requirements
in all material respects.
16
<PAGE>
Section 4.16 LABOR MATTERS.
(a) Neither Parent nor any of the Parent Subsidiaries is a
party to, or bound by, any material collective bargaining agreement with a labor
union or labor organization; (b) there is no unfair labor practice or labor
arbitration proceeding pending or, to the knowledge of Parent, threatened
against Parent or the Parent Subsidiaries relating to their business, except for
any such proceeding which would not individually or in the aggregate have a
Parent Material Adverse Effect; and (c) to the knowledge of Parent, there are no
organizational efforts with respect to the formation of a collective bargaining
unit presently being made or threatened involving a material number of employees
of Parent or any of the Parent Subsidiaries.
Section 4.17 EMPLOYEE BENEFIT PLANS; ERISA.
(a) With respect to each material bonus, deferred
compensation, incentive compensation, stock purchase, stock option, severance or
termination pay, hospitalization or other medical, life or other insurance,
supplemental unemployment benefits, profit-sharing, pension, or retirement plan,
program, agreement or arrangement, and each other employee benefit plan,
program, agreement (including but not limited to employment agreements) or
arrangement (the "Parent Plans"), currently maintained or contributed to or
required to be contributed to by (i) Parent, (ii) any Parent Subsidiary or (iii)
any trade or business, whether or not incorporated (a "Parent ERISA Affiliate"),
that together with Parent is a "single employer" within the meaning of Section
4001 of the Employee Retirement Income Security Act of 1974, as amended, and the
rules and regulations promulgated thereunder ("ERISA"), for the benefit of any
employee or former employee of Parent, any Parent Subsidiary or any Parent ERISA
Affiliate, Parent has heretofore delivered or will after the date hereof make
available to Company, upon request, true and complete copies of each of the
following documents:
(i) a copy of each Parent Plan that is in writing
(including all amendments thereto);
17
<PAGE>
(ii) a copy of the annual report and actuarial report,
if required under ERISA, with respect to each such Parent Plan
for the last two plan years ending prior to the date hereof;
(iii) a copy of the most recent Summary Plan
Description, together with each Summary of Material
Modifications, if required under ERISA, with respect to such
Parent Plan;
(iv) if the Parent Plan is funded through a trust or
any other third party funding vehicle, a copy of the trust or
other funding agreement (including all amendments thereto) and
the latest financial statements with respect to the last
reporting period ended immediately prior to the date hereof;
and
(v) the most recent determination letter received prior
to the date hereof from the Internal Revenue Service with
respect to each Parent Plan intended to qualify under section
401 of the Code.
(b) No liability under Title IV of ERISA has been incurred
by Parent, any Parent Subsidiary or any Parent ERISA Affiliate that has not been
satisfied in full when due, and no condition exists that presents a material
risk to Parent or any Parent Subsidiary or any Parent ERISA Affiliate of
incurring a liability under such Title which will, individually or in the
aggregate, have a Parent Material Adverse Effect, or give rise to a lien under
Title IV of ERISA.
(c) No Parent Plan subject to the minimum funding
requirements of section 412 of the Code or section 302 of ERISA or any trust
established thereunder has incurred any "accumulated funding deficiency" (as
defined in Section 302 of ERISA and section 412 of the Code), whether or not
waived, as of the last day of the most recent fiscal year of such Parent Plan
ended prior to the date hereof; and all contributions required to be made with
respect thereto (whether pursuant to the terms of
18
<PAGE>
any such Parent Plan or otherwise) on or prior to the date hereof have been
timely made.
(d) No Parent Plan is a "multiemployer pension plan," as
defined in Section 3(37) of ERISA, nor is any Parent Plan a plan described in
Section 4063(a) of ERISA.
(e) Each Parent Plan intended to be "qualified" within the
meaning of section 401(a) of the Code has received a favorable determination
letter from the Internal Revenue Service as to its qualification and, to
Parent's knowledge, no amendment has been made to any such Parent Plan since the
date of such letter that is likely to result in the disqualification of such
Plan.
(f) Each of the Parent Plans has been operated and
administered in all respects in accordance with applicable laws, including, but
not limited to, ERISA and the Code, except for any failure to so operate or
administer such Parent Plans that would not, individually or in the aggregate,
have a material adverse effect on any such Parent Plan.
(g) Except as expressly provided in this Agreement, any
exhibit hereto, a Parent Plan or as otherwise agreed in writing by Parent and
Company, the consummation of the transactions contemplated by this Agreement
will not
(i) entitle any current or former employee or officer of
Parent or any Parent Subsidiary to severance pay, unemployment
compensation or any other payment, or
(ii) accelerate the time of payment or vesting, or
increase the amount of compensation due any such employee or
officer.
(h) With respect to each Parent Plan that is funded wholly
or partially through an insurance policy, the Parent and the Parent Subsidiaries
do not have any current liability under any such insurance policy in the nature
of a retroactive rate adjustment or loss sharing arrangement arising wholly or
partially out of events occurring prior to the closing other than any such
lia-
19
<PAGE>
bility that, individually or in the aggregate, would not have a material
adverse effect on the applicable Parent Plan.
(i) There are no pending or, to Parent's knowledge,
threatened claims by or on behalf of any of the Parent Plans, by any employee or
beneficiary covered under any such Parent Plan involving any such Parent Plan
(other than routine claims for benefits), other than any such claims that would
not, individually or in the aggregate, have a Parent Material Adverse Effect.
(j) Neither Parent nor any Parent Subsidiary or, to the
Parent's knowledge, any Parent ERISA Affiliate, any of the Parent Plans, any
trust created thereunder, or any trustee or administrator thereof has engaged in
a transaction in connection with which Parent or any Parent Subsidiary or, to
Parent's knowledge, any Parent ERISA Affiliate, any of the Parent Plans, any
such trust, or any trustee or administrator thereof, or any party dealing with
the Parent Plans or any such trust is likely to be subject to either a civil
liability under section 409 of ERISA or Section 502(i) of ERISA, or a tax
imposed pursuant to section 4975 or 4976 of the Code, other than any such
liability or tax that would not, individually or in the aggregate, have a
Parent Material Adverse Effect.
Section 4.18 VOTE REQUIRED. Authorization of the issuance of the
Parent Shares to be issued in the Merger will require the affirmative vote of a
majority of Parent Common Stock voted at the stockholders' meeting referred to
in Section 7.4(b).
Section 4.19 OPINION OF FINANCIAL ADVISOR. Each of the Board of
Directors of Parent and Sub (at a meeting duly called and held) has unanimously
determined that the transactions contemplated hereby are fair to and in the best
interests of Parent and Sub. The Board of Directors of Parent has received the
opinion of Donaldson, Lufkin & Jenrette Securities Corporation ("DLJ"), Parent's
financial advisor, substantially to the effect that the Exchange Ratio is fair
to Parent from a financial point of view.
Section 4.20 CERTAIN ACTIONS UNDER NEVADA LAW. The Board of
Directors of Parent has taken all
20
<PAGE>
appropriate action so that the entry into this Agreement and the consummation of
the transactions contemplated hereunder shall be exempted from the provisions of
Sections 78.411-78.444 of the General Corporation Law of Nevada.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF COMPANY
Except as otherwise disclosed to Parent and Sub in a letter
delivered to them prior to the execution hereof (which letter shall contain
appropriate references to identify the representations and warranties herein to
which the information in such letter relates) (the "Company Disclosure Letter"),
the Company represents and warrants to Parent and Sub as follows:
Section 5.1 ORGANIZATION. Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware and has the corporate power to carry on its business as it is now being
conducted or presently proposed to be conducted. Company is duly qualified as a
foreign corporation to do business, and is in good standing, in each
jurisdiction where the character of its properties owned or held under lease or
the nature of its activities makes such qualification necessary, except where
the failure to be so qualified would not individually or in the aggregate have a
material adverse effect on the business, assets, liabilities, results of
operations or financial condition of Company and its subsidiaries, taken as a
whole (a "Company Material Adverse Effect").
Section 5.2 CAPITALIZATION. The authorized capital stock of
Company consists of 200,000,000 Shares and 10,000,000 shares of Preferred Stock,
par value $.01 per share (the "Company Preferred Stock"). As of August 31,
1996, (i) 58,250,996 Shares were issued and outstanding, (ii) employee and
non-employee director stock options to acquire 5,195,458 Shares (the "Employee
Stock Options") were outstanding under all stock option plans and agreements of
Company, (iii) warrants to purchase 92,600 Shares (the "Warrants") were
outstanding pursuant to the Warrant Agreement dated as of April 30, 1990,
between Company and Ameritrust Texas National Association (the "Warrant
Agreement"); (iv) 1,300,000 Shares were re-
21
<PAGE>
served for issuance under the Company Stock Purchase Plan, of which 62,460
Shares were purchased as of September 20, 1996; and (v) approximately 122,704
Shares were reserved for issuance under Company's 401(k) savings plan (the
Shares reserved for issuance referred to in clauses (iv) and (v) above, the
"Employee Shares"). As of August 31, 1996, the Company had no treasury shares
and no Shares were held by Company's subsidiaries. All of the issued and
outstanding Shares are validly issued, fully paid and nonassessable and free of
preemptive rights. Except as set forth above and as otherwise provided for in
this Agreement, there are not now, and at the Effective Time there will not be,
any shares of capital stock of Company issued or outstanding or any options,
warrants, subscriptions, calls, rights, convertible securities or other
agreements or commitments obligating Company to issue, transfer or sell any
shares of its capital stock. Except as provided in this Agreement, after the
Effective Time, Company will have no obligation to issue, transfer or sell any
shares of its capital stock pursuant to any employee benefit plan or otherwise.
Section 5.3 SUBSIDIARIES. Company does not directly or
indirectly own any interest in any other corporation, partnership, joint venture
or other business association or entity, foreign or domestic. (Such
corporations, partnerships, joint ventures or other business entities of which
Company owns, directly or indirectly, greater than fifty percent of the shares
of capital stock or other equity interests (including partnership interests)
entitled (without regard to the occurrence of any contingency) to cast at least
a majority of the votes that may be cast by all shares or equity interests
having ordinary voting power for the election of directors or other governing
body of such entity are hereinafter referred to as the "Company Subsidiaries".)
(a) Each Company Subsidiary that is a corporation is a
corporation duly organized, validly existing and in good standing under the laws
of its jurisdiction of incorporation. Each Company Subsidiary that is a
partnership or a limited liability company is duly formed and validly existing
under the laws of its jurisdiction of formation.
(b) Each Company Subsidiary has the corporate power or the
partnership power, as the case may
22
<PAGE>
be, to carry on its business as it is now being conducted or presently proposed
to be conducted.
(c) Each Company Subsidiary that is a corporation is duly
qualified as a foreign corporation to do business, and is in good standing, in
each jurisdiction where the character of its properties owned or held under
lease or the nature of its activities makes such qualification necessary, except
where the failure to be so qualified would not individually or in the aggregate
have a Company Material Adverse Effect. Each Company Subsidiary that is a
partnership is duly qualified as a foreign partnership authorized to do
business, and is in good standing, in each jurisdiction where the character of
its properties owned or held under lease or the nature of its activities makes
such qualification necessary, except where the failure to be so qualified would
not individually or in the aggregate have a Company Material Adverse Effect.
(d) All of the outstanding shares of capital stock of the
Company Subsidiaries that are corporations are validly issued, fully paid and
nonassessable.
(e) All of the outstanding shares of capital stock of, or
other ownership interests in, each of the Company Subsidiaries owned by Company
or a Company Subsidiary are owned by Company or by a Company Subsidiary free and
clear of any liens, claims, charges or encumbrances. Except as set forth in
Section 5.2 hereof, there are not now, and at the Effective Time there will not
be, any outstanding options, warrants, subscriptions, calls, rights, convertible
securities or other agreements or commitments obligating Company or any Company
Subsidiary to issue, transfer or sell any securities of Company or any Company
Subsidiary.
(f) There are not now, and at the Effective Time there will
not be, any voting trusts, standstill, stockholder or other agreements or
understandings to which Company or any of the Company Subsidiaries is a party or
is bound with respect to the voting of the capital stock of Company or any of
the Company Subsidiaries.
Section 5.4 AUTHORITY RELATIVE TO THIS AGREEMENT. Company
has the corporate power and authority
23
<PAGE>
to enter into the Transaction Documents, as applicable, to which it is a party
and to carry out its obligations hereunder and thereunder and to consummate the
transactions contemplated hereby and thereby. The execution and delivery of
this Agreement and each of the Stock Option Agreements by Company and the
consummation by Company of the transactions contemplated hereby have been duly
authorized by Company's Board of Directors and, except for the approval of
Company's stockholders to be sought at the stockholders meeting contemplated by
Section 7.4(a) hereof, no other corporate action or proceedings on the part of
Company are necessary to authorize this Agreement or the transactions
contemplated hereby. This Agreement has been duly and validly executed and
delivered by Company and constitutes a valid and binding agreement of Company,
enforceable against Company in accordance with its terms, subject to bankruptcy,
insolvency, reorganization, moratorium or similar laws now or hereafter in
effect relating to creditors' rights generally or to general principles of
equity.
Section 5.5 CONSENTS AND APPROVALS; NO VIOLATIONS. Except
for applicable requirements of the HSR Act, the Securities Act, the Exchange
Act, state securities or blue sky laws, certain state and local regulatory
filings relating to healthcare licensing and similar matters, and the filing and
recordation of the Certificate of Merger as required by the GCL, no filing with,
and no permit, authorization, consent or approval of, any public body or
authority is necessary for the consummation by Company of the transactions
contemplated by the Transaction Documents, except for such filings, permits,
authorizations, consents or approvals the failure of which to be made or
obtained would not individually or in the aggregate have a Company Material
Adverse Effect. Neither the execution and delivery of this Agreement by
Company, nor the consummation by Company of the transactions contemplated
hereby, nor compliance by Company with any of the provisions hereof, will (a)
conflict with or result in any breach of any provisions of the Certificate of
Incorporation or By-Laws of Company or any of the Company Subsidiaries, (b)
result in a violation or breach of, or constitute (with or without due notice or
lapse of time or both) a default (or give rise to any right of termination,
cancellation or acceleration) under, any of the terms, conditions or provisions
of any note, bond, mortgage, indenture, license, con-
24
<PAGE>
tract, agreement or other instrument or obligation to which Company or any of
the Company Subsidiaries is a party or by which any of them or any of their
properties or assets may be bound, or (c) violate any order, writ, injunction,
decree, statute, rule or regulation applicable to Company, any of the Company
Subsidiaries or any of their properties or assets, except in the case of clauses
(b) and (c) for violations, breaches or defaults which would not individually or
in the aggregate have a Company Material Adverse Effect.
Section 5.6 REPORTS AND FINANCIAL STATEMENTS. Company has
timely filed all reports required to be filed with the SEC pursuant to the
Exchange Act since January 1, 1993 (collectively, the "Company SEC Reports").
None of such Company SEC Reports, as of their respective dates, contained any
untrue statement of a material fact or omitted to state a material fact required
to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading. Each of the
balance sheets (including the related notes) included in the Company SEC Reports
fairly presents the consolidated financial position of Company and the Company
Subsidiaries as of the respective dates thereof, and the other related
statements (including the related notes) included therein fairly present the
results of operations and the changes in financial position of Company and the
Company Subsidiaries for the respective periods or as of the respective dates
set forth therein, all in conformity with GAAP consistently applied during the
periods involved, except as otherwise noted therein.
Section 5.7 ABSENCE OF CERTAIN CHANGES OR EVENTS. Except as
set forth in the Company SEC Reports, since May 31, 1996 neither Company nor any
of the Company Subsidiaries has: (a) taken any of the actions set forth in
Sections 6.1(b), 6.1(c) or 6.1(e) hereof; (b) suffered any material adverse
change in the business, financial condition, results of operations, properties,
assets or liabilities of Company and the Company Subsidiaries taken as a whole
(other than any change relating to the United States economy in general or to
the United States investor owned hospital business in general); or (c)
subsequent to the date hereof, except as permitted by Section 6.1 hereof,
conducted its business and operations other
25
<PAGE>
than in the ordinary course of business and consistent with past practices.
Section 5.8 LITIGATION. Except for litigation disclosed in
(i) the notes to the financial statements included in Company's Annual Report to
Stockholders for the year ended August 31, 1995 or (ii) the Company SEC Reports,
there is no suit, action or proceeding pending or, to the best of Company's
knowledge, threatened against or affecting Company or any of the Company
Subsidiaries, the outcome of which, in the reasonable judgment of Company, is
likely individually or in the aggregate to have a Company Material Adverse
Effect; nor is there any judgment, decree, injunction, citation, settlement
agreement, rule or order of any court, governmental department, commission,
agency, instrumentality or arbitrator outstanding against Company or any of the
Company Subsidiaries having, or which, insofar as can reasonably be foreseen, in
the future may have, any such effect.
Section 5.9 INFORMATION IN DISCLOSURE DOCUMENTS AND
REGISTRATION STATEMENT. None of the information to be supplied by Company for
inclusion or incorporation by reference in the Proxy Statement or the
Registration Statement will, in the case of the Registration Statement, at the
time it becomes effective and at the Effective Time, or, in the case of the
Proxy Statement or any amendments thereof or supplements thereto, at the time of
the mailing of the Proxy Statement and any amendments or supplements thereto and
at the time of the meetings of stockholders to be held in connection with the
Merger, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they are made, not
misleading. The Proxy Statement will comply as to form in all material respects
with the provisions of the Exchange Act, and the rules and regulations
promulgated thereunder.
Section 5.10 ABSENCE OF UNDISCLOSED LIABILITIES. Except for
liabilities or obligations which (i) are accrued or reserved against in
Company's financial statements (or reflected in the notes thereto) included in
the Company SEC Reports, or (ii) were incurred after May 31, 1996 in the
ordinary course of business and consistent with past practices, neither Company
nor any
26
<PAGE>
Company Subsidiary has any liabilities or obligations (whether absolute,
accrued, contingent or otherwise) of a nature required by GAAP to be reflected
in a corporate balance sheet or the notes thereto.
Section 5.11 NO DEFAULT. Neither Company nor any of the
Company Subsidiaries is in default or violation (and no event has occurred which
with notice or the lapse of time or both would constitute a default or
violation) of any term, condition or provision of (a) its Certificate of
Incorporation or By-Laws, (b) any note, bond, mortgage, indenture, license,
agreement, contract, lease, commitment or other obligation to which Company or
any of the Company Subsidiaries is a party or by which they or any of their
properties or assets may be bound, or (c) any order, writ, injunction, decree,
statute, rule or regulation applicable to Company or any of the Company
Subsidiaries, except in the case of clauses (b) and (c) above for defaults or
violations which would not individually or in the aggregate have a Company
Material Adverse Effect.
Section 5.12 TAXES.
(a) Company and the Company Subsidiaries have duly filed all
material Tax Returns required to be filed by Company or the Company Subsidiaries
and have paid the Taxes shown to be due thereon. The most recent financial
statements contained in the Company SEC Reports provide an adequate accrual for
the payment of Taxes for the periods covered by such Company SEC Reports. No
material deficiencies for Taxes have been assessed or asserted by a "30-Day
Letter" or a notice of deficiency as defined in section 6212 of the Code (or
similar notice under state, local, or foreign law) which would have a Company
Material Adverse Effect and for which adequate reserves have not been
established in the most recent financial statements contained in the most recent
Company SEC Reports as of the date hereof.
(b) Neither Company nor any of the Company Subsidiaries is a
party to any agreement, contract or arrangement that would result, separately or
in the aggregate, in the payment of any "excess parachute payments" within the
meaning of section 280G of the Code.
Section 5.13 TITLE TO PROPERTIES; ENCUMBRANCES.
27
<PAGE>
Except as otherwise provided in this Section 5.13, each of Company
and the Company Subsidiaries has good, valid and marketable title to, or a valid
leasehold interest in, all of its properties and assets (real, personal and
mixed, tangible and intangible), including, without limitation, all the
properties and assets reflected in the consolidated balance sheet of Company and
the Company Subsidiaries as of May 31, 1996 included in Company's Quarterly
Report on Form 10-Q for the period ended on such date (except for properties and
assets disposed of in the ordinary course of business and consistent with past
practices since May 31, 1996). None of such properties or assets are subject to
any liability, obligation, claim, lien, mortgage, pledge, security interest,
conditional sale agreement, charge or encumbrance of any kind (whether absolute,
accrued, contingent or otherwise), except for (i) minor imperfections of title
and encumbrance, if any, which are not substantial in amount, do not materially
detract from the value of the property or assets subject thereto, and do not
impair the operations of Company and the Company Subsidiaries, (ii) liens for
Taxes that are not yet due or that are being contested in good faith by
appropriate proceedings and for which adequate reserves have been established in
accordance with GAAP and (iii) mortgages on real property in an aggregate amount
not greater than $100,000,000.
Section 5.14 COMPLIANCE WITH APPLICABLE LAW. Each of Company
and the Company Subsidiaries is in compliance with all applicable Laws, except
where the failure to be in such compliance would not individually or in the
aggregate have a Company Material Adverse Effect.
Section 5.15 MEDICARE PARTICIPATION/ACCREDITATION.
(a) All hospitals or significant healthcare facilities owned
or operated as continuing operations by Company or any Company Subsidiary (each,
a "Company Facility") are certified for participation or enrollment in the
Medicare and Medicaid programs, have a current and valid provider contract with
the Medicare and Medicaid programs, are in substantial compliance with the
conditions of participation of such programs and have received all approvals or
qualifications necessary for capital reimbursement of Company's assets except
where the failure to be so certified, to have such contracts, to be in such
compliance or to have such approvals or
28
<PAGE>
qualifications would not individually or in the aggregate have a Company
Material Adverse Effect. Neither Company nor any of the Company Subsidiaries
has received notice from the regulatory authorities which enforce the statutory
or regulatory provisions in respect of either the Medicare or the Medicaid
program of any pending or threatened investigations or surveys, and neither
Company nor any of the Company Subsidiaries has any reason to believe that any
such investigations are pending, threatened or imminent which may individually
or in the aggregate have a Company Material Adverse Effect. Each Company
Facility eligible for such accreditation is accredited by the Joint Commission
on Accreditation of Healthcare Organizations, the Commission on Accreditation of
Rehabilitation or other appropriate accreditation agency.
(b) Each such Company Facility is licensed by the proper
state department of health to conduct its business in substantially the manner
conducted by such Company Facility and is authorized to operate the number of
beds utilized therein. The Company Facilities are presently in substantial
compliance with all of the terms, conditions and provisions of such licenses.
Company has heretofore made available to Parent correct and complete copies of
all such licenses. The facilities, equipment, staffing and operations of the
Company Facilities satisfy the applicable state hospital licensing requirements
in all material respects.
Section 5.16 LABOR MATTERS.
(a) Neither Company nor any of the Company Subsidiaries is a
party to, or bound by, any material collective bargaining agreement with a labor
union or labor organization; (b) there is no unfair labor practice or labor
arbitration proceeding pending or, to the knowledge of Company, threatened
against Company or the Company Subsidiaries relating to their business, except
for any such proceeding which would not individually or in the aggregate have a
Company Material Adverse Effect; and (c) to the knowledge of Company, there are
no organizational efforts with respect to the formation of a collective
bargaining unit presently being made or threatened involving a material number
of employees of Company or any of the Company Subsidiaries.
Section 5.17 EMPLOYEE BENEFIT PLANS; ERISA.
29
<PAGE>
(a) With respect to each material bonus, deferred
compensation, incentive compensation, stock purchase, stock option, severance or
termination pay, hospitalization or other medical, life or other insurance,
supplemental unemployment benefits, profit-sharing, pension, or retirement plan,
program, agreement or arrangement, and each other employee benefit plan,
program, agreement (including but not limited to employment agreements) or
arrangement (the "Plans"), currently maintained or contributed to or required to
be contributed to by (i) Company, (ii) any Company Subsidiary or (iii) any trade
or business, whether or not incorporated (a "Company ERISA Affiliate"), that
together with Company is a "single employer" within the meaning of Section 4001
of ERISA, for the benefit of any employee or former employee of Company, any
Company Subsidiary or any Company ERISA Affiliate, Company has heretofore
delivered or will after the date hereof make available to Parent, upon request,
true and complete copies of each of the following documents:
(i) a copy of each Plan that is in writing (including
all amendments thereto);
(ii) a copy of the annual report and actuarial report,
if required under ERISA, with respect to each such Plan for
the last two plan years ending prior to the date hereof;
(iii) a copy of the most recent Summary Plan
Description, together with each Summary of Material
Modifications, if required under ERISA, with respect to such
Plan;
(iv) if the Plan is funded through a trust or any other
third party funding vehicle, a copy of the trust or other
funding agreement (including all amendments thereto) and the
latest financial statements with respect to the last reporting
period ended immediately prior to the date hereof; and
30
<PAGE>
(v) the most recent determination letter received prior
to the date hereof from the Internal Revenue Service with
respect to each Plan intended to qualify under section 401 of
the Code.
(b) No liability under Title IV of ERISA has been incurred
by Company, any Company Subsidiary or any Company ERISA Affiliate that has not
been satisfied in full when due, and no condition exists that presents a
material risk to Company or any Company Subsidiary or any Company ERISA
Affiliate of incurring a liability under such Title which will, individually or
in the aggregate, have a Company Material Adverse Effect, or give rise to a lien
under Title IV of ERISA.
(c) No Plan subject to the minimum funding requirements of
section 412 of the Code or section 302 of ERISA or any trust established
thereunder has incurred any "accumulated funding deficiency" (as defined in
section 302 of ERISA and section 412 of the Code), whether or not waived, as of
the last day of the most recent fiscal year of such Plan ended prior to the date
hereof; and all contributions required to be made with respect thereto (whether
pursuant to the terms of any such Plan or otherwise) on or prior to the date
hereof have been timely made.
(d) Except as set forth in Section 5.17(f) of the Company
Disclosure Letter, no Plan is a "multiemployer pension plan," as defined in
section 3(37) of ERISA, nor is any Plan a plan described in Section 4063(a) of
ERISA.
(e) Each Plan intended to be "qualified" within the meaning
of section 401(a) of the Code has received a favorable determination letter from
the Internal Revenue Service as to its qualification and, to Company's
knowledge, no amendment has been made to any such Plan since the date of such
letter that is likely to result in the disqualification of such Plan.
(f) Each of the Plans has been operated and administered in
all respects in accordance with applicable laws, including, but not limited to,
ERISA and the Code, except for any failure to so operate or administer such
Plans that would not, individually or in the
31
<PAGE>
aggregate, have a material adverse effect on any such Plan.
(g) Except as expressly provided in this Agreement, any
exhibit hereto, a Plan or as otherwise agreed in writing by Parent and Company,
the consummation of the transactions contemplated by this Agreement will not
(i) entitle any current or former employee or officer
of Company or any Company Subsidiary to severance pay,
unemployment compensation or any other payment, or
(ii) accelerate the time of payment or vesting, or
increase the amount of compensation due any such employee or
officer.
(h) With respect to each Plan that is funded wholly or
partially through an insurance policy, the Company and the Company Subsidiaries
do not have any current liability under any such insurance policy in the nature
of a retroactive rate adjustment or loss sharing arrangement arising wholly or
partially out of events occurring prior to the closing other than any such
liability that, individually or in the aggregate, would not have a material
adverse effect on the applicable Plan.
(i) There are no pending or, to the Company's knowledge,
threatened claims by or on behalf of any of the Plans, by any employee or
beneficiary covered under any such Plan involving any such Plan (other than
routine claims for benefits), other than any such claims that would not,
individually or in the aggregate, have a Company Material Adverse Effect.
(j) Neither Company nor any Company Subsidiary or, to the
Company's knowledge, any Company ERISA Affiliate, any of the ERISA Plans, any
trust created thereunder, or any trustee or administrator thereof has engaged in
a transaction in connection with which Company or any Company Subsidiary or, to
Parent's knowledge, any Company ERISA Affiliate, any of the ERISA Plans, any
such trust or any trustee or administrator thereof, or any party dealing with
the ERISA Plans or any such trust is
32
<PAGE>
likely to be subject to either a civil liability under Section 409 of ERISA or
Section 502(i) of ERISA, or a tax imposed pursuant to section 4975 or 4976 of
the Code other than any such liability or tax that would not, individually or in
the aggregate, have a Company Material Adverse Effect.
Section 5.18 VOTE REQUIRED. Approval of the Merger by the
stockholders of Company will require the affirmative vote of the holders of a
majority of the outstanding Shares at the stockholders' meeting referred to in
Section 7.4(a).
Section 5.19 OPINION OF FINANCIAL ADVISOR. The Board of
Directors of Company has received the opinion of Merrill Lynch & Co., Company's
financial advisor, substantially to the effect that the Exchange Ratio is fair
to the holders of the Shares (other than Parent and its affiliates) from a
financial point of view.
Section 5.20 TAKEOVER STATUS. The Board of Directors of the
Company has taken all appropriate action so that neither Parent nor Sub will be
an "interested stockholder" within the meaning of Section 203 of the GCL by
virtue of the execution of the Stockholder Agreements, the Company's entry into
this Agreement and the consummation of the transactions contemplated hereunder.
ARTICLE VI
CONDUCT OF BUSINESS PENDING THE MERGER
Section 6.1 CONDUCT OF BUSINESS BY COMPANY PENDING THE
MERGER. From the date of this Agreement to the Effective Time, unless Parent
shall otherwise agree in writing, or as otherwise contemplated by this
Agreement, or any Exhibit hereto, or the Company Disclosure Letter:
(a) the respective businesses of Company and the Company
Subsidiaries shall be conducted only in the ordinary and usual course of
business and consistent with past practices, and there shall be no material
changes in the conduct of the operations of Company or any Company Subsidiary;
33
<PAGE>
(b) Company shall not (i) sell or pledge or agree to sell or
pledge any stock owned by it in any of the Company Subsidiaries; (ii) amend its
Certificate of Incorporation or By-Laws; or (iii) split, combine or reclassify
any shares of its outstanding capital stock or declare, set aside or pay any
dividend or other distribution payable in cash, stock or property, or redeem or
otherwise acquire any shares of its capital stock or shares of the capital stock
of any of the Company Subsidiaries;
(c) neither Company nor any of the Company Subsidiaries
shall (i) authorize for issuance, issue or sell any additional shares of, or
rights of any kind to acquire any shares of, its capital stock of any class
(whether through the issuance or granting of options, warrants, commitments,
subscriptions, rights to purchase or otherwise), except for (a) unissued Shares
reserved for issuance upon the exercise of Employee Stock Options, (b) Shares to
be issued pursuant to the Warrant Agreement and (c) the Employee Shares; (ii)
acquire, dispose of, transfer, lease, license, mortgage, pledge or encumber any
fixed or other assets in excess of $5,000,000 in any one or a series of related
transactions other than in the ordinary course of business and consistent with
past practices; (iii) incur, assume or prepay any indebtedness or any other
material liabilities other than in the ordinary course of business and
consistent with past practices; (iv) assume, guarantee, endorse or otherwise
become liable or responsible (whether directly, contingently or otherwise) for
the obligations of any other person other than a Company Subsidiary in the
ordinary course of business and consistent with past practices; (v) make any
loans, advances or capital contributions to, or investments in, any other
person, other than to Company Subsidiaries and other than in the ordinary course
of business and consistent with past practices; (vi) authorize capital
expenditures substantially in excess of the amount currently budgeted therefor;
(vii) permit any insurance policy naming Company or any Company Subsidiary as a
beneficiary or a loss payee to be cancelled or terminated other than in the
ordinary course of business; or (viii) enter into any contract, agreement,
commitment or arrangement with respect to any of the foregoing;
(d) Company shall use reasonable efforts to preserve intact
the business organization of Company
34
<PAGE>
and the Company Subsidiaries, to keep available the services of its and their
present officers and key employees, and to preserve the goodwill of those having
business relationships with it and the Company Subsidiaries;
(e) neither Company nor any of the Company Subsidiaries
shall make any change in the compensation payable or to become payable to any of
its officers, directors or employees, enter into or amend any employment,
severance, termination or other similar agreement, adopt any new Plan or amend
in any material respect any existing Plan, or make any loans to any of its
officers, directors or employees or make any changes in its existing borrowing
or lending arrangements for or on behalf of any of such persons, whether
contingent on consummation of the Merger or otherwise, other than (i) in the
ordinary course of business and consistent with past practice, (ii) as may be
required under applicable Law or the terms of any existing Plan or agreement,
and (iii) the granting of retention bonuses to certain officers and employees in
an aggregate amount not to exceed $2,000,000; and
(f) neither Company nor any of the Company Subsidiaries
shall (i) knowingly take or allow to be taken any action which would jeopardize
the treatment of Parent's acquisition of Company as a pooling of interests for
accounting purposes; or (ii) knowingly take any action that would jeopardize
qualification of the Merger as a reorganization within the meaning of section
368(a) of the Code.
Section 6.2 CONDUCT OF BUSINESS BY PARENT PENDING THE
MERGER. From the date of this Agreement to the Effective Time, unless Company
shall otherwise agree in writing, or as otherwise contemplated by this Agreement
or the Parent Disclosure Letter:
(a) the respective businesses of Parent and the Parent
Subsidiaries shall be conducted only in the ordinary and usual course of
business and consistent with past practices, and there shall be no material
changes in the conduct of the operations of Parent or any Parent Subsidiary;
35
<PAGE>
(b) Parent shall not (i) sell or pledge or agree to sell or
pledge any stock owned by it in any of the Parent Subsidiaries; (ii) amend its
Articles of Incorporation or By-Laws; or (iii) split, combine or reclassify any
shares of its outstanding capital stock or declare, set aside or pay any
dividend or other distribution payable in cash, stock or property, or redeem or
otherwise acquire any shares of its capital stock or shares of the capital stock
of any of the Parent Subsidiaries;
(c) neither Parent nor any of the Parent Subsidiaries shall
(i) authorize for issuance, issue or sell any additional shares of, or rights of
any kind to acquire any shares of, its capital stock of any class (whether
through the issuance or granting of options, warrants, commitments,
subscriptions, rights to purchase or otherwise), except for unissued shares of
Parent Common Stock reserved for issuance upon the exercise of Parent Employee
Stock Options, (ii) incur, assume or prepay any indebtedness or any other
material liabilities other than in the ordinary course of business and
consistent with past practices; (iii) assume, guarantee, endorse or otherwise
become liable or responsible (whether directly, contingently or otherwise) for
the obligations of any other person other than a Parent Subsidiary in the
ordinary course of business and consistent with past practices; or (iv) enter
into any contract, agreement, commitment or arrangement with respect to any of
the foregoing;
(d) Parent shall use reasonable efforts to preserve intact
the business organization of Parent and the Parent Subsidiaries, to keep
available the services of its and their present officers and key employees, and
to preserve the goodwill of those having business relationships with it and the
Parent Subsidiaries; and
(e) neither Parent nor any of the Parent Subsidiaries shall
(i) knowingly take or allow to be taken any action which would jeopardize the
treatment of Parent's acquisition of Company as a pooling of interests for
accounting purposes; or (ii) knowingly take any action that would jeopardize
qualification of the Merger as a reorganization within the meaning of section
368(a) of the Code.
36
<PAGE>
Section 6.3 CONDUCT OF BUSINESS OF SUB. From the date
hereof to the Effective Time, Sub shall not engage in any activities of any
nature except as provided in or contemplated by this Agreement.
Section 6.4 CERTAIN TAX MATTERS. (a) Without the prior
approval of Parent, neither the Company nor any Company Subsidiaries shall,
prior to the Effective Time, (i) settle any Audit if such settlement requires
Tax payments in excess of $10,000,000, or (ii) file any amended Tax Return that
increases the Tax liabilities reflected on such Return by more than $10,000,000
over the Tax liabilities reflected on the Tax Return that is being amended; and
(b) Without prior timely notice and consultation with Parent,
neither the Company nor any Company Subsidiaries shall make or change any
material Tax election.
ARTICLE VII
ADDITIONAL AGREEMENTS
Section 7.1 ACCESS AND INFORMATION. Company and Parent
shall each afford to the other and to the other's financial advisors, legal
counsel, accountants consultants and other representatives full access at all
reasonable times throughout the period prior to the Effective Time to all of its
books, records, properties, plants and personnel and, during such period, each
shall furnish promptly to the other (a) a copy of each report, schedule and
other document filed or received by it pursuant to the requirements of federal
or state securities laws, and (b) all other information as such other party may
reasonably request, provided that no investigation pursuant to this Section 7.1
shall affect any representations or warranties made herein or the conditions to
the obligations of the respective parties to consummate the Merger. Each party
and their respective affiliates, representatives and agents shall hold in
confidence all nonpublic information in accordance with the terms of the
December 8, 1994 Confidentiality Letters, as amended, between Company and Parent
until such time as such information is otherwise publicly available and, if this
Agreement is terminated, each party will deliver to the other all documents,
work papers and other material
37
<PAGE>
(including copies) obtained by such party or on its behalf from the other party
as a result of this Agreement or in connection herewith, whether so obtained
before or after the execution hereof.
Section 7.2 ACQUISITION PROPOSALS. From the date hereof
until the termination hereof, Parent, the Parent Subsidiaries, the Company and
the Company Subsidiaries will not, and will cause their respective officers,
directors, employees or other agents (including, without limitation, investment
bankers, attorneys or accountants) not to, directly or indirectly, (i) take any
action to solicit, initiate, encourage, enter into any agreement or otherwise
facilitate any offer or proposal for, or any indication of interest in, a merger
or other business combination involving Parent or Company or the acquisition of
any equity interest in, or a substantial portion of the assets of Parent or
Company, other than the transactions contemplated by the Transaction Documents
(an "Acquisition Proposal"), (ii) give any approval of the type referred to in
Section 4.20 or 5.20 with respect to any Acquisition Proposal, (iii) waive any
provision of any standstill or similar agreements entered into by Parent, the
Parent Subsidiaries, Company or the Company Subsidiaries, or (iv) engage in or
continue discussions or negotiations with, or disclose any nonpublic information
relating to Parent, the Parent Subsidiaries, Company or the Company
Subsidiaries, respectively, or afford access to their respective properties,
books or records to, any person that may be considering making, or has made, an
Acquisition Proposal, or otherwise facilitate any effort or attempt to make or
implement an Acquisition Proposal. Notwithstanding the foregoing, nothing
contained in this Section 7.2 shall prohibit Parent or Company and their
respective Boards of Directors from (i) taking and disclosing a position with
respect to a tender offer by a third party pursuant to Rules 14d-9 and 14e-2(a)
promulgated by the SEC under the Exchange Act, or (ii) furnishing information
to, or entering into negotiations with, any person or entity that makes an
unsolicited bona fide proposal to acquire Parent or Company pursuant to a
merger, consolidation, share exchange, purchase of a substantial portion of the
assets, business combination or other similar transaction, if, and only to the
extent that, (A) such Board of Directors determines in good faith upon advice of
counsel that such action is required for the Board of Directors
38
<PAGE>
to comply with its fiduciary duties to stockholders imposed by Law, (B) prior to
furnishing such information to, or entering into discussions or negotiations
with, such person or entity, Parent or Company provides written notice to the
other party to this Agreement to the effect that it is furnishing information
to, or entering into discussions or negotiations with, such person or entity,
and Parent or Company keeps the other informed of the status and principal
financial terms of any such negotiations or discussions.
Section 7.3 REGISTRATION STATEMENT; LISTING APPLICATION.
(a) As promptly as practicable, Parent and Company shall prepare and file with
the SEC the Proxy Statement and Parent shall prepare and file with the SEC the
Registration Statement. Each of Parent and Company shall use its reasonable
efforts to have the Registration Statement declared effective as promptly as
practicable. Parent shall use its reasonable efforts to take any action
required to be taken under state securities or blue sky laws in connection with
the issuance of the Parent Shares pursuant hereto. Company shall furnish Parent
with all information concerning Company and the holders of its capital stock and
shall take such other action as Parent may reasonably request in connection with
such Registration Statement and issuance of Parent Shares.
(b) Parent shall promptly prepare and submit to each of the
New York Stock Exchange and Pacific Stock Exchange a listing application
covering the Parent Shares to be issued in connection with the Merger and this
Agreement, and shall use its reasonable efforts to obtain, prior to the
Effective Time, approval for the listing of such Parent Shares, subject to
official notice of issuance.
Section 7.4 PROXY STATEMENTS; STOCKHOLDER APPROVALS.
(a) Company, acting through its Board of Directors, shall, in
accordance with applicable law and its Certificate of Incorporation and By-Laws:
(i) promptly and duly call, give notice of, convene and hold
as soon as practicable following the date upon which the
Registration
39
<PAGE>
Statement becomes effective a meeting of its stockholders for the
purpose of voting to approve and adopt this Agreement and shall use
its reasonable efforts to obtain such stockholder approval;
PROVIDED, HOWEVER, upon the written request of Parent, that
Company shall adjourn any such meeting of its stockholders in the
event that any of the certain stockholders that are parties to the
Stockholder Voting Agreements are in breach of such Stockholder
Voting Agreements until such time as the certain stockholders are in
compliance therewith.
(ii) recommend approval and adoption of this Agreement by the
stockholders of Company and include in the Proxy Statement such
recommendation, and take all lawful action to solicit such approval.
(b) Parent, acting through its Board of Directors, shall, in
accordance with applicable law and its Articles of Incorporation and By-Laws:
(i) promptly and duly call, give notice of, convene and hold
as soon as practicable following the date upon which the
Registration Statement becomes effective a meeting of its
stockholders for the purpose of voting to authorize the issuance of
the Parent Shares to be issued in the Merger and shall use its best
efforts to obtain such stockholder approval; and
(ii) recommend authorization of the issuance of the Parent
Shares to be issued in the Merger by the stockholders of Parent and
include in the Proxy Statement such recommendation, and take all
lawful action to solicit such approval.
(c) Parent and Company, as promptly as practicable, shall
cause the definitive Proxy Statement to be mailed to their respective
stockholders. At the stockholders' meetings, each of Parent and Company shall
vote or cause to be voted in favor of approval and adoption of this Agreement
all Parent Common Stock or Shares, as the case may be, as to which it holds
proxies at such time.
40
<PAGE>
(d) Each of Company's and Parent's obligations under this
Section 7.4 shall at all times remain subject to their fiduciary duties imposed
under applicable law, in the event that, if required by such fiduciary duties as
advised by counsel, the Board of Directors of Company or Parent, as the case may
be, shall have withdrawn or modified its recommendation that stockholders
approve and adopt this Agreement, in the case of Company, or that stockholders
authorize the issuance of the Parent Shares to be issued in connection with the
Merger, in the case of Parent.
Section 7.5 COMPLIANCE WITH THE SECURITIES ACT.
(a) Prior to the Effective Time, Company shall cause to be
delivered to Parent a list identifying all persons who were, in its reasonable
judgment, at the record date for Company stockholders' meeting convened in
accordance with Section 7.4(a) hereof, "affiliates" of Company as that term is
used in paragraphs (c) and (d) of Rule 145 under the Securities Act (each, an
"Affiliate").
(b) Company shall use its reasonable efforts to cause each
person who is identified as an Affiliate in the list referred to above to
deliver to Parent at or prior to the Effective Time a written agreement, in
substantially the form attached hereto as Exhibit E (the "Affiliate Letters").
Section 7.6 ANTITRUST LAWS. As promptly as practicable,
Company, Parent and Sub shall make all filings and submissions under the HSR Act
as may be reasonably required to be made in connection with this Agreement and
the transactions contemplated hereby. Subject to Section 7.1 hereof, Company
will furnish to Parent and Sub, and Parent and Sub will furnish to Company, such
information and assistance as the other may reasonably request in connection
with the preparation of any such filings or submissions. Subject to Section 7.1
hereof, Company will provide Parent and Sub, and Parent and Sub will provide
Company, with copies of all correspondence, filings or communications (or
memoranda setting forth the substance thereof) between such party or any of its
representatives, on the one hand, and any governmental agency or authority or
members of their respective
41
<PAGE>
staffs, on the other hand, with respect to this Agreement and the transactions
contemplated hereby.
Section 7.7 VOTING AGREEMENTS. Concurrently herewith,
Parent is entering into the Stockholder Voting Agreements with each of Joseph
Littlejohn & Levy Fund, L.P. and Charles N. Martin, substantially in the forms
attached hereto as Exhibits A-1 and A-2.
Section 7.8 EMPLOYEE STOCK OPTIONS. Except as provided in
this Agreement or pursuant to the provisions of any Plan or employee or director
stock option agreement as in effect on the date hereof, from the date hereof
Company will not accelerate the vesting or exercisability of or otherwise modify
the terms and conditions applicable to the Employee Stock Options. At the
Effective Time, each of the Employee Stock Options which is outstanding and
unexercised at the Effective Time shall be converted automatically into an
option to purchase Parent Shares in an amount and at an exercise price
determined as provided below (and otherwise subject to the terms of the stock
option plans of Company governing the Employee Stock Options (the "Company Stock
Option Plans")):
(1) The number of Parent Shares to be subject to the new
option shall be equal to the product of the number of Shares subject
to the original option and the Exchange Ratio, PROVIDED that any
fractional Parent Shares resulting from such multiplication shall be
rounded down to the nearest share and, except with respect to any
options which are intended to qualify as "incentive stock options"
(as defined in section 422 of the Code ("ISOs")), Parent shall pay
an amount in cash to the holder of such Employee Stock Option equal
to the fair market value immediately prior to the Effective Time of
such fractional Parent Shares calculated based on the average
closing price on the New York Stock Exchange for the last five
trading days immediately preceding the day prior to the Effective
Time; and
(2) The exercise price per Parent Share under the new option
shall be equal to the aggregate exercise price of the original
option
42
<PAGE>
divided by the total number of full Parent Shares subject to the new
option (as determined under (1) immediately above), PROVIDED that
such exercise price shall be rounded up to the nearest cent.
The adjustment provided herein with respect to any ISOs shall be and is intended
to be effected in a manner that is consistent with section 424(a) of the Code.
The duration and other terms of the new option shall be the same as that of the
original option, except that all references to Company shall be deemed to be
references to Parent. Parent shall file with the SEC a registration statement
on Form S-8 (or other appropriate form) or a post-effective amendment to the
Registration Statement as promptly as practicable after the Effective Time for
purposes of registering all Parent Shares issuable after the Effective Time upon
exercise of the Employee Stock Options, and shall have such registration
statement or post-effective amendment become effective and comply, to the extent
applicable, with state securities or blue sky laws with respect thereto at the
Effective Time.
Section 7.9 PUBLIC ANNOUNCEMENTS. Parent and Sub, on the
one hand, and Company, on the other hand, agree that they will not issue any
press release or otherwise make any public statement or respond to any press
inquiry with respect to this Agreement or the transactions contemplated hereby
without the prior approval of the other party, except as may be required by law.
Section 7.10 CONTINUANCE OF EXISTING INDEMNIFICATION RIGHTS.
(a) For a period of six years from and after the Effective Time, Parent shall
indemnify, and advance expenses in matters that may be subject to
indemnification to, persons who served as directors and officers of Company or
any Company Subsidiary on or before the Effective Time with respect to
liabilities and claims (and related expenses) made against them resulting from
their service as such prior to the Effective Time with and subject to the
requirements and other provisions of Company's Certificate of Incorporation,
By-Laws and indemnification agreements in effect on the date of this Agreement
and applicable provisions of Law.
43
<PAGE>
(b) Parent shall cause to be maintained in effect for a period
ending not sooner than the sixth anniversary of the Effective Time directors'
and officers' liability insurance providing at least the same coverage with
respect to Company's officers and directors as the policies maintained on behalf
of directors and officers of Company as of the date hereof, and containing terms
and conditions which are no less advantageous, with respect to matters occurring
on or prior to the Effective Time (to the extent such insurance is available
with respect to such matters); PROVIDED, that in no event shall Parent be
required to expend to maintain or procure insurance coverage pursuant to this
Section 7.10 an amount per annum in excess of 200% of the current annual
premiums for the twelve-month period ended May 31, 1997 (the "Maximum Premium")
with respect to such insurance, or, if the cost of such coverage exceeds the
Maximum Premium, the maximum amount of coverage that can be purchased or
maintained for the Maximum Premium.
Section 7.11 EXPENSES. (a) Except as set forth in this
Section 7.11, whether or not the Merger is consummated all costs and expenses
incurred in connection with this Agreement and the transactions contemplated
hereby and thereby shall be paid by the party incurring such expenses, except
that those expenses incurred in connection with printing the Registration
Statement and the related Proxy Statement, as well as the filing fee relating to
the Registration Statement will be shared equally by Parent and Company.
Section 7.12 ADDITIONAL AGREEMENTS. Subject to the terms and
conditions herein provided, each of the parties hereto agrees to use all
reasonable efforts to take, or cause to be taken, all action and to do, or cause
to be done, all things necessary, proper or advisable under applicable laws and
regulations to consummate and make effective the transactions contemplated by
this Agreement, including using all reasonable efforts to obtain all necessary
waivers, consents and approvals and to effect all necessary registrations and
filings. In case at any time after the Effective Time any further action is
necessary or desirable to carry out the purposes of this Agreement, the proper
officers and/or directors of Parent, Sub and Company shall take all such
necessary action.
44
<PAGE>
Section 7.13 DIRECTORS OF PARENT. Parent agrees that
promptly after the Effective Time, Parent shall take such action as may be
necessary to enable Charles N. Martin for so long as Mr. Martin is an employee
of Parent, and Paul S. Levy and J. Peter Joseph, to be appointed to the Board of
Directors of Parent.
Section 7.14 CERTAIN BENEFITS. Parent and the Company agree
to take the actions described in Exhibit C hereto.
Section 7.15 REGISTRATION STATEMENT FOR SECURITIES ACT
AFFILIATES. Parent shall enter into the Registration Rights Agreements
substantially in the form attached as Exhibit B, providing for the registration
under the Securities Act covering the Parent Shares receivable by Securities Act
Affiliates (as therein defined), which registration statement will permit such
Securities Act affiliates and their partners, shareholders, beneficiaries or
other similar persons to whom they may distribute Parent Shares through a
dividend, partnership distribution or other similar distribution to sell such
Parent Shares.
Section 7.16 PUBLICATION OF POST MERGER FINANCIAL
RESULTS. Parent and Company agree to publish financial results covering at
least 30 days of combined operations as soon as practicable after the Effective
Time.
ARTICLE VIII
CONDITIONS TO CONSUMMATION OF THE MERGER
Section 8.1 CONDITIONS TO EACH PARTY'S OBLIGATION TO EFFECT
THE MERGER. The respective obligations of each party to effect the Merger
shall be subject to the satisfaction at or prior to the Effective Time of the
following conditions:
(a) Any waiting period applicable to the consummation of the
Merger under the HSR Act shall have expired or been terminated, and no action
shall have been instituted by the Department of Justice or Federal Trade
Commission challenging or seeking to enjoin the consumma-
45
<PAGE>
tion of this transaction, which action shall have not been withdrawn or
terminated.
(b) The Registration Statement shall have become effective
in accordance with the provisions of the Securities Act and no stop order
suspending the effectiveness of the Registration Statement shall be in effect
and no proceeding for such purpose shall be pending before or threatened by the
SEC.
(c) This Agreement and the transactions contemplated hereby
shall have been approved and adopted by the requisite vote of the stockholders
of Company and the issuance of the Parent Shares in connection with the Merger
shall have been authorized by the requisite vote of the stockholders of Parent,
in each case in accordance with applicable law.
(d) No preliminary or permanent injunction or other order by
any federal or state court in the United States which prohibits the consummation
of the Merger shall have been issued and remain in effect.
(e) Each of Company and Parent shall have obtained such
consents from third parties and government instrumentalities in addition to
pursuant to the HSR Act as shall be required and which are material to Parent
and Company and to consummation of the transactions contemplated hereby.
(f) Parent and Company shall have each received a letter of
KPMG Peat Marwick LLP dated the Effective Time, addressed to Parent and Company
stating that the Merger will qualify as a pooling of interests transaction under
Opinion No. 16 of the Accounting Principles Board.
Section 8.2 CONDITIONS TO OBLIGATION OF COMPANY TO EFFECT THE
MERGER. The obligation of Company to effect the Merger shall be subject to the
satisfaction at or prior to the Effective Time of the following additional
conditions:
(a) Each of Parent and Sub shall have performed in all
material respects its obligations under this Agreement required to be performed
by it at or prior to the Effective Time and the representations and warran-
46
<PAGE>
ties of Parent and Sub contained in this Agreement shall be true and correct in
all material respects at and as of the Effective Time as if made at and as of
such time, except as contemplated by this Agreement, and Company shall have
received a certificate of the Chairman of the Board, the President or an
Executive Vice President of Parent as to the satisfaction of this condition.
(b) Company shall have received an opinion of Debevoise &
Plimpton, counsel to Company, in form and substance reasonably satisfactory to
Company, dated on or about the date of the mailing of the Proxy Statement to
stockholders, which opinion shall be reconfirmed as of the Effective Time,
substantially to the effect that the Merger will constitute a reorganization for
Federal income tax purposes within the meaning of section 368(a) of the Code.
In rendering such opinion Debevoise & Plimpton may require and rely upon
representations contained in certificates of officers of Parent and Company and
others, as well as certificates of stockholders who beneficially own five
percent or more of the votes or value of any class of stock of Company and
others.
(c) Company shall have received an opinion from Scott M.
Brown, Senior Vice President, General Counsel and Secretary of Parent, or from
Skadden, Arps, Slate, Meagher & Flom, special counsel to Parent, dated the
Effective Time, to the effect that:
(i) Each of Parent and Sub is a corporation validly existing
under the laws of the state of its incorporation.
(ii) Each of Parent and Sub has the corporate power to enter
into this Agreement and the Registration Rights Agreements and to
consummate the transactions contemplated hereby; and the execution
and delivery of this Agreement and the Registration Rights
Agreements and the consummation of the transactions contemplated
hereby have been duly authorized by requisite corporate action taken
on the part of Parent and Sub.
(iii) This Agreement has been executed and delivered by each
of Parent and Sub and is a valid and binding obligation of each of
Par-
47
<PAGE>
ent and Sub, enforceable against Parent and Sub in accordance
with its terms, except (A) as may be limited by or subject to any
bankruptcy, insolvency, reorganization, moratorium or other similar
laws now or hereafter in effect relating to creditors' rights, and
(B) that the remedies of specific performance, injunction and other
forms of equitable relief are subject to certain tests of equity
jurisdiction, equitable defenses and the discretion of the court
before which any proceeding therefor may be brought. Each of the
Registration Rights Agreements has been executed and delivered by
Parent.
(iv) Neither the execution and delivery of this Agreement by
Parent and Sub, nor the consummation by Parent and Sub of the
transactions contemplated hereby, will violate the charter documents
or By-Laws of Parent or Sub or, to the best knowledge of such
counsel, and except as set forth in the Parent Disclosure Letter
without having made any independent investigation, will constitute a
violation of or a default under (except for any such violation or
default as to which requisite waivers or consents either shall have
been obtained by Parent or Sub, as the case may be, prior to the
Effective Time or shall have been waived by Company in writing) any
material contract, agreement or instrument to which Parent or Sub,
as the case may be, is subject and which has been specifically
identified to such counsel by Parent or Sub, as the case may be, in
connection with rendering such opinion.
(v) The Parent Shares to be issued in connection with the
transactions contemplated by this Agreement are duly authorized and
reserved for issuance and, when issued as contemplated by this
Agreement, will be validly issued, fully paid and nonassessable.
(vi) While such counsel assumes no responsibility for any
event, occurrence or statement of fact relating to Parent, or for
the accuracy completeness or fairness of any
48
<PAGE>
statements contained in or omitted from the Registration Statement
or the Proxy Statement and while such counsel expresses no opinion
as to the financial statements or other financial or statistical
data contained therein with respect to information in the
Registration Statement or the Proxy Statement relating to Parent,
the Registration Statement complies as to form in all material
respects with the requirements of the Securities Act, and the
applicable rules and regulations promulgated thereunder; and
In addition, in such opinion, such counsel shall state
that such counsel has no reason to believe that the Registration
Statement or the Proxy Statement, as amended or supplemented to the
date of such opinion, contains any untrue statement of a material
fact or omits to state any material fact required to be stated
therein or necessary to make the statements therein (in the light of
the circumstances in which they were made) not misleading, except
such counsel expresses no belief as to the financial statements or
other financial or statistical data contained in the Registration
Statement or the Proxy Statement.
As to any matter in such opinion which involves matters of
fact or matters relating to laws other than federal securities or Nevada or
Delaware corporate law, such counsel may rely upon the certificates of officers
and directors of Parent and Sub and of public officials and opinions of local
counsel, reasonably acceptable to Company.
(d) The listing application referred to in Section 7.3(b)
shall have been approved by the New York Stock Exchange.
(e) Parent shall have executed and delivered the
Registration Rights Agreements, substantially in the form of Exhibit B hereto.
Section 8.3 CONDITIONS TO OBLIGATIONS OF PARENT AND SUB TO
EFFECT THE MERGER. The obligations of Parent and Sub to effect the Merger
shall be subject to
49
<PAGE>
the satisfaction at or prior to the Effective Time of the following additional
conditions:
(a) Company shall have performed in all material respects
its obligations under this Agreement required to be performed by it at or prior
to the Effective Time and the representations and warranties of Company
contained in this Agreement shall be true and correct in all material respects
at and as of the Effective Time as if made at and as of such time except as
contemplated by this Agreement, and Parent and Sub shall have received a
Certificate of the Chairman of the Board, the President or an Executive Vice
President of Company as to the satisfaction of this condition.
(b) Parent and Sub shall have received an opinion of
Skadden, Arps, Slate, Meagher & Flom, counsel to Parent and Sub in form and
substance reasonably satisfactory to Parent and Sub, dated on or about the date
of the mailing of the Proxy Statement to stockholders, which opinion shall be
reconfirmed as of the Effective Time, substantially to the effect that the
Merger will constitute a reorganization for Federal income tax purposes within
the meaning of section 368(a) of the Code. In rendering such opinion, Skadden,
Arps, Slate, Meagher & Flom may require and rely upon representations contained
in certificates of officers of Parent, Sub, Company and others as well as
certificates of shareholders who beneficially own five percent or more of the
votes or value of any class of stock of Company and others.
(c) Parent and Sub shall have received an opinion from
Ronald P. Soltman, Senior Vice President and General Counsel of Company or
Debevoise & Plimpton, special counsel for Company, dated the Effective Time, to
the effect that:
(i) Company is a corporation validly existing under the laws
of the State of Delaware.
(ii) Company has the corporate power to enter into this
Agreement and to consummate the transactions contemplated hereby;
and the execution and delivery of this Agreement and the
consummation of the transactions contemplated
50
<PAGE>
hereby have been duly authorized by requisite corporate action taken
on the part of Company.
(iii) This Agreement has been executed and delivered by
Company and is a valid and binding obligation of Company,
enforceable against Company in accordance with its terms, except (A)
as may be limited by or subject to any bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in
effect relating to creditors' rights, and (B) that the remedies of
specific performance, injunction and other forms of equitable relief
are subject to certain tests of equity jurisdiction, equitable
defenses and the discretion of the court before which any proceeding
therefor may be brought.
(iv) Neither the execution and delivery of this Agreement by
Company, nor the consummation by Company of the transactions
contemplated hereby, will violate the Certificate of Incorporation
or By-Laws of Company or, to the best knowledge of such counsel, and
except as set forth in the Company Disclosure Letter without having
made any independent investigation, will constitute a violation of
or a default under (except for any such violation or default as to
which requisite waivers or consents either shall have been obtained
by Company prior to the Effective Time or shall have been waived by
Parent and Sub in writing) any material contract, agreement or
instrument to which Company or any of the Company Subsidiaries is
subject and which has been specifically identified to such counsel
by Company in connection with rendering such opinion.
(v) While such counsel assumes no responsibility for any
event, occurrence or statement of fact relating to Company, or for
the accuracy, completeness or fairness of any statements contained
in or omitted from the Registration Statement or the Proxy
Statement, and while such counsel expresses no opinion as to the
financial statements or other financial or statistical data
contained therein, with re-
51
<PAGE>
spect to information in the Registration Statement or the Proxy
Statement relating to Company, the Proxy Statement complies as to
form in all material respects with the requirements of the Exchange
Act, and the applicable rules and regulations promulgated
thereunder.
In addition, in such opinion, such counsel shall state
that such counsel has no reason to believe that the Registration
Statement or the Proxy Statement, as amended or supplemented to the
date of such opinion, contains any untrue statement of a material
fact or omits to state any material fact required to be stated
therein or necessary to make the statements therein (in the light of
the circumstances in which they were made) not misleading, except
such counsel expresses no belief as to the financial statements or
other financial or statistical data contained in the Registration
Statement or the Proxy Statement.
As to any matter in such opinion which involves matters of fact or
matters relating to laws other than federal securities or Delaware corporate
law, such counsel may rely upon the certificates of officers and directors of
Company and of public officials and opinions of local counsel, reasonably
acceptable to Parent and Sub.
(d) Parent and Sub shall have received a letter from Ernst &
Young, LLP, Company's independent accountants, dated the Effective Time and
addressed to Parent and Sub, in form and substance reasonably satisfactory to
Parent in connection with the procedures undertaken by them with respect to the
financial statements and other financial information of Company and Company
Subsidiaries contained in the Registration Statement and the other matters
contemplated by the AICPA Statement No. 72 and customarily included in comfort
letters relating to transactions similar to the Merger.
ARTICLE IX
TERMINATION, AMENDMENT AND WAIVER
Section 9.1 TERMINATION. This Agreement may be terminated
at any time before the Effective Time,
52
<PAGE>
either before or after the approval of the stockholders of Company shall have
been obtained, in each case as authorized by the respective Board of Directors
of Parent or Company:
(a) By mutual written consent of the parties;
(b) By either Parent or Company if the Merger shall not have
been consummated on or before May 31, 1997 (the "Termination Date"); PROVIDED,
HOWEVER, that the right to terminate this Agreement under this Section 9.1(b)
shall not be available to any party whose failure to fulfill any obligation
under this Agreement has been the cause of, or resulted in, the failure of the
Effective Time to occur on or before the Termination Date; and PROVIDED,
FURTHER, that if on the Termination Date the conditions to the Closing set
forth in Sections 8.1(a) or (e) shall not have been fulfilled, but all other
conditions to the Closing shall be fulfilled or shall be capable of being
fulfilled, then the Termination Date shall be extended to July 31, 1997.
(c) By either Parent or Company if a court of competent
jurisdiction or governmental, regulatory or administrative agency or commission
shall have issued an order, decree or ruling or taken any other action (which
order, decree or ruling the parties shall use their commercially reasonable
efforts to lift), in each case permanently restraining, enjoining or otherwise
prohibiting the transactions contemplated by this Agreement, and such order,
decree, ruling or other action shall have become final and nonappealable;
(d) (i) By Parent, if there shall have been any material
adverse change in the business, financial condition, results of operations,
properties, assets or liabilities of the Company and the Company Subsidiaries
taken as a whole (other than any change relating to the United States economy in
general or to the United States investor-owned hospital business in general)
since the date hereof which is not cured within 30 days after notice thereof to
the Company, or if the Company shall be in material breach of Section 7.2 or
Section 7.4 and, in the case of Section 7.4 only, such breach has not been cured
within 30 days' notice thereof to the Company; or (ii) by Company, if there
shall have been any material
53
<PAGE>
adverse change in the business, financial condition, results of operations,
properties, assets or liabilities of Parent and the Parent Subsidiaries taken as
a whole (other than any change relating to the United States economy in general
or to the United States investor-owned hospital business in general) since the
date hereof which is not cured within 30 days after notice thereof to the
Parent, or if Parent shall be in material breach of Section 7.2 or Section 7.4
and, in the case of Section 7.4 only, such breach has not been cured within 30
days' notice thereof to Parent;
(e) By either Parent or Company if the Board of Directors of
the other (i) shall withdraw or modify (or publicly announce an intention to
withdraw or modify) in any adverse manner its approval or recommendation of this
Agreement or the Merger or, in the case of the Board of Directors of Parent, the
authorization of the issuance of Parent Shares pursuant to the Merger Agreement,
(ii) shall approve or recommend any Acquisition Proposal, other than by a party
or an affiliate thereof, or (iii) shall resolve to take any of the actions
specified in clause (i) or (ii) above;
(f) By either Parent or Company if any of the required
approvals of the stockholders of Company or of Parent shall fail to have been
obtained at a duly held stockholders meeting of either such company, including
any adjournments thereof;
(g) By either Parent or Company, prior to the approval of
this Agreement by the stockholders of such party, upon five days' prior written
notice to the other, if, as a result of an Acquisition Proposal (as defined in
Section 7.2 hereof) received by such party from a person other than a party to
this Agreement or any of its affiliates, the Board of Directors of such party
determines in good faith that the members' fiduciary obligations under
applicable law require that such Acquisition Proposal be accepted; PROVIDED,
HOWEVER, that (i) the Board of Directors of such party shall have determined
in good faith, after considering applicable provisions of state law and after
giving effect to all concessions, if any, which have been offered by the other
party pursuant to clause (ii) below, on the basis of oral or written advice of
outside counsel, that such action is required by the members' fiduciary
obligations under
54
<PAGE>
applicable law, and (ii) prior to any such termination, such party shall, and
shall cause its respective financial and legal advisors to, negotiate with the
other party to this Agreement to make such adjustments in the terms and
conditions of this Agreement as would enable such party to proceed with the
transactions contemplated hereby; PROVIDED, HOWEVER, that no termination
shall be effective pursuant to Sections 9.1(e), (f) or (g) under circumstances
in which a Company Termination Fee (as defined below) or a Parent Termination
Fee (as defined below) is payable by the terminating party under Section 9.3(b)
or (c), as the case may be, unless concurrently with such termination, such
termination fee is paid in full by the terminating party in accordance with the
provisions of Sections 9.3(b) or (c), as the case may be;
(h) By Parent if the Board of Directors of Company shall
have failed to take any of the actions contemplated by Section 7.4(a) as a
result of the exercise of its rights under Section 7.4(d); or
(i) By Company if the Board of Directors of Parent shall
have failed to take any of the actions contemplated by Section 7.4(b) as a
result of the exercise of its rights under Section 7.4(d).
Section 9.2 This Section Intentionally Left Blank.
Section 9.3 EFFECT OF TERMINATION. (a) In the event of
termination of this Agreement as provided in Section 9.1 hereof, and subject to
the provisions of Section 10.1 hereof, this Agreement shall forthwith become
void and there shall be no liability on the part of any of the parties, except
(i) as set forth in this Section 9.3 and in Sections 7.1, 7.11 and 10.2 hereof,
and (ii) nothing herein shall relieve any party from liability for any willful
breach hereof.
(b) If this Agreement is terminated (i) by Parent pursuant
to Section 9.1(e) hereof, (ii) by Parent or Company pursuant to Section 9.1(f)
hereof because of the failure to obtain the required approval from the Company
stockholders and at the time of such termination or prior to the meeting of
Company's stockholders there shall have been an offer or proposal for, an
announcement of any intention with respect to (including,
55
<PAGE>
without limitation, the filing of a statement of beneficial ownership on
Schedule 13D discussing the possibility of or reserving the right to engage in),
or any agreement with respect to, a transaction that would constitute an
Alternative Transaction (as defined below) involving Company or any of the
Company Subsidiaries (whether or not such offer, proposal, announcement or
agreement shall have been rejected or shall have been withdrawn prior to the
time of such termination or of the meeting), (iii) by Company pursuant to
Section 9.1(g) hereof, (iv) by Parent as a result of Company's material breach
of Section 7.2 or 7.4 hereof which, in the case of Section 7.4 only, is not
cured within 30 days after notice thereof to Company, or (v) by Parent pursuant
to Section 9.1(h) hereof, Company shall pay to Parent a termination fee of $50
million (the "Company Termination Fee").
(c) If this Agreement is terminated (i) by Company pursuant
to Sections 9.1(e) hereof or (ii) by Parent or Company pursuant to Section
9.1(f) hereof because of the failure to obtain the required approval from the
Parent stockholders and at the time of such termination or prior to the meeting
of Parent's stockholders there shall have been an offer or proposal for, an
announcement of any intention with respect to (including, without limitation,
the filing of a statement of beneficial ownership on Schedule 13D discussing the
possibility of or reserving the right to engage in), any agreement with respect
to, a transaction that would constitute an Alternative Transaction involving
Parent or any of the Parent Subsidiaries (whether or not such offer, proposal,
announcement or agreement shall have been rejected or shall have been withdrawn
prior to the time of such termination or of the meeting), (iii) by Parent
pursuant to Section 9.1(g) hereof, (iv) by the Company as a result of Parent's
material breach of Section 7.2 or 7.4 hereof which, in the case of Section 7.4
only, is not cured within 30 days after notice thereof to Parent, or (v) by the
Company pursuant to Section 9.1(i) hereof, Parent shall pay to Company a
termination fee of $50 million (the "Parent Termination Fee").
(d) Each termination fee payable under Sections 9.3(b) and
(c) above shall be payable in cash.
(e) Parent and Company agree that the agreements contained
in Sections 9.3(b) and (c) above are
56
<PAGE>
an integral part of the transaction contemplated by this Agreement and
constitute liquidated damages and not a penalty. If one party fails to promptly
pay to the other any fee due under such Sections 9.3(b) and (c), the defaulting
party shall pay the costs and expenses (including legal fees and expenses) in
connection with any action, including the filing of any lawsuit or other legal
action, taken to collect payment, together with interest on the amount of any
unpaid fee at the publicly announced prime rate of Citibank, N.A. from the date
such fee was required to be paid.
(f) As used herein, "Alternative Transaction" means any of
(i) a transaction or series of transactions pursuant to which any person (or
group of persons) other than Parent or its subsidiaries and other than Company
and its subsidiaries (a "Third Party") acquires or would acquire, directly or
indirectly, beneficial ownership (as defined in Rule 13d-3 under the Exchange
Act) of more than 20% of the outstanding shares of Parent or Company, as the
case may be, whether from Parent or Company or pursuant to a tender offer or
exchange offer or otherwise, (ii) any acquisition or proposed acquisition of
Parent or any of its significant subsidiaries or Company or any of its
significant subsidiaries, as the case may be, by a merger or other business
combination (including any so-called "merger of equals" and whether or not
Parent or any of its significant subsidiaries or Company or any of its
significant subsidiaries, as the case may be, is the entity surviving any such
merger or business combination) or (iii) any other transaction pursuant to which
any Third Party acquires or would acquire, directly or indirectly, control of
assets (including for this purpose the outstanding equity securities of
subsidiaries of Parent or Company, as the case may be, and any entity surviving
any merger or combination including any of them) of Parent or any of its
subsidiaries or Company or any of its subsidiaries for consideration equal to
20% or more of the fair market value of all of the shares of Parent Common Stock
or all of the Company Shares, as the case may be, on the date prior to the date
hereof.
Section 9.4 AMENDMENT. This Agreement may be amended by the
parties pursuant to a writing adopted by action taken by all of the parties at
any time before the Effective Time; PROVIDED, HOWEVER, that, after approval
57
<PAGE>
by the stockholders of Company or Parent, whichever shall occur first, no
amendment may be made which would (a) alter or change the amount or kinds of
consideration to be received by the holders of Shares upon consummation of the
Merger, (b) alter or change any term of the Certificate of Incorporation of
Company or the Articles of Incorporation of Parent, or (c) alter or change any
of the terms and conditions of this Agreement if such alteration or change would
adversely affect the holders of any class or series of securities of Company or
Parent. This Agreement may not be amended except by an instrument in writing
signed by the Parties.
Section 9.5 WAIVER. At any time before the Effective Time, any
party hereto may (a) extend the time for the performance of any of the
obligations or other acts of the other parties, (b) waive any inaccuracies in
the representations and warranties contained herein or in any document delivered
pursuant hereto and (c) waive compliance with any of the agreements or
conditions contained herein. Any agreement on the part of a party to any such
extension or waiver shall be valid only as against such party and only if set
forth in an instrument in writing signed by such party.
ARTICLE X
GENERAL PROVISIONS
Section 10.1 SURVIVAL OF REPRESENTATIONS, WARRANTIES AND
AGREEMENTS. No representations, warranties or agreements contained herein
shall survive beyond the Effective Time, except that the representations,
warranties or agreements contained in Sections 3.1, 3.2, 3.3, 3.4, 3.5, 3.6,
7.1, 7.9, 7.10, 7.11, 7.12, 7.13, 7.14, 7.15, 7.16 and 10.2 hereof shall survive
beyond the Effective Time.
Section 10.2 BROKERS. Company represents and warrants that,
(i) except for Merrill Lynch & Co., its financial advisors, no broker, finder or
financial advisor is entitled to any brokerage, finder's or other fee or
commission in connection with the Merger or the transactions contemplated by
this Agreement based upon arrangements made by or on behalf of Company and (ii)
Company's fee arrangements with Merrill Lynch & Co., have been disclosed to
Parent and Sub. Each of Parent and Sub
58
<PAGE>
represents and warrants that, (i) except for DLJ, its financial advisor, no
broker, finder or financial advisor is entitled to any brokerage, finder's or
other fee or commission in connection with the Merger or the transactions
contemplated by this Agreement based upon arrangements made by or on behalf of
Parent or Sub and (ii) Parent's fee arrangements with DLJ, have been disclosed
to Company.
Section 10.3 NOTICES. All notices, claims, demands and other
communications hereunder shall be in writing and shall be deemed duly given or
made as follows: (a) if delivered personally, upon receipt; (b) if sent by
registered or certified mail (postage prepaid, return receipt requested), upon
receipt; (c) if sent by reputable overnight air courier (such as Federal Express
or DHL), two business days after mailing; or (d) if sent by facsimile
transmission, with a copy mailed as provided in clauses (b) or (c) above, when
transmitted and receipt is confirmed by telephone. Such notices, claims,
demands and other communications shall be sent to the respective parties at the
following addresses (or at such other address for a party as shall be specified
by like notice):
(a) If to Parent, to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue
Suite 3400
Los Angeles, California 90071
Attention: Brian J. McCarthy
59
<PAGE>
(b) if to Sub, to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue
Suite 3400
Los Angeles, California 90071
Attention: Brian J. McCarthy
(c) if to Company, to:
3401 West End Avenue
Nashville, Tennessee 37203
Attention: General Counsel
with a copy to:
Debevoise & Plimpton
875 Third Avenue
New York, NY 10022
Attention: Alan H. Paley
Section 10.4 DESCRIPTIVE HEADINGS. The headings contained in
this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.
Section 10.5 ENTIRE AGREEMENT; ASSIGNMENT. This Agreement
(including the Exhibits, Schedules and other documents and instruments referred
to herein) together with the Stock Option Agreements (a) constitutes the entire
agreement and supersedes all other prior agreements and understandings, both
written and oral among the parties or any of them, with respect to the
60
<PAGE>
subject matter hereof; (b) except for the provisions of Section 7.10 hereof, is
not intended to confer upon any other person any rights or remedies hereunder;
and (c) shall not be assigned by operation of law or otherwise, provided that
Parent or Sub may assign its rights and obligations hereunder to a direct or
indirect subsidiary of Parent, but no such assignment shall relieve Parent or
Sub of its obligations hereunder.
Section 10.6 SEVERABILITY. If any provision of this
Agreement or the application of any such provision shall be held invalid,
illegal or unenforceable in any respect by a court of competent jurisdiction,
such invalidity, illegality or unenforceability shall not affect any other
provision hereof. In lieu of any such invalid, illegal or unenforceable
provision, the parties hereto intend that there shall be added as part of this
Agreement a provision as similar in terms to such invalid, illegal or
unenforceable provision as may be possible and be valid, legal and enforceable.
Section 10.7 GOVERNING LAW. This Agreement shall be governed
by and construed in accordance with the laws of the State of Delaware without
giving effect to the provisions thereof relating to conflicts of law.
Section 10.8 SPECIFIC PERFORMANCE. The parties hereto agree
that irreparable damage would occur in the event any of the provisions of this
Agreement were not performed in accordance with the terms hereof and that the
parties shall be entitled to specific performance of the terms hereof, in
addition to any other remedy at law or equity.
Section 10.9 COUNTERPARTS. This Agreement may be executed in
two or more counterparts, each of which shall be deemed to be an original but
all of which shall constitute one and the same agreement.
61
<PAGE>
IN WITNESS WHEREOF, each of the parties hereto has caused this
Agreement to be executed on its behalf by its officers thereunto duly
authorized, all as of the date first above written.
TENET HEALTHCARE CORPORATION
By: /s/ Jeffrey C. Barbakow
--------------------------------------------
Name: Jeffrey C. Barbakow
Title: Chairman and Chief Executive Officer
Attest:
/s/ Patricia Campana
- ----------------------------------
Name: Patricia Campana
Title: Senior Executive Assistant
OHC ACQUISITION CO.
By: /s/ Jeffrey C. Barbakow
-------------------------------------------
Name: Jeffrey C. Barbakow
Title: Chairman and Chief Executive Officer
Attest:
/s/ Patricia Campana
- -----------------------------
Name: Patricia Campana
Title: Senior Vice President
ORNDA HEALTHCORP
By: /s/ Charles N. Martin, Jr.
-------------------------------------------
Name: Charles N. Martin, Jr.
Title: President and Chief Executive Officer
Attest:
/s/ Ronald P. Soltman
- -----------------------------
Name: Ronald P. Soltman
Title: Senior Vice President
<PAGE>
EXHIBIT A-1
FORM OF
STOCKHOLDER VOTING AGREEMENT
THIS STOCKHOLDER VOTING AGREEMENT (this "Agreement") is made and
entered into as of this 17th day of October, 1996, by and among Tenet Healthcare
Corporation, a Nevada corporation ("Acquiror"), and the stockholder named on the
signature page hereto ("Stockholder"). On the date hereof the Stockholder
Beneficially Owns (as defined in Section 11(a) hereof) the number of shares of
common stock, par value $.01 per share (the "Company Shares"), of OrNda
Healthcorp, a Delaware corporation ("Company"), set forth next to the
Stockholder's name on the signature page hereto.
WHEREAS, Acquiror and the Company concurrently herewith are entering
into an Agreement and Plan of Merger, dated as of the 16th day of October, 1996
(the "Merger Agreement"), providing for, among other things, the merger (the
"Merger") of a wholly owned subsidiary of Acquiror with and into the Company,
with the Company as the surviving corporation; and
WHEREAS, as an essential condition and inducement to Acquiror's
execution of the Merger Agreement, Acquiror has requested that the Stockholder
agree, and the Stockholder has agreed, to vote (or consent with regard to) all
Company Shares as to which the Stockholder has voting power in favor of the
Merger as provided herein.
NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements contained herein and in
the Merger Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto, intending
to be legally bound hereby, agree as follows:
1. VOTING RIGHTS.
VOTING AGREEMENT. The Stockholder agrees that, at any time the
Merger Agreement remains in effect, it will vote all Stockholder Shares (as
defined below) on matters as to which the Stockholder is entitled to vote
1
<PAGE>
at any annual, special or other meeting of the Stockholders of the Company, and
at any adjournment or adjournments thereof, or by written consent without a
meeting with respect to all Stockholder Shares as follows: (i) in favor of
approval and adoption of the Merger Agreement, the terms thereof and each of the
other transactions contemplated by the Merger Agreement; and (ii) against any
action or agreement (other than the Merger Agreement or the transactions
contemplated thereby) that would impede, interfere with, delay, postpone or
attempt to discourage the Merger, including without limitation: (A) any
extraordinary corporate transaction, such as a merger, consolidation or other
business combination involving the Company and its subsidiaries; or (B) a sale
or transfer of a material amount of assets of the Company and its subsidiaries
or a reorganization, recapitalization or liquidation of the Company and its
subsidiaries.
"Stockholder Shares" shall mean the shares of Company capital stock
(including without limitation the Company Shares) Beneficially Owned by such
Stockholder as of the date hereof, or Beneficially Owned by such Stockholder at
any time hereafter (including, without limitation, by way of exercise of options
or by way of dividend, distribution, exchange, merger, consolidation,
recapitalization, reorganization, stock split, grant of proxy or otherwise) by
such Stockholder (as adjusted as set forth herein). The Stockholder hereby
agrees to promptly notify Acquiror of the number of any new Stockholder Shares
acquired by the Stockholder, if any, after the date hereof. In the event of any
change in the Company Shares by reason of a stock dividend, stock split, split
up, recapitalization, combination, exchange of shares or similar transaction,
the type and number of shares or securities that constitute Stockholder Shares
hereunder shall be adjusted appropriately.
2. TERMINATION.
a. This Agreement shall terminate upon the earlier to occur of
(i) the termination of the Merger Agreement in accordance with its terms
pursuant to Section 9.1 thereof, or (ii) the Effective Time (as defined in the
Merger Agreement).
b. Upon termination, this Agreement shall have no further force
or effect, except for Section 7
2
<PAGE>
which shall continue to apply to any case, action or proceeding relating to the
enforcement of this Agreement.
3. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER. The
Stockholder hereby represents and warrants to Acquiror as follows:
a. DUE AUTHORIZATION. The Stockholder has the legal capacity
and all necessary power and authority to execute and deliver this Agreement and
to consummate the transactions contemplated hereby. As of the date hereof, the
Stockholder Beneficially Owns the number of the Stockholder Shares listed on the
signature page hereof and specified as so owned with no restrictions on the
voting rights (except as specified in this Agreement) or rights of disposition
pertaining thereto, which constitute all Company Shares Beneficially Owned by
such Stockholder. Assuming this Agreement has been duly and validly authorized,
executed and delivered by Acquiror, this Agreement constitutes a valid and
binding agreement of the Stockholder, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency, moratorium or
other similar laws affecting creditors' rights generally or by the principles
governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by the Stockholder of the transactions
contemplated hereby will conflict with or constitute a violation of or default
under any contract, commitment, agreement, arrangement or restriction of any
kind to which the Stockholder is a party or by which the Stockholder is bound.
4. REPRESENTATIONS AND WARRANTIES OF ACQUIROR. Acquiror hereby
represents and warrants to the Stockholder as follows:
a. DUE AUTHORIZATION. Acquiror has the requisite corporate
power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly
authorized by all necessary corporate action on the part of Acquiror and this
Agreement has been duly executed by a duly authorized officer of Acquiror.
Assuming this Agreement has been duly and
3
<PAGE>
validly executed and delivered by the Stockholder, this Agreement constitutes a
valid and binding agreement of Acquiror, enforceable against it in accordance
with its terms, except as enforceability may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting creditors' rights
generally or by the principles governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by Acquiror of the transactions contemplated
hereby will conflict with or constitute a violation of or default under any
contract, commitment, agreement, arrangement or restriction of any kind to which
Acquiror is a party or by which Acquiror is bound.
5. NO TRANSFER. Except as provided in this Agreement or the
Merger Agreement, the Stockholder hereby agrees, without the prior written
consent of Acquiror, except pursuant to the terms hereof, not to (i) sell,
transfer, assign, pledge or otherwise dispose of or hypothecate any of his
Stockholder Shares other than to a "Permitted Transferee" (as defined below) and
except that the Stockholder may transfer Stockholder Shares to Company in order
to pay the exercise price or withholding taxes applicable in connection with the
exercise of employee stock options ; (ii) grant any proxies, deposit any
Stockholder Shares into a voting trust or enter into a voting agreement with
respect to any Stockholder Shares; (iii) take any action that would make any
representation or warranty of the Stockholder contained herein untrue or
incorrect or have the effect of preventing or disabling the Stockholder from
performing his obligations under this Agreement; or (iv) take any action which
would jeopardize the treatment of Acquiror's acquisition of Company as a pooling
of interests for accounting purposes. For purposes of this Agreement,
"Permitted Transferee" shall mean an organization that qualifies for treatment
under section 501(c)(3) of the Internal Revenue Code of 1986, as amended. Any
Permitted Transferee of Stockholder Shares must become a party to this Agreement
and any purported transfer of Stockholder Shares to a person or entity that has
not become a party hereto shall be null and void. In furtherance of this
Agreement, concurrently herewith the Stockholder shall and hereby does authorize
the Company's counsel to notify the Company's transfer agent that there is a
stop transfer order with
4
<PAGE>
respect to all of the Stockholder Shares (and that this Agreement places limits
on the voting and transfer of such shares).
6. ENTIRE AGREEMENT. Other than the Merger Agreement
(including the exhibits, schedules and other documents and instruments referred
to therein), this Agreement (including the documents and instruments referred to
herein) (a) constitutes the entire agreement among the parties hereto with
respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties, or any of them,
with respect to the subject matter hereof; (b) shall not be assigned by
operation of law or otherwise without the prior written consent of the other
parties hereto, except that Acquiror may assign, in its sole discretion, all or
any of its rights, interests and obligations hereunder to any direct or indirect
wholly owned subsidiary of Acquiror; (c) shall not be amended, altered or
modified in any manner whatsoever, except by a written instrument executed by
the parties hereto; and (d) shall be governed in all respects, including
validity, interpretation and effect, by the laws of the State of Delaware
(without giving effect to the provisions thereof relating to conflicts of law).
7. REMEDIES. The parties acknowledge that it would be
impossible to fix money damages for violations of this Agreement and that such
violations will cause irreparable injury for which adequate remedy at law is not
available and, therefore, this Agreement must be enforced by specific
performance or injunctive relief. The parties hereto agree that any party may,
in its sole discretion, apply to any court of competent jurisdiction for
specific performance or injunctive or such other relief as such court may deem
just and proper in order to enforce this Agreement or prevent any violation
hereof and, to the extent permitted by applicable law, each party waives any
objection or defense to the imposition of such relief. Nothing herein shall be
construed to prohibit any party from bringing any action for damages in addition
to an action for specific performance or an injunction for a breach of this
Agreement.
8. LEGENDS ON CERTIFICATES. Until such time as this Agreement
shall terminate pursuant to Section 2
5
<PAGE>
hereof, all certificates representing Stockholder Shares shall bear the
following legend:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
OF A STOCKHOLDER VOTING AGREEMENT, DATED AS OF OCTOBER 17, 1996, BY AND
BETWEEN TENET HEALTHCARE CORPORATION AND THE STOCKHOLDER. ANY TRANSFEREE
OF THESE SHARES TAKES SUBJECT TO THE TERMS OF SUCH AGREEMENT, COPIES OF
WHICH ARE ON FILE AT THE OFFICES OF TENET HEALTHCARE CORPORATION.
9. PARTIES IN INTEREST. Subject to the provisions of Sections
5 and 6(b) hereof, this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors,
permitted assigns, heirs, executors, administrators and other legal
representatives, and nothing in this Agreement, express or implied, is intended
to confer upon any other person any rights or remedies of any nature whatsoever
under or by reason of this Agreement.
10. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same agreement.
11. DEFINITIONS. The following terms shall have the following
respective meanings:
a. "Beneficial Owner" has the meaning set forth in Rule 13d-3 of
the Rules and Regulations to the Exchange Act, and "Beneficially Owned" and
"Beneficially Owns" shall have correlative meanings; PROVIDED, HOWEVER, that
for purposes of this Agreement a person shall be deemed to be the Beneficial
Owner of Company Shares that may be acquired pursuant to the exercise of an
option or other right regardless of when such option is exercisable.
b. A "person" means a corporation, association, partnership,
joint venture, organization, business, individual, trust, estate or any other
entity or group (within the meaning of Section 13(d)(3) of the Exchange Act).
6
<PAGE>
12. NOTICES. All notices and other communications hereunder
shall be in writing and shall be deemed given if delivered personally,
telecopied (which is confirmed) or mailed by registered or certified mail
(return receipt requested) to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):
(a) If to Acquiror to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue, Suite 3400
Los Angeles, California 90071
Telecopy No. (213) 687-5600
Attention: Brian J. McCarthy
(b) If to the Stockholder, to the address set forth on the
signature page, hereto.
13. INTERPRETATION. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
14. SEVERABILITY. Any term or provision of this Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction. If any provision of
this Agreement is so broad as to be unenforceable, the provision shall be
interpreted to be only so broad as is enforceable.
15. FURTHER ASSURANCES. The Stockholder further agrees to
execute all additional writings, con-
7
<PAGE>
sents and authorizations as may be reasonably requested by Acquiror to evidence
the agreements herein.
8
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
TENET HEALTHCARE CORPORATION
By
------------------------------------
Name:
Title:
CHARLES N. MARTIN
By
------------------------------------
Name:
Title:
---------------------------------------
No. of Shares Beneficially Owned:
Address for Notices:
3401 West End Avenue
Nashville, Tennessee 37203
<PAGE>
EXHIBIT A-2
FORM OF
STOCKHOLDER VOTING AGREEMENT
THIS STOCKHOLDER VOTING AGREEMENT (this "Agreement") is made and
entered into as of this 17th day of October, 1996, by and among Tenet Healthcare
Corporation, a Nevada corporation ("Acquiror"), and the stockholder named on the
signature page hereto ("Stockholder"). On the date hereof the Stockholder
Beneficially Owns (as defined in Section 11(a) hereof) the number of shares of
common stock, par value $.01 per share (the "Company Shares"), of OrNda
Healthcorp, a Delaware corporation ("Company"), set forth next to the
Stockholder's name on the signature page hereto.
WHEREAS, Acquiror and the Company concurrently herewith are entering
into an Agreement and Plan of Merger, dated as of the 16th day of October, 1996
(the "Merger Agreement"), providing for, among other things, the merger (the
"Merger") of a wholly owned subsidiary of Acquiror with and into the Company,
with the Company as the surviving corporation; and
WHEREAS, as an essential condition and inducement to Acquiror's
execution of the Merger Agreement, Acquiror has requested that the Stockholder
agree, and the Stockholder has agreed, to vote (or consent with regard to) all
Company Shares as to which the Stockholder has voting power in favor of the
Merger as provided herein.
NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements contained herein and in
the Merger Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto, intending
to be legally bound hereby, agree as follows:
1. VOTING RIGHTS.
VOTING AGREEMENT. The Stockholder agrees that, at any time the
Merger Agreement remains in effect, it will vote all Stockholder Shares (as
defined below) on matters as to which the Stockholder is entitled to vote
1
<PAGE>
at any annual, special or other meeting of the Stockholders of the Company, and
at any adjournment or adjournments thereof, or by written consent without a
meeting with respect to all Stockholder Shares as follows: (i) in favor of
approval and adoption of the Merger Agreement, the terms thereof and each of the
other transactions contemplated by the Merger Agreement; and (ii) against any
action or agreement (other than the Merger Agreement or the transactions
contemplated thereby) that would impede, interfere with, delay, postpone or
attempt to discourage the Merger, including without limitation: (a) any
extraordinary corporate transaction, such as a merger, consolidation or other
business combination involving the Company and its subsidiaries; or (b) a sale
or transfer of a material amount of assets of the Company and its subsidiaries
or a reorganization, recapitalization or liquidation of the Company and its
subsidiaries.
"Stockholder Shares" shall mean the shares of Company capital stock
(including without limitation the Company Shares) Beneficially Owned by such
Stockholder as of the date hereof, or Beneficially Owned by such Stockholder at
any time hereafter (including, without limitation, by way of exercise of options
or by way of dividend, distribution, exchange, merger, consolidation,
recapitalization, reorganization, stock split, grant of proxy or otherwise) by
such Stockholder (as adjusted as set forth herein). The Stockholder hereby
agrees to promptly notify Acquiror of the number of any new Stockholder Shares
acquired by the Stockholder, if any, after the date hereof. In the event of any
change in the Company Shares by reason of a stock dividend, stock split, split
up, recapitalization, combination, exchange of shares or similar transaction,
the type and number of shares or securities that constitute Stockholder Shares
hereunder shall be adjusted appropriately.
2. TERMINATION.
a. This Agreement shall terminate upon the earlier to occur of
(i) the termination of the Merger Agreement in accordance with its terms
pursuant to Section 9.1 thereof, or (ii) the Effective Time (as defined in the
Merger Agreement).
b. Upon termination, this Agreement shall have no further force
or effect, except for Section 7
2
<PAGE>
which shall continue to apply to any case, action or proceeding relating to the
enforcement of this Agreement.
3. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER. The
Stockholder hereby represents and warrants to Acquiror as follows:
a. DUE AUTHORIZATION. The Stockholder has the legal capacity
and all necessary power and authority to execute and deliver this Agreement and
to consummate the transactions contemplated hereby. As of the date hereof, the
Stockholder Beneficially Owns the number of the Stockholder Shares listed on the
signature page hereof and specified as so owned with no restrictions on the
voting rights (except as specified in this Agreement) or rights of disposition
pertaining thereto, which constitute all Company Shares Beneficially Owned by
such Stockholder. Assuming this Agreement has been duly and validly authorized,
executed and delivered by Acquiror, this Agreement constitutes a valid and
binding agreement of the Stockholder, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency, moratorium or
other similar laws affecting creditors' rights generally or by the principles
governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by the Stockholder of the transactions
contemplated hereby will conflict with or constitute a violation of or default
under any contract, commitment, agreement, arrangement or restriction of any
kind to which the Stockholder is a party or by which the Stockholder is bound.
4. REPRESENTATIONS AND WARRANTIES OF ACQUIROR. Acquiror hereby
represents and warrants to the Stockholder as follows:
a. DUE AUTHORIZATION. Acquiror has the requisite corporate
power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly
authorized by all necessary corporate action on the part of Acquiror and this
Agreement has been duly executed by a duly authorized officer of Acquiror.
Assuming this Agreement has been duly and
3
<PAGE>
validly executed and delivered by the Stockholder, this Agreement constitutes a
valid and binding agreement of Acquiror, enforceable against it in accordance
with its terms, except as enforceability may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting creditors' rights
generally or by the principles governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by Acquiror of the transactions contemplated
hereby will conflict with or constitute a violation of or default under any
contract, commitment, agreement, arrangement or restriction of any kind to which
Acquiror is a party or by which Acquiror is bound.
5. NO TRANSFER. Except as provided in this Agreement or the
Merger Agreement, the Stockholder hereby agrees, without the prior written
consent of Acquiror, except pursuant to the terms hereof, not to (i) sell,
transfer, assign, pledge or otherwise dispose of or hypothecate any of his
Stockholder Shares; (ii) grant any proxies, deposit any Stockholder Shares
into a voting trust or enter into a voting agreement with respect to any
Stockholder Shares; or (iii) take any action that would make any representation
or warranty of the Stockholder contained herein untrue or incorrect or have
the effect of preventing or disabling the Stockholder from performing his
obligations under this Agreement. Any permitted transferee of Stockholder
Shares must become a party to this Agreement and any purported transfer of
Stockholder Shares to a person or entity that has not become a party hereto
shall be null and void. In furtherance of this Agreement, concurrently
herewith the Stockholder shall and hereby does authorize the Company's counsel
to notify the Company's transfer agent that there is a stop transfer order
with respect to all of the Stockholder Shares (and that this Agreement places
limits on the voting and transfer of such shares).
6. ENTIRE AGREEMENT. Other than the Merger Agreement
(including the exhibits, schedules and other documents and instruments referred
to therein), this
4
<PAGE>
Agreement (including the documents and instruments referred to
herein) (a) constitutes the entire agreement among the parties hereto with
respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties, or any of them,
with respect to the subject matter hereof; (b) shall not be assigned by
operation of law or otherwise without the prior written consent of the other
parties hereto, except that Acquiror may assign, in its sole discretion, all or
any of its rights, interests and obligations hereunder to any direct or indirect
wholly owned subsidiary of Acquiror; (c) shall not be amended, altered or
modified in any manner whatsoever, except by a written instrument executed by
the parties hereto; and (d) shall be governed in all respects, including
validity, interpretation and effect, by the laws of the State of Delaware
(without giving effect to the provisions thereof relating to conflicts of law).
7. REMEDIES. The parties acknowledge that it would be
impossible to fix money damages for violations of this Agreement and that such
violations will cause irreparable injury for which adequate remedy at law is not
available and, therefore, this Agreement must be enforced by specific
performance or injunctive relief. The parties hereto agree that any party may,
in its sole discretion, apply to any court of competent jurisdiction for
specific performance or injunctive or such other relief as such court may deem
just and proper in order to enforce this Agreement or prevent any violation
hereof and, to the extent permitted by applicable law, each party waives any
objection or defense to the imposition of such relief. Nothing herein shall be
construed to prohibit any party from bringing any action for damages in addition
to an action for specific performance or an injunction for a breach of this
Agreement.
8. LEGENDS ON CERTIFICATES. Until such time as this Agreement
shall terminate pursuant to Section 2 hereof, all certificates representing
Stockholder Shares shall bear the following legend:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
OF A STOCKHOLDER VOTING AGREEMENT, DATED AS OF OCTOBER 17, 1996, BY AND
BETWEEN TENET HEALTHCARE CORPORATION AND THE STOCKHOLDER. ANY TRANSFEREE
OF THESE
5
<PAGE>
SHARES TAKES SUBJECT TO THE TERMS OF SUCH AGREEMENT, COPIES OF
WHICH ARE ON FILE AT THE OFFICES OF TENET HEALTHCARE CORPORATION.
9. PARTIES IN INTEREST. Subject to the provisions of Sections
5 and 6(b) hereof, this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors,
permitted assigns, heirs, executors, administrators and other legal
representatives, and nothing in this Agreement, express or implied, is intended
to confer upon any other person any rights or remedies of any nature whatsoever
under or by reason of this Agreement.
10. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same agreement.
11. DEFINITIONS. The following terms shall have the following
respective meanings:
a. "Beneficial Owner" has the meaning set forth in Rule 13d-3 of
the Rules and Regulations to the Exchange Act, and "Beneficially Owned" and
"Beneficially Owns" shall have correlative meanings; PROVIDED, HOWEVER, that
for purposes of this Agreement a person shall be deemed to be the Beneficial
Owner of Company Shares that may be acquired pursuant to the exercise of an
option or other right regardless of when such option is exercisable.
b. A "person" means a corporation, association, partnership,
joint venture, organization, business, individual, trust, estate or any other
entity or group (within the meaning of Section 13(d)(3) of the Exchange Act).
12. NOTICES. All notices and other communications hereunder
shall be in writing and shall be deemed given if delivered personally,
telecopied (which is confirmed) or mailed by registered or certified mail
(return receipt requested) to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):
6
<PAGE>
(a) If to Acquiror to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue, Suite 3400
Los Angeles, California 90071
Telecopy No. (213) 687-5600
Attention: Brian J. McCarthy
(b) If to the Stockholder, to the address set forth on the
signature page, hereto.
13. INTERPRETATION. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
14. SEVERABILITY. Any term or provision of this Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction. If any provision of
this Agreement is so broad as to be unenforceable, the provision shall be
interpreted to be only so broad as is enforceable.
15. FURTHER ASSURANCES. The Stockholder further agrees to
execute all additional writings, consents and authorizations as may be
reasonably requested by Acquiror to evidence the agreements herein.
7
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
TENET HEALTHCARE CORPORATION
By
-----------------------------------
Name:
Title:
JOSEPH, LITTLEJOHN & LEVY FUND, L.P.
By
-----------------------------------
Name:
Title:
No. of Shares Beneficially Owned:
-----------------------------------
Address for Notices:
50 Main Street, Suite 1000
White Plains, New York 10606
<PAGE>
EXHIBIT B
FORM OF
REGISTRATION RIGHTS AGREEMENT
This REGISTRATION RIGHTS AGREEMENT (the "Agreement") is made and
entered into as of [ ], 1997, by and between Tenet Healthcare
Corporation, a Nevada corporation (together with its permitted successors and
assigns, the "Company"), and the person whose signature appears on the execution
page of this Agreement (together with permitted transferees, Affiliates and
Distributees (each as defined herein), the "Stockholder").
This Agreement is made pursuant to the Agreement and Plan of Merger
by and among Company, Acquisition Company, a Delaware corporation, and Company,
a Delaware corporation, dated as of October 16, 1996 (the "Merger Agreement"),
pursuant to which the Stockholder will receive shares of Common Stock (as
defined below) of the Company.
The parties hereto, for good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, intending to be bound hereby,
agree as follows:
SECTION 1. DEFINITIONS.
As used in this Agreement, the following terms shall have the
following meanings:
ADVICE: See Section 5 hereof.
AFFILIATE means, with respect to any specified person, any other person
directly or indirectly controlling or controlled by or under direct or indirect
common control with such specified person. For the purposes of this definition,
"control" when used with respect to any specified person means the power to
direct the management and policies of such person, directly or indirectly,
whether through the ownership of voting securities, by contract or otherwise;
and the terms "CONTROLLING" and "CONTROLLED" have meanings correlative to
the foregoing.
1
<PAGE>
BUSINESS DAY means any day that is not a Saturday, a Sunday or a legal
holiday on which banking institutions in the State of New York are not required
to be open.
COMMON STOCK means the Common Stock, par value $.075 per share, of the
Company, or any other shares of capital stock of the Company into which such
stock shall be reclassified or changed (by operation of law or otherwise). If
the Common Stock has been so reclassified or changed, or if the Company pays a
dividend or makes a distribution on its Common Stock in shares of capital stock,
or subdivides (or combines) its outstanding shares of Common Stock into a
greater (or smaller) number of shares of Common Stock, a share of Common Stock
shall be deemed to be such number of shares of capital stock and amount of other
securities to which a holder of a share of Common Stock outstanding immediately
prior to such reclassification, exchange, dividend, distribution, subdivision or
combination would be entitled.
DELAY PERIOD: See Section 2(b) hereof.
DISTRIBUTEE: See Section 7(d) hereof.
EFFECTIVENESS PERIOD: See Section 2(b) hereof.
EXCHANGE ACT means the Securities Exchange Act of 1934, as amended.
PERSON means any individual, corporation, partnership, joint venture,
association, joint-stock company, trust, unincorporated organization or
government or any agency or political subdivision thereof.
PROSPECTUS means the prospectus included in any Registration Statement
(including, without limitation, a prospectus that discloses information
previously omitted from a prospectus filed as part of an effective registration
statement in reliance upon Rule 430A), as amended or supplemented by any
prospectus supplement, with respect to the terms of the offering of any portion
of the Registrable Shares covered by such Registration Statement and all other
amendments and supplements to the prospectus, including post-effective
amendments, and all material incorporated by reference or deemed to be
incorporated by reference in such Prospectus.
2
<PAGE>
REGISTRABLE SHARES means the shares of Common Stock issued to the
Stockholder pursuant to the Merger Agreement or thereafter distributed by the
Stockholder to a Distributee, until in the case of any such share (i) it has
been effectively registered under Section 5 of the Securities Act and disposed
of pursuant to an effective registration statement under the Securities Act;
(ii) it has been transferred other than pursuant to Rule "4(1-1/2)" (or any
similar private transfer exemption) under the Securities Act; or (iii) it may be
transferred by a holder without registration pursuant to Rule 144 under the
Securities Act or any successor rule without regard to the volume limitation
contained in such rule.
REGISTRATION STATEMENT means any registration statement of the Company
that covers any of the Registrable Shares pursuant to the provisions of this
Agreement, including the Prospectus, amendments and supplements to such
registration statement, including post-effective amendments, all exhibits, and
all material incorporated by reference or deemed to be incorporated by reference
in such registration statement.
SEC means the Securities and Exchange Commission.
SECURITIES ACT means the Securities Act of 1933, as amended.
SHELF REGISTRATION: SEE SECTION 2(a) HEREOF.
STOCKHOLDER: See the introductory clauses hereof.
UNDERWRITTEN REGISTRATION OR UNDERWRITTEN OFFERING means a registration
in which securities of the Company are sold to or through one or more
underwriters for reoffering or sale to the public.
SECTION 2. DEMAND REGISTRATION.
(a) At any time after the Effective Time, upon written
notice from the Stockholder, subject to Section 2(e), requesting that Company
effect the registration under the Securities Act of any or all of the
Registrable Shares held by such Stockholder, which notice shall specify the
intended method or methods of disposition of such Registrable Shares, the
Company shall, in accordance with and in the manner set forth in Section 5
3
<PAGE>
hereof, use its best efforts to prepare and file a Registration Statement under
the Securities Act relating to the Registrable Shares with the SEC within 30
days, which Registration Statement shall provide for the sale by the holders
thereof of the Registrable Shares from time to time on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act (a "Shelf Registration"),
and shall use its best efforts to cause the same to be declared effective by the
SEC as promptly as practicable.
(b) Subject to Section 2(d), the Company agrees to use its
best efforts to keep the Registration Statement filed pursuant to this Section 2
continuously effective and usable for the resale of Registrable Shares for a
period ending on the earlier of (i) one year from the effective date of the
Registration Statement (the "Effective Date") and (ii) the first date on which
all the Registrable Shares covered by such Shelf Registration have been sold
pursuant to such Registration Statement. The foregoing notwithstanding, the
Company shall have the right in its sole discretion, based on any valid business
purpose (including without limitation to avoid the disclosure of any corporate
development that the Company is not otherwise obligated to disclose or to
coordinate such distribution with other shareholders that have registration
rights with respect to any securities of the Company or with other distributions
of the Company (whether for the account of the Company or otherwise)), to
suspend the use of the Registration Statement for a reasonable length of time (a
"Delay Period") and from time to time; provided, that (i) the aggregate number
of days in all Delay Periods occurring in any period of twelve consecutive
months shall not exceed 90 and (ii) the Parent shall not have the right to
commence any Delay Period prior to the 90th day after the first Effective Date.
The Company shall provide written notice to each holder of Registrable Shares
covered by each Shelf Registration of the beginning and end of each Delay Period
and such holders shall cease all disposition efforts with respect to Registrable
Shares held by them immediately upon receipt of notice of the beginning of any
Delay Period. The one year time period for which the Company is required to
maintain the effectiveness of the Registration Statement shall be extended by
the aggregate number of days of all Delay Periods and such one-year period or
the extension thereof required by the preceding sentence is hereafter referred
to as the "Effectiveness Period."
4
<PAGE>
(c) The Company may, with the consent of a majority of the
Stockholders for whom a Registration Statement has been filed, which consent
shall not be unreasonably withheld, include other securities in such Shelf
Registration (whether for the account of the Company or otherwise, including
without limitation any securities of the Company held by security holders, if
any, who have piggyback registration rights with respect thereto) or otherwise
combine the offering of the Registrable Shares with any offering of other
securities of the Company (whether for the account of the Company or otherwise).
(d) If, while a registration request is pending pursuant to
Section 2(b), Company has determined in good faith that (a) the filing of a
registration statement could jeopardize or delay any contemplated material
transaction other than a financing plan involving Company or would require the
disclosure of material information that Company had a bona fide business purpose
for preserving as confidential; or (b) Company then is unable to comply with SEC
requirements applicable to the requested registration (notwithstanding its best
efforts to so comply), Company shall not be required to effect a registration
pursuant to Section 2(b) until the earlier of (1) the date upon which such
contemplated transaction is completed or abandoned or such material information
is otherwise disclosed to the public or ceases to be material or Company is able
to so comply with applicable SEC requirements, as the case may be, and (2) 45
days after Company makes such good-faith determination.
(e) Company shall not be obligated to file a Registration
Statement relating to a registration request pursuant to Section 2(a): (a) more
than two times; (b) within a period of six months after the effective date of
any other Registration Statement of Company demanded pursuant to Section 2(b) in
any other Registration Rights Agreement entered into in connection with the
Merger; or (c) if such registration request is for a number of Registrable
Shares which have an aggregate market value less than $50 million of the issued
and outstanding common equity of Company.
(f) Notwithstanding any other provision of this Agreement to
the contrary, a Registration Statement will not be deemed to have been effected
by this
5
<PAGE>
Section 2 unless it is declared effective by the SEC and at least 75% of the
Registrable Shares requested to be registered have been distributed in
accordance with the plan of distribution set forth in the Registration
Statement; PROVIDED, HOWEVER, that a registration requested by a Stockholder
pursuant to this Section 2 and later withdrawn at the request of such
Stockholder shall be deemed to have been effected (and, therefore, requested for
purpose of Section 2(a)), whether withdrawn by the Stockholder prior to or after
the Effective Date unless the Stockholder bears the registration expenses for
any such withdrawn registration, in which case such registration shall not count
as a requested registration pursuant to Section 2(a).
(g) In the event that any registration pursuant to this
Section 2 shall involve, in whole or in part, an underwritten offering, Company,
on the one hand, and the Stockholder initiating the demand pursuant to Section
2(a), on the other hand, shall each have the right to designate an underwriter
as the sole lead managing underwriters of such underwritten offering (with such
co-lead managing underwriters sharing lead managing underwriter compensation
equally). Company and such Stockholder shall together select which of the
co-lead managing underwriters shall serve as "books-running" underwriter;
PROVIDED that if Company and such Stockholder cannot, within 10 days following
the notice from such Stockholder referred to in Section 2(a), reach a mutual
agreement on such selection, then (i) Company shall have the right (in the case
of the first such underwritten offering) to select the "books-running"
underwriter for such first offering; (ii) such Stockholder shall have the right
(in the case of the next such underwritten offering as to which no agreement can
be reached as provided) to select the "books-running" underwriter for such next
offering; and (iii) the selection right shall thereafter alternate for each
subsequent offering as to which no agreement can be reached as provided.
(h) Stockholders other than the Stockholder initiating the
demand pursuant to Section 2(b) shall have the right to include their shares of
Registrable Shares in any registration pursuant to Section 2(b). In connection
with those registrations in which multiple Stockholders participate, in the
event such registration
6
<PAGE>
involves an underwritten offering and the lead managing underwriter advises that
marketing factors require a limitation on the number of shares to be
underwritten, the number of shares to be included in the underwriting and
registration shall be allocated PRO RATA among the Stockholders on the basis
of the shares of Registrable Shares held by each such Stockholder.
SECTION 3. PIGGYBACK REGISTRATION.
At any time if the Company proposes to register any of its Common
Stock or any other of its common equity securities (collectively, "Other
Securities") under the Securities Act (other than a registration on Form S-4 or
S-8 or any successor form thereto), whether or not for sale for its own account,
in a manner which would permit registration of Registrable Shares for sale for
cash to the public under the Securities Act, it will each such time give prompt
written notice to the Stockholder of its intention to do so at least 10 business
days prior to the anticipated filing date of the registration statement relating
to such registration. Such notice shall offer each such Stockholder the
opportunity to include in such registration statement such number of Registrable
Shares as each such Stockholder may request. Upon the written request of any
such Stockholder made within five business days after the receipt of the
Company's notice (which request shall specify the number of Registrable Shares
intended to be disposed of and the intended method of disposition thereof), the
Company shall effect, in the manner set forth in Section 5, in connection with
the registration of the Other Securities, the registration under the Securities
Act of all Registrable Shares which the Company has been so requested to
register, to the extent required to permit the disposition (in accordance with
such intended methods thereof) of the Registrable Shares so requested to be
registered; PROVIDED that:
(a) if at any time after giving written notice of its
intention to register any securities and prior to the effective date of such
registration, the Company shall determine for any reason not to register or to
delay registration of such securities, the Company may, at its election, give
written notice of such determination to the Stockholder and, thereupon, (a) in
the case of a determination not to register, the Company shall be relieved of
its obligation to register any
7
<PAGE>
Registrable Shares in connection with such registration and (b) in the case of a
determination to delay such registration, the Company shall be permitted to
delay registration of any Registrable Shares requested to be included in such
registration for the same period as the delay in registering such other
securities;
(b) (i) if the registration referred to in the first
sentence of this Section 3 is to be an underwritten primary registration on
behalf of the Company, and the managing underwriter advises the Company in
writing that, in such firm's opinion, such offering would be materially and
adversely affected by the inclusion therein of the Registrable Shares requested
to be included therein, the Company shall include in such registration: (1)
first, all securities the Company proposes to sell for its own account ("Company
Securities") and (2) second, up to the full number of Registrable Shares in
excess of the number or dollar amount of Company Securities, which, in the
good-faith opinion of such managing underwriter, can be so sold without
materially and adversely affecting such offering (and, if less than the full
number of such Registrable Shares, allocated PRO RATA among the Stockholders
of such Registrable Shares on the basis of the number of securities requested to
be included therein by each such Stockholder) and (ii) if the registration
referred to in the first sentence of this Section 3 is to be an underwritten
secondary registration on behalf of holders of securities (other than
Registrable Shares) of the Company (the "Other Stockholders"), and the managing
underwriter advises the Company in writing that in their good-faith opinion such
offering would be materially and adversely affected by the inclusion therein of
the Registrable Shares requested to be included therein, the Company shall
include in such registration the amount of securities (including Registrable
Shares) that such managing underwriter advises allocated as follows: (1) first,
that number of Registrable Shares requested to be included therein by the other
Stockholder and (2) second, PRO RATA among the Stockholders on the basis of
the number of remaining securities (including Registrable Shares) requested to
be included therein by each Other Stockholder and each Stockholder; and
(c) no registration of Registrable Shares effected under
this Section 3 shall relieve the Company
8
<PAGE>
of its obligation to effect a registration of Registrable Shares pursuant to
Section 2 hereof.
SECTION 4. HOLD-BACK AGREEMENT.
Each holder of Registrable Shares agrees, if such holder is
requested by an underwriter in an underwritten offering for the Company (whether
for the account of the Company or otherwise), not to effect any public sale or
distribution of any of the Company's equity securities, including a sale
pursuant to Rule 144 (except as part of such underwritten registration), during
the 10-day period prior to, and during the 80-day period beginning on, the
closing date of such underwritten offering; PROVIDED, that neither the Company
nor any underwriter may request a holder not to effect any such sales or
distributions prior to the 90th day after the Effective Date.
SECTION 5. REGISTRATION PROCEDURES.
In connection with the registration obligations of the Company
pursuant to and in accordance with Section 2 or 3 hereof (and subject to the
Company's rights under Section 2 or 3), the Company will use its best efforts to
effect such registration to permit the sale of such Registrable Shares in
accordance with the intended method or methods of disposition thereof, and
pursuant thereto the Company shall as expeditiously as possible:
(a) Prepare and file with the SEC as soon as practicable a
Registration Statement and cause such Registration Statement to become effective
and remain effective as provided herein; PROVIDED, HOWEVER, that before
filing such Registration Statement or any Prospectus or any amendments or
supplements thereto, the Parent shall, if requested, furnish to and afford
promptly to the Stockholder, its counsel, and the managing underwriter or
underwriters, if any, a reasonable opportunity to review copies of all such
documents proposed to be filed to be filed a reasonable time prior to the
proposed filing thereof. The Parent shall not file any Registration Statement
or Prospectus or any amendments or supplements thereto if the Stockholder
covered by such Registration Statement, their counsel or the managing
underwriter or underwriters, if any, shall reasonably object in writing.
9
<PAGE>
(b) prepare and file with the SEC such amendments (including
post-effective amendments) to the Registration Statement, and such supplements
to the Prospectus, as may be required by the rules, regulations or instructions
applicable to the Securities Act or the rules and regulations thereunder during
the applicable period in accordance with the intended methods of disposition by
the sellers thereof and cause the Prospectus as so supplemented to be filed
pursuant to Rule 424 under the Securities Act;
(c) notify the selling holders of Registrable Shares
promptly and (if requested by any such person) confirm such notice in writing,
(i) when a Prospectus or any Prospectus supplement or post-effective amendment
has been filed, and, with respect to a Registration Statement or any
post-effective amendment, when the same has become effective, (ii) of any
request by the SEC for amendments or supplements to a Registration Statement or
related Prospectus or for additional information regarding such holder, (iii) of
the issuance by the SEC of any stop order suspending the effectiveness of a
Registration Statement or the initiation of any proceedings for that purpose,
(iv) of the receipt by the Company of any notification with respect to the
suspension of the qualification or exemption from qualification of any of the
Registrable Shares for sale in any jurisdiction or the initiation or threatening
of any proceeding for such purpose, and (v) of the happening of any event that
requires the making of any changes in such Registration Statement, Prospectus or
documents so that they will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading;
(d) use commercially reasonable efforts to prevent the
issuance of any order suspending the effectiveness of a Registration Statement,
or the lifting of any suspension of the qualification or exemption from
qualification of any of the Registrable Shares for sale in any jurisdiction in
the United States and, if any such order is issued, to obtain the withdrawal of
such order as soon as practicable;
(e) if requested by the selling holder, furnish to the
selling holder of Registrable Shares and
10
<PAGE>
counsel for the selling holder of Registrable Shares, without charge, one
conformed copy of each Registration Statement as declared effective by the SEC
and of each post-effective amendment thereto, in each case including financial
statements and schedules and all exhibits and reports incorporated or deemed to
be incorporated therein by reference; and such number of copies of the
preliminary prospectus, each amended preliminary prospectus, each final
Prospectus and each post-effective amendment or supplement thereto, as the
selling holder may reasonably request in order to facilitate the disposition of
the Registrable Shares covered by each Registration Statement in conformity with
the requirements of the Securities Act;
(f) prior to any public offering of Registrable Shares
register or qualify such Registrable Shares for offer and sale under the
securities or Blue Sky laws of such jurisdictions in the United States as any
selling holder shall reasonably request in writing; and do any and all other
reasonable acts or things necessary or advisable to enable such holders to
consummate the disposition in such jurisdictions of such Registrable Shares
covered by the Registration Statement; PROVIDED, HOWEVER, that the Company
shall in no event be required to qualify generally to do business as a foreign
corporation or as a dealer in any jurisdiction where it is not at the time so
qualified or to execute or file a general consent to service of process in any
such jurisdiction where it has not theretofore done so or to take any action
that would subject it to general service of process or taxation in any such
jurisdiction where it is not then subject;
(g) except during any Delay Period, upon the occurrence of
any event contemplated by paragraph 5(c)(ii) or 5(c)(v) above, prepare a
supplement or post-effective amendment to each Registration Statement or related
Prospectus or any document incorporated or deemed to be incorporated therein by
reference or file any other required document so that, as thereafter delivered
to the purchasers of the Registrable Shares being sold thereunder, such
Prospectus will not contain an untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made,
not misleading;
11
<PAGE>
(h) use commercially reasonable efforts to cause all
Registrable Shares to be registered with or approved by such other governmental
agencies, authorities or self-regulatory bodies as may be necessary by virtue of
the business or operations of the Company to enable the seller or sellers
thereof to consummate the disposition of such Registrable Shares in accordance
with the intended method or methods of disposition thereof;
(i) cooperate with the holders of Registrable Shares to
facilitate the timely preparation and delivery of certificates representing
Registrable Shares to be sold, which certificates shall not bear any restrictive
legends whatsoever and shall be in a form eligible for deposit with The
Depositary Trust Company;
(j) otherwise use its best efforts to comply with all
applicable rules and regulations of the SEC; and
(k) cause all Registrable Shares covered by the Registration
Statement to be listed on each securities exchange, if any, on which similar
securities issued by the Company are then listed.
The Company may require each seller of Registrable Shares as to
which any registration is being effected to furnish such information regarding
the distribution of such Registrable Shares and as to such seller as it may from
time to time reasonably request. If any such information with respect to any
seller is not furnished prior to the filing of the Registration Statement, the
Company may exclude such seller's Registrable Shares from such Registration
Statement.
Each holder of Registrable Shares (including, without limitation,
any Distributee) agrees by acquisition of such Registrable Shares that, upon
receipt of any notice from the Company of the happening of any event of the kind
described in Section 5(c)(ii), 5(c)(iii), 5(c)(iv) or 5(c)(v) hereof or upon
notice of the commencement of any Delay Period, such holder shall forthwith
discontinue disposition of such Registrable Shares covered by such Registration
Statement or Prospectus until such holder's receipt of the copies of the
supplemented or amended Prospectus contemplated by Section 5(g) hereof, or until
it is advised in writing (the "Advice")
12
<PAGE>
by the Company that the use of the applicable Prospectus may be resumed, and has
received copies of any amended or supplemented Prospectus or any additional or
supplemental filings which are incorporated, or deemed to be incorporated, by
reference in such Prospectus and, if requested by the Company, such holder shall
deliver to the Company (at the expense of the Company) all copies, other than
permanent file copies then in such holder's possession, of the Prospectus
covering such Registrable Shares at the time of receipt of such request. In the
event that the Company shall give any such notice, the Effectiveness Period
shall be extended by the number of days during the period from and including the
date of the giving of such notice to and including the date when each seller of
Registrable Shares shall have received (x) the copies of the supplemented or
amended Prospectus contemplated by Section 5(g) or (y) the Advice.
Each holder of Registrable Shares further agrees not to utilize any
material other than the applicable current Prospectus in connection with the
offering of Registrable Shares pursuant to the Shelf Registration.
SECTION 6. REGISTRATION EXPENSES.
Whether or not any Registration Statement becomes effective, the
Company shall pay all costs, fees and expenses incident to the Company's
performance of or compliance with this Agreement including, without limitation,
(i) all registration and filing fees, (ii) fees and expenses of compliance with
federal or state securities or Blue Sky laws, (iii) printing expenses
(including, without limitation, expenses of printing of prospectuses if the
printing of prospectuses is requested by the holders of a majority of the
Registrable Shares included in any Registration Statement), (iv) fees and
disbursements of counsel for the Company, (v) fees and disbursements of all
independent certified public accountants of the Company and all other Persons
retained by the Company in connection with the Registration Statement and (vi)
the fees and expenses (not to exceed $50,000) for one counsel on behalf of all
of the holders of Registrable Shares. Notwithstanding the foregoing, the fees
and expenses of counsel to, or any other Persons retained by, any holder of
Registrable Shares, and any discounts, commissions, underwriting or advisory
fees, brokers' fees or fees of similar securities industry professional
13
<PAGE>
(including any "qualified independent underwriter" retained for the purpose of
Section 3 of Schedule E of the By-laws of the National Association of Securities
Dealers, Inc.) relating to the distribution of the Registrable Shares, will be
payable by such holder and the Company will have no obligation to pay any such
amounts.
SECTION 7. MISCELLANEOUS.
(a) TERMINATION. This Agreement and the obligations of
the Company hereunder shall terminate on the earliest of (i) the first date on
which no Registrable Shares remain outstanding, and (ii) the close of business
on the last day of the Effectiveness Period.
(b) AMENDMENTS AND WAIVERS. The provisions of this
Agreement, including the provisions of this sentence, may not be amended,
modified or supplemented, and waivers or consents to departures from the
provisions hereof may not be given, unless the Company has obtained the written
consent of holders representing a majority of the Registrable Shares.
Notwithstanding the foregoing, a waiver or consent to depart from the provisions
hereof with respect to a matter which relates exclusively to the rights of
holders of Registrable Shares whose securities are being sold pursuant to a
Registration Statement and that does not directly or indirectly affect the
rights of a holder whose securities are not being sold pursuant to such
Registration Statement may be given by holders of a majority of the Registrable
Shares being sold by such holders; PROVIDED, HOWEVER, that the provision of
this sentence may not be amended, modified, or supplemented except in accordance
with the provisions of the immediately preceding sentence.
(c) NOTICES. All notices, requests, demands and other
communications required or permitted hereunder shall be in writing and shall be
deemed duly given or made as follows: (a) if delivered personally, upon
receipt; (b) if sent by registered or certified mail (postage prepaid, return
receipt requested), upon receipt; (c) if sent by reputable overnight air courier
(such as Federal Express or DHL), two business days after mailing; or (d) if
sent by facsimile transmission, with a copy mailed as provided in clause (b) or
(c) above, when transmitted and receipt is confirmed by telephone. Such
notices, claims, demands and other communications shall
14
<PAGE>
be sent to the respective parties at the following addresses (or at such other
address for a party as shall be specified by like notice):
(i) if to a holder, at the most current address given
by such holder to the Company in accordance with the provisions of this
Section 7(c), which address initially is with respect to each holder, the
address set forth on the signature pages hereto; and
(ii) if to the Company, initially at Tenet Healthcare
Corporation, 3820 State Street, Santa Barbara, California 93105,
Attention: General Counsel, with a copy to Skadden, Arps, Slate, Meagher &
Flom, 300 South Grand Avenue, Los Angeles, California 90071, Attention:
Brian J. McCarthy.
(d) SUCCESSORS AND ASSIGNS. This Agreement shall inure to
the benefit of and be binding upon the successors and assigns of each of the
parties; PROVIDED that the holders may not assign their rights hereunder
except to an Affiliate of such holder or a Distributee (as defined below) and no
person (other than any such Affiliate or Distributee) who acquires Registrable
Shares from a holder shall have any rights hereunder. For purposes of this
Agreement, the term "Distributee" shall mean any person that is a stockholder or
partner of a Stockholder, or any person that is a stockholder or partner of a
Distributee, to which Registrable Shares are transferred or distributed by such
Stockholder or Distributee. This Agreement shall survive any transfer of
Registrable Shares to a Distributee and shall inure to the benefit of such
Distributee.
(e) COUNTERPARTS. This Agreement may be executed in any
number of counterparts and by the parties hereto in separate counterparts, each
of which when so executed shall be deemed to be an original and all of which
taken together shall constitute one and the same agreement.
(f) HEADINGS. The headings in this Agreement are for
convenience of reference only and shall not limit or otherwise affect the
meaning hereof.
15
<PAGE>
(g) GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY
AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF DELAWARE
WITHOUT GIVING EFFECT TO THE PROVISIONS THEREOF GOVERNING CONFLICT OF LAWS
PRINCIPLES.
(h) SEVERABILITY. If any term, provision, covenant or
restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions,
covenants and restrictions set forth herein shall remain in full force and
effect and shall in no way be affected, impaired or invalidated, and the parties
hereto shall use their best efforts to find and employ an alternative means to
achieve the same or substantially the same result as that contemplated by such
term, provision, covenant or restriction. It is hereby stipulated and declared
to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that
may be hereafter declared invalid, illegal, void or unenforceable.
(i) ENTIRE AGREEMENT. Other than the Merger Agreement
(including the exhibits, schedules and other documents and instruments referred
to therein), this Agreement is intended by the parties as a final expression of
their agreement and a complete and exclusive statement of the agreement and
understanding of the parties hereto in respect of the subject matter contained
herein. There are no restrictions, promises, warranties or undertakings, other
than those set forth or referred to herein, with respect to the registration
rights granted by the Company with respect to the Registrable Shares issued
pursuant to the Merger Agreement. This Agreement supersedes all prior
agreements and understandings between the parties with respect to such subject
matter.
(j) CALCULATION OF TIME PERIODS. Except as otherwise
indicated, all periods of time referred to herein shall include all Saturdays,
Sundays and holidays; PROVIDED, that if the date to perform the act or give
any notice with respect to this Agreement shall fall on a day other than a
Business Day, such act or notice may be timely performed or given if performed
or given on the next succeeding Business Day.
16
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first written above.
TENET HEALTHCARE CORPORATION
By:
-----------------------------
Name:
Title:
STOCKHOLDER
--------------------------------
Name:
Address for
Notice:
<PAGE>
EXHIBIT C
CERTAIN BENEFITS
1. From and after the Effective Time, Parent will cause the
Surviving Corporation to honor, pay and perform all obligations under each Plan
(including but not limited to under each employment, severance, termination or
similar agreement or arrangement with any current or former officer or other
employee of Company or any Company Subsidiary) in accordance with the terms
thereof in effect as of the date hereof (or, with the written approval of
Parent, as the same may be amended from time to time after the date hereof).
2. Except as may otherwise be required under any collective
bargaining agreement, Parent will cause each employee pension, welfare,
incentive, fringe and other benefit and compensation plan and program of Parent
and its subsidiaries (the "Parent Benefit Programs") to provide for the
participation therein of the officers and other employees of Company and the
Company Subsidiaries (collectively, the "Company Employees"), in each case,
pursuant to the terms of such Parent Benefit Program applicable to similarly
situated officers and other employees of Parent and its subsidiaries. In
connection therewith, Parent will cause each Parent Benefit Program to (i)
recognize for all purposes under each such program all service completed by each
Company Employee prior to the Effective Time with Company, any Company
Subsidiary or any of their respective affiliates or predecessors to the same
extent such service was recognized immediately prior to the Effective Time under
a comparable Plan and (ii) waive (except with respect to any Parent Benefit
Program providing disability benefits) any actively-at-work requirements and
exclusions for pre-existing conditions of the Company Employees and their
dependents and to recognize any co-payments, deductibles or similar amounts or
costs incurred by any such Company Employee under a comparable Plan during the
plan year in which the commencement of such Company Employee's participation in
the applicable Parent Benefit Program occurs.
3. Effective on the date hereof, Company (subject to consultation
with Parent as to the specific terms thereof) will implement and, for the
two-year
<PAGE>
period following the Effective Time, Parent will, or will cause the Surviving
Corporation to, continue to maintain a severance plan (the "Severance Plan") (i)
covering all of the employees of Company located at (or otherwise employed
full-time to perform services for) the Company's headquarters in Nashville,
Tennessee or one of its regional offices located in Irvine, California, Phoenix,
Arizona or Miami, Florida and the Chief Executive Officer of each hospital
operated by Company or a Company Subsidiary (each, a "Hospital CEO"), other than
any such employee who, as of the Effective Time, is covered by an effective
employment agreement or Severance Protection Agreement, and (ii) otherwise
containing the terms and providing the benefits described herein. The Severance
Plan will provide for the payment of the severance benefits described herein to
each covered employee whose employment is terminated after the date hereof and
on or prior to the second anniversary of the Effective Time by Company, a
Company Subsidiary or the Surviving Corporation (other than for "cause" as to be
defined in the Severance Plan) or by such employee for "Good Reason," as defined
in Section 4. Severance benefits provided under the Severance Plan will be paid
in cash, on a salary continuation basis consistent with Parent's existing
payroll practices, commencing upon an eligible employee's termination of
employment, at a rate equal to such employee's highest rate of annual base
salary in effect during the period from the date hereof to the date of such
termination (the "Measurement Period") for a period of time as follows: (i) in
the case of an employee having the title at the relevant time of Assistant
Vice-President or Hospital CEO, one year, (ii) in the case of an employee having
the title at the relevant time of Director, nine months, (iii) in the case of an
employee having the title at the relevant time of Manager, six months, (iv) in
the case of an employee who, at the relevant time, is otherwise classified as an
exempt employee, four months and (v) in the case of an employee who, at the
relevant time, is classified as a non-exempt employee, a period of months
determined in accordance with the following schedule:
2
<PAGE>
- --------------------------------------------------------------------------------
NUMBER OF YEARS OF SERVICE
COMPLETED PRIOR TO TERMI- FACTOR FOR DETERMINING
NATION OF EMPLOYMENT SEVERANCE PAY
- --------------------------------------------------------------------------------
less than one year two months
- --------------------------------------------------------------------------------
one year but less than three years three months
- --------------------------------------------------------------------------------
three years but less than five years four months
- --------------------------------------------------------------------------------
five or more years five months
- --------------------------------------------------------------------------------
Solely in the case of an employee having the title at the relevant
time of Assistant Vice-President, such employee will also receive at the time
such employee would next have been eligible to receive an annual bonus, an
amount equal to the greatest of (I) such employee's highest annual target
incentive bonus for any fiscal or calendar year beginning during the Measurement
Period, (II) such employee's highest annual bonus paid for any fiscal or
calendar year ending during the Measurement Period or (III) such employee's
annual target bonus for the fiscal year of the Company ending August 31, 1996.
Any covered Employee entitled to severance benefits under the
Severance Plan will, in addition to the payments described above, be entitled to
continue participation in Parent's 401(k) qualified savings plan (or, if such
participation is not permitted under the terms of such plan, equivalent benefits
on a non-qualified basis) and in those Parent Benefit Programs providing
medical, life, and other welfare benefits (excluding any Parent Benefit Program
providing disability benefits) in which such employee was a participant
immediately prior to the date of termination of employment, for the period
ending on the earlier of (x) the last date with respect to which salary
continuation payments are required to be made to such employee in accordance
with the terms hereof and (y) the date comparable coverage (including coverage
of pre-existing conditions) is provided to such employee under a plan of a new
employer, at a cost to such employee no greater than the cost, if any, of such
coverage to such employee immediately prior to his termination of employment.
Benefits under the Sever-
3
<PAGE>
ance Plan will be in lieu of any other severance benefits to which any such
covered employee may otherwise be entitled under the terms of any other plan or
arrangement of Parent, Company or any subsidiary.
4. For purposes of Section 3, "Good Reason" for termination by the
employee of the employee's employment shall mean the occurrence (without the
employee's express written consent) of any one of the following acts or failures
to act by Parent, the Company, or the Surviving Corporation, as the case may be,
unless, in the case of any act or failure to act described below, such act or
failure to act is corrected prior to the date of termination of employment:
(I) a material diminution in the employee's title,
authorities or responsibilities from those in effect immediately prior to such
termination or, if greater, those in effect immediately prior to the Effective
Time;
(II) a reduction in the employee's annual base salary or
hourly salary as in effect immediately prior to the Effective Time except for
across-the-board salary reductions similarly affecting all similarly situated
employees of the Company and all similarly situated employees of any person in
control of the Company;
(III)the relocation of the employee's office at which he is
to perform his duties, to a location that increases his one-way commute by
more than thirty (30) miles from his commute to the location at which the
employee performed his duties immediately prior to the Effective Time, except
for required travel on Company's business to an extent substantially
consistent with his business travel obligations prior to the Effective Time;
or
(IV) the failure to continue to provide the employee with
benefits substantially similar in value to the employee in the aggregate to
those enjoyed by the employee under Company's pension, life insurance, medical,
health and accident, or disability plans in which the employee was participating
immediately prior to the Effective Time, unless the employee participates after
the Effective Time in other comparable benefit plans
4
<PAGE>
generally available to employees of the Company and employees of any person in
control of the Company.
5. The Company shall take all necessary action to provide that,
not later than five (5) business days prior to the Effective Time, (i) any
outstanding options to purchase Shares under Company's Stock Purchase Plan shall
terminate (the "Stock Purchase Plan Termination Date"), and (ii) all amounts
allocated to each participant's account under the Company Stock Purchase Plan
shall thereupon (x) be used to purchase from Company newly-issued whole Shares
at a price equal to the lesser of (a) 85% of the closing price per Share on the
New York Stock Exchange on September 1, 1996 and (b) 85% of the closing price
per Share on the New York Stock Exchange on the Stock Purchase Plan Termination
Date, or (y) returned to the participant. At the Effective Time, any Shares so
purchased will be treated as provided in Section 3.1 of the Agreement. From and
after the date hereof, participants in the Stock Purchase Plan will not be
permitted to increase the rate of their contributions to the Stock Purchase
Plan.
6. With respect to the Plans listed on Schedule A hereto (the
"Change in Control Plans"), Parent and Company confirm that, pursuant to the
terms of the Change in Control Plans as in effect on the date hereof, the
approval by Company shareholders of the Merger (or, with respect to the form of
Indemnification Agreement, the consummation of the Merger) will constitute a
Change in Control for purposes of such plans (assuming, where explicitly
provided in the applicable plan or agreement, that the Company's Chief Executive
Officer, Chief Operating Officer or Chief Financial Officer (i) changes after
the Change of Control or within 180 days thereafter, except as the result of
their death or Disability, or (ii) changes prior to the Change of Control at the
direction of Parent).
7. Parent hereby acknowledges and agrees that, effective as of
the date hereof and to induce Executive (as defined below) to remain in the
employment of Company during the transition period beginning on the date hereof,
the Employment Agreement, dated as of May 1, 1996 (the "Employment Agreement"),
by and between Company and William L. Hough (the "Executive") will be amended
5
<PAGE>
and supplemented to provide that (i) on or prior to December 15, 1996, the
Company will make a lump sum cash payment to Executive (the "Advance") in an
amount equal to approximately $1.2 million, as an advance payment of a portion
of the benefits that are payable to executive under Section 11(d)(ii) of the
Employment Agreement in the event of a Change in Control of Company (as defined
therein) and the subsequent termination of Executive's employment, (ii) in the
event of the termination of Executive's employment under the circumstances
described in Section 11(d)(ii) of the Employment Agreement, the lump sum cash
payment to which Executive will then be entitled under Section 11(d)(ii) of the
Employment Agreement in connection with such termination will be reduced by an
amount equal to the Advance and will otherwise be paid to Executive in
accordance with Section 11(d)(iv) of the Employment Agreement and (iii) in the
event that (x) the Merger is not consummated on or prior to August 1, 1997 (the
"Expiration Date") or (y) Executive's employment is not terminated under the
circumstances described in Section 11(d)(i) of the Employment Agreement prior to
the first anniversary of the Effective Time (the "First Anniversary"),
Executive's base salary, annual and long-term incentive compensation bonuses,
stock option compensation, severance payments and other compensation will be
reduced by an aggregate amount equal to the Advance in such manner and in such
increments as Company or the Surviving Corporation, as the case may be, deems
appropriate; provided, however, that in the event Executive's employment is
terminated by Executive without Good Reason or by Parent, Company or the
Surviving Corporation for "cause" (as defined in the Employment Agreement),
Executive shall repay to Company within ten (10) business days following the
date of such termination of employment an amount equal to the excess, if any, of
(a) the amount of the Advance over (b) the aggregate amount by which Executive's
base salary, annual and long-term incentive compensation bonuses, stock option
compensation, severance payments and other compensation have been reduced as
provided above. In addition, Company and Parent shall cooperate in taking such
reasonable actions as may be necessary to preserve the deductibility under
section 162(m) of the Code of the Advance, including (without limitation) by
terminating Executive's employment with or position as an executive officer of
Company prior to the Effective Time, provided, that no such action will be taken
that would adversely affect Executive's entitlement
6
<PAGE>
to the severance benefits provided under Section 11(d)(ii) of the Employment
Agreement or preclude the acceleration of the exercisability of Executive's
employee stock options pursuant to the terms of Company's 1994 Management Equity
Plan.
8. From and after the date hereof, Parent acknowledges and agrees
that, in the case of each Company Employee who (i) may be subject to the excise
tax on "excess parachute payments" under Section 280G of the Code by reason of
the acceleration of the vesting of certain Employee Stock Options in connection
with the Merger and (ii) elects to exercise any vested Employee Stock Options
prior to the end of the 1996 calendar year, to assist such Company Employee in
satisfying his obligations to pay the exercise price and income tax withholding
obligations associated with the exercise of any such Employee Stock Options (the
"Aggregate Exercise Obligations"), Company may, upon the request of such Company
Employee, and in accordance with the terms of the applicable stock option
agreement and stock option plan (i) withhold a number of Shares having a fair
market value, as defined in the Company's 1994 Management Equity Plan, equal to
the applicable Aggregate Exercise Obligations, or (ii) subject to all
applicable margin rules, extend a loan to such Company Employee, in the
principal amount of such Aggregate Exercise Obligations, which loan shall (w)
bear interest at an annual rate equal to the average cost of Company's bank
indebtedness obligations outstanding as of the date of such loan, (x) be secured
by all the Shares purchased with the proceeds of such loan (or by other property
of equal value acceptable to Company and Parent), (y) have a term not to exceed
one year, with such loan coming due upon the earlier sale of the Shares securing
such loan, and (z) be subject to such other terms and conditions as Company and
Parent shall reasonably require; provided, that such Share withholding or
secured loan shall be subject to the condition that such action would not
preclude the treatment of the Merger as a pooling of interests for accounting or
financial reporting purposes.
9. It is agreed that the "caps" described under the employment
agreements for Messrs. Martin, Pitts and Hough and under the form of Severance
Protection Agreement for purposes of Section 280G of the Code apply only to
reduce severance and other amounts payable under
7
<PAGE>
such agreements, and do not apply to the acceleration of stock options under
Company's 1994 Management Equity Plan.
8
<PAGE>
SCHEDULE A
1. Martin, Pitts and Hough Employment Agreements
2. Indemnification Agreement with Ronald P. Soltman and any other
indemnification agreement of substantially the same form (the "form of
Indemnification Agreement")
3. 1994 Management Equity Plan and any stock option agreement
evidencing options granted thereunder that does not define the term "Change of
Control" other than as defined in such plan
4. Outside Directors Stock Option Plan and any stock option
agreement evidencing options granted thereunder that does not define the term
"Change of Control" other than as defined in such plan
5. Incentive Bonus Plan
6. 1994 Annual Incentive Plan for Officers
7. Severance Protection Agreement with Ronald P. Soltman and any
other severance protection agreement of substantially the same form (the "form
of Severance Protection Agreement")
9
<PAGE>
EXHIBIT E
, 199
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Ladies and Gentlemen:
Each of the undersigned has been advised that as of the date of this
letter [he/she] may be deemed to be an "affiliate" of OrNda Healthcorp, a
Delaware corporation ("Company"), as the term "affiliate" is (i) defined for
purposes of paragraphs (c) and (d) of Rule 145 of the rules and regulations (the
"Rules and Regulations") of the Securities and Exchange Commission (the
"Commission") under the Securities Act of 1933, as amended (the "Act"), or (ii)
used in and for purposes of Accounting Series, Releases 130 and 135, as amended,
of the Commission. Pursuant to the terms of the Agreement and Plan of Merger
dated as of October 16, 1996 (the "Agreement") among Tenet Healthcare
Corporation, a Nevada corporation ("Parent"), Company and OHC Acquisition, Co.
("OHC"), OHC, a wholly owned subsidiary of Parent, will be merged with and into
Company (the "Merger").
At the effective time of the Merger (the "Effective Time"), the
undersigned will have the right to receive shares of common stock, par value
$.075 per share, of Parent (the "Common Stock"), together with any associated
purchase rights under the Rights Agreement, dated as of December 7, 1988, as
amended from time to time, between Parent and Bank of America, NTS, as successor
to Bankers Trust Company (the "Rights"; and together with the Common Stock, the
"Parent Common Stock"), in exchange for shares owned by [him/her] of common
stock, par value $.01 per share, of Company (the "Company Common Stock").
<PAGE>
Tenant Healthcare Corporation
, 199
Page 2
The undersigned has been advised that the offering of shares of
Parent Common Stock to [him/her] pursuant to the Merger has been registered with
the Commission under the Act on a Registration Statement on Form S-4. The
undersigned has also been advised, however, that, since at the time the Merger
was submitted for a vote of the stockholders of Company, the undersigned may be
deemed to have been an affiliate of Company, and the distribution by the
undersigned of the shares of Parent Common Stock has not been registered under
the Act, the undersigned may not and the undersigned will not sell, transfer or
otherwise dispose of the Parent Common Stock issued to the undersigned in the
Merger unless: (i) such sale, transfer or other disposition has been registered
under the Act; (ii) such sale, transfer or other disposition is made in
conformity with Rule 145 promulgated by the Commission under the Act; or (iii)
in the opinion of counsel reasonably acceptable to Parent, or a "no action"
letter obtained by the undersigned from the staff of the Commission states that,
such sale, transfer or other disposition is otherwise exempt from registration
under the Act.
The undersigned understands that Parent is under no obligation to
register the sale, transfer or other disposition of the Parent Common Stock by
the undersigned or on the undersigned's behalf under the Act or to take any
other action necessary in order to make compliance with an exemption from such
registration available, except as otherwise provided in that certain
Registration Rights Agreement between the Parent and the Stockholders listed
therein, dated , 199 .
The undersigned also understands that stop transfer instructions
will be given to Parent's transfer agents with respect to the Parent Common
Stock and that there will be placed on the certificates for the Parent Common
Stock issued to the undersigned, or any substitutions therefor, a legend stating
in substance:
<PAGE>
Tenant Healthcare Corporation
, 199
Page 3
"THE SHARES REPRESENTED BY THIS CERTIFICATE WERE ISSUED IN A TRANSACTION
TO WHICH RULE 145 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, APPLIES. THE SHARES REPRESENTED BY THIS CERTIFICATE MAY ONLY BE
TRANSFERRED IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE
REGISTERED HOLDER HEREOF AND TENET HEALTHCARE CORPORATION, A COPY OF WHICH
AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICES OF TENET HEALTHCARE
CORPORATION."
It is understood and agreed that the legend set forth above shall be
removed by delivery of substitute certificates without such legend if such
legend is not required for purposes of the Act. It is understood and agreed
that such legend and the stop orders referred to above will be removed if: (i)
two years shall have elapsed from the date the undersigned acquired the Parent
Common Stock received in the Merger and the provisions of Rule 145(d)(2) are
then available to the undersigned; (ii) three years shall have elapsed from the
date the undersigned acquired the Parent Common Stock received in the Merger and
the provisions of Rule 145(d)(3) are then applicable to the undersigned; or
(iii) Parent has received either an opinion of counsel, which opinion and
counsel shall be reasonably satisfactory to Parent, or a "no action" letter
obtained by the undersigned from the staff of the Commission, to the effect that
the restrictions imposed by Rule 145 under the Act no longer apply to the
undersigned.
Each of the undersigned has carefully read this letter and the
Agreement and discussed the requirements of such documents and other applicable
limitations upon the undersigned's ability to sell, transfer or otherwise
dispose of the Parent Common Stock to the extent the undersigned felt necessary,
with the undersigned's counsel or counsel for Company.
Execution of this letter is not an admission on the undersigned's
part that the undersigned is an "affil-
<PAGE>
Tenant Healthcare Corporation
, 199
Page 4
iate" of Company as described in the first paragraph of this letter or a waiver
of any rights the undersigned may have to object to any claim that the
undersigned is such an affiliate on or after the date of this letter.
Not all signatures need appear on the same copy of this letter.
Very truly yours,
--------------------
--------------------
--------------------
Accepted and Agreed this
day of , 199
Tenet Healthcare Corporation
By:
----------------------
Name:
-----------------
Title:
----------------
<PAGE>
EXHIBIT F-1
FORM OF
STOCK OPTION AGREEMENT
THIS STOCK OPTION AGREEMENT (this "AGREEMENT"), dated October 17,
1996, between OrNda Healthcorp, a Delaware corporation ("GRANTEE"), and Tenet
Healthcare Corporation, a Nevada corporation ("ISSUER"),
W I T N E S S E T H:
WHEREAS, Grantee and Issuer, among others, have entered into an
Agreement and Plan of Merger, dated as of October 16, 1996 (the "MERGER
AGREEMENT"), which agreement has been executed by the parties hereto prior to
this Agreement (capitalized terms used herein without definition shall have the
respective meanings specified in the Merger Agreement); and
WHEREAS, as a condition to Grantee's entering into the Merger
Agreement and in consideration therefor, Issuer has agreed to grant Grantee the
Option (as hereinafter defined);
NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth herein and in the Merger Agreement, the
parties hereto agree as follows:
1. GRANT OF OPTION. Issuer hereby grants to Grantee an
unconditional, irrevocable option (the "OPTION") to purchase, subject to the
terms hereof, 28,388,098 shares of fully paid and nonassessable common stock of
the Issuer, par value $.075 per share ("COMMON STOCK"), equal to 10.46% of
the number of shares of Common Stock (on a fully diluted basis after giving
effect to the exercise of the Option), together with any associated purchase
rights (the "Rights") under the Rights Agreement, dated as of December 7,
1988, as amended from time to time, between Issuer and Bank of America, NTS
as successor trustee to Bankers Trust Company (references to shares
purchasable upon exercise of the Option shall be deemed to include the
associated Rights), as of the date hereof at a purchase price of $22.125 per
share of Common Stock, as adjusted in accordance with the provisions of
<PAGE>
Section 5 of this Agreement (such price, as adjusted if applicable, the "OPTION
PRICE").
2. (a) EXERCISE OF OPTION. Grantee may exercise the Option, in
whole or part, and from time to time, if, but only if, a Triggering Event (as
hereinafter defined) shall have occurred prior to the occurrence of an Option
Termination Event (as hereinafter defined), provided that Grantee shall have
sent the written notice of such exercise (as provided in subsection (f) of this
Section 2 on or prior to the last date of the 18-month period following such
Triggering Event (the "Option Expiration Date").
(b) OPTION TERMINATION EVENTS. The term "OPTION TERMINATION
EVENT" shall mean either of the following events: (i) immediately prior to the
Effective Time of the Merger; or (ii) termination of the Merger Agreement (A) by
either party pursuant to Section 9.1(c) of the Merger Agreement, whether or not
such termination occurs prior to the occurrence of a Triggering Event, provided
that the matter giving rise to the order, decree, ruling or other action
providing the basis for termination under Section 9.1(c) shall not have been
initiated by Issuer or any Bidder, (B) by Issuer pursuant to Section 9.1(d)(i)
of the Merger Agreement because of a material adverse change after the date
hereof in the business, financial condition, results of operations, properties,
assets or liabilities of Grantee and its subsidiaries taken as a whole (other
than any change relating to the United States economy in general or to the
United States investor-owned hospital business in general) that is caused by the
matters described in Schedule 5.8(a) to the Company Disclosure Letter if such
termination occurs prior to the occurrence of a Triggering Event described in
clause (i) of Section 2(c) hereof or (iii) by either party pursuant to any other
provision of the Merger Agreement if such termination occurs prior to the
occurrence of a Triggering Event.
(c) TRIGGERING EVENTS. The term "TRIGGERING EVENT" shall mean
either of the following events occurring after the date hereof:
(i) Any event shall have occurred that would entitle either
party to terminate the Merger Agreement and permit Grantee to
receive
2
<PAGE>
any fee from Issuer pursuant to Section 9.3 of the Merger Agreement
(a "SECTION 9.3 EVENT"); or
(ii) Any person (the term "PERSON" for purposes of this
Agreement having the meaning assigned thereto in Sections 3(a)(9)
and 13(d)(3) of the Securities Exchange Act of 1934, as amended (the
"EXCHANGE ACT"), and the rules and regulations thereunder), other
than Grantee or any of its subsidiaries or affiliates (such person,
the "BIDDER"), shall make an offer or proposal for, or an
announcement of any intention with respect to (including, without
limitation, the filing of a statement of beneficial ownership on
Schedule 13D discussing the possibility of, or reserving the right
to engage in), an Alternative Transaction.
(d) NOTICE OF TRIGGERING EVENT. Issuer shall notify Grantee
promptly in writing of the occurrence of any Triggering Event, it being
understood that the giving of such notice by Issuer shall not be a condition to
the right of Grantee to exercise the Option or for a Triggering Event to have
occurred.
(e) NOTICE OF EXERCISE; CLOSING. In the event Grantee is
entitled to and wishes to exercise the Option, it shall send to Issuer a written
notice (the date of which being herein referred to as the "NOTICE DATE")
specifying (i) the total number of shares it will purchase pursuant to such
exercise and (ii) a place and date not earlier than three business days nor
later than 60 business days from the Notice Date for the closing of such
purchase (the "CLOSING DATE"); PROVIDED, that if the closing of the purchase
and sale pursuant to the Option (the "CLOSING") cannot be consummated, in the
reasonable opinion of Grantee, by reason of any applicable judgment, decree,
order, law or regulation, the period of time that otherwise would run pursuant
to this sentence shall run instead from the date on which such restriction on
consummation has expired or been terminated; and PROVIDED FURTHER, without
limiting the foregoing, that if, in the reasonable opinion of Grantee, prior
notification to or approval of any regulatory agency is required in connection
with such purchase, Grantee shall promptly file the required notice or
application for approval and shall
3
<PAGE>
expeditiously process the same and the period of time that otherwise would run
pursuant to this sentence shall run instead from the date on which any required
notification periods have expired or been terminated or such approvals have been
obtained and any requisite waiting period or periods shall have passed. Any
exercise of the Option shall be deemed to occur on the Notice Date relating
thereto. Notwithstanding this subsection (e), in no event shall any Closing
Date be more than 18 months after the related Notice Date, and if the Closing
Date shall not have occurred within 18 months after the related Notice Date due
to the failure to obtain any such required approval, the exercise of the Option
effected on the Notice Date shall be deemed to have expired. In the event (x)
Grantee receives official notice that an approval of any regulatory authority
required for the purchase of Option Shares (as hereinafter defined) would not be
issued or granted, (y) a Closing Date shall not have occurred within 18 months
after the related Notice Date due to the failure to obtain any such required
approval or (z) Grantee shall have the right pursuant to the last sentence of
Section 8 (or Section 10) to exercise the Option (or Substitute Option), Grantee
shall nevertheless be entitled to exercise its right as set forth in Section 8
and Grantee shall be entitled to exercise the Option (or Substitute Option) in
connection with the resale of Issuer Common Stock or other securities pursuant
to a registration statement as provided in Section 6.
(f) PURCHASE PRICE. At the Closing referred to in subsection (e)
of this Section 2, Grantee shall pay to Issuer the aggregate purchase price for
the shares of Common Stock purchased pursuant to the exercise of the Option in
immediately available funds by wire transfer to a bank account designated by
Issuer, PROVIDED that failure or refusal of Issuer to designate such a bank
account shall not preclude Grantee from exercising the Option.
(g) ISSUANCE OF COMMON STOCK. At such Closing, simultaneously
with the delivery of immediately available funds as provided in subsection (f)
of this Section 2, Issuer shall deliver to Grantee a certificate or certificates
representing the number of shares of Common Stock purchased by the Grantee and,
if the Option should be exercised in part only, a new Option evidencing the
rights of Grantee thereof to purchase the balance of
4
<PAGE>
the shares purchasable hereunder, and the Grantee shall deliver to Issuer a copy
of this Agreement and a letter agreeing that Grantee will not offer to sell or
otherwise dispose of such shares in violation of applicable law or the
provisions of this Agreement. If at the time of issuance of any Option Shares
pursuant to an exercise of all or part of the Option hereunder, Issuer shall not
have redeemed the Parent Rights, or shall have issued any similar securities,
then each Option Share issued pursuant to such exercise shall also represent
rights or new rights with terms substantially the same as and at least as
favorable to Grantee as are provided under Issuer's shareholder rights agreement
or any similar agreement then in effect.
(h) LEGEND. Certificates for Common Stock delivered at a closing
hereunder may be endorsed with a restrictive legend that shall read
substantially as follows:
"The transfer and voting of the shares represented by this
certificate is subject to certain provisions of an agreement between
the registered holder hereof and Issuer and to resale restrictions
arising under the Securities Act of 1933, as amended. A copy of
such agreement is on file at the principal office of Issuer and will
be provided to the holder hereof without charge upon receipt by
Issuer of a written request therefor."
It is understood and agreed that: (i) the reference to the resale restrictions
of the Securities Act of 1933, as amended (the "SECURITIES ACT"), in the above
legend shall be removed by delivery of substitute certificate(s) without such
reference if Grantee shall have delivered to Issuer a copy of a letter from the
staff of the SEC, or an opinion of counsel, in form and substance reasonably
satisfactory to Issuer, to the effect that such legend is not required for
purposes of the Securities Act; (ii) the reference to the provisions of this
Agreement in the above legend shall be removed by delivery of substitute
certificate(s) without such reference if the shares have been sold or
transferred in compliance with the provisions of this Agreement and under
circumstances that do not require the retention of such reference; and (iii) the
legend shall be removed in its entirety if the condi-
5
<PAGE>
tions in the preceding clauses (i) and (ii) are both satisfied. In addition,
such certificates shall bear any other legend as may be required by law.
(i) RECORD GRANTEE; EXPENSES. Upon the giving by Grantee to
Issuer of the written notice of exercise of the Option provided for under
subsection (e) of this Section 2 and the tender of the applicable purchase price
in immediately available funds, Grantee shall be deemed to be the holder of
record of the shares of Common Stock issuable upon such exercise,
notwithstanding that the stock transfer books of Issuer shall then be closed or
that certificates representing such shares of Common Stock shall not then be
actually delivered to Grantee or the Issuer shall have failed or refused to
designate the bank account described in subsection (f) of this Section 2.
Issuer shall pay all expenses, and any and all United States federal, state and
local taxes and other charges that may be payable in connection with the
preparation, issuance and delivery of stock certificates under this Section 2 in
the name of Grantee or its assignee, transferee or designee.
3. RESERVATION OF SHARES. Issuer agrees: (i) that it shall at
all times maintain, free from preemptive rights, sufficient authorized but
unissued or treasury shares of Common Stock (and other securities issuable
pursuant to Section 5(a)) so that the Option may be exercised without additional
authorization of Common Stock (or such other securities) after giving effect to
all other options, warrants, convertible securities and other rights to purchase
Common Stock (or such other securities); (ii) that it will not, by charter
amendment or through reorganization, consolidation, merger, dissolution or sale
of assets, or by any other voluntary act, avoid or seek to avoid the observance
or performance of any of the covenants, stipulations or conditions to be
observed or performed hereunder by Issuer; (iii) promptly to take all action as
may from time to time be required (including without limitation complying with
all premerger notification, reporting and waiting periods in 15 U.S.C.
Section 18a the rules and regulations thereunder) in order to permit Grantee
to exercise the Option and the Issuer duly and effectively to issue shares of
Common Stock pursuant hereto; and (iv) promptly to take all action provided
herein to protect the rights of Grantee against dilution.
6
<PAGE>
4. DIVISION OF OPTION; LOST OPTIONS. This Agreement (and the
Option granted hereby) are exchangeable, without expense, at the option of
Grantee, upon presentation and surrender of this Agreement at the principal
office of Issuer, for other Agreements providing for Options of different
denominations entitling the holder thereof to purchase, on the same terms and
subject to the same conditions as are set forth herein, in the aggregate the
same number of shares of Common Stock purchasable hereunder. The terms
"Agreement" and "Option" as used herein include any Stock Option Agreements and
related Options for which this Agreement (and the Option granted hereby) may be
exchanged. Upon receipt by Issuer of evidence reasonably satisfactory to it of
the loss, theft, destruction or mutilation of this Agreement, and (in the case
of loss, theft or destruction) of reasonably satisfactory indemnification, and
upon surrender and cancellation of this Agreement, if mutilated, Issuer will
execute and deliver a new Agreement of like tenor and date. Any such new
Agreement executed and delivered shall constitute an additional contractual
obligation on the part of Issuer, whether or not the Agreement so lost, stolen,
destroyed or mutilated shall at any time be enforceable by anyone.
5. ADJUSTMENT UPON CHANGES IN CAPITALIZATION. The number of
shares of Common Stock purchasable upon the exercise of the Option shall be
subject to adjustment from time to time as provided in this Section 5.
(a) In the event that any additional shares of Common Stock, or any
rights, options, warrants, subscriptions, calls, convertible securities or other
agreements or commitments obligating Issuer to issue any shares of Common Stock,
are issued or otherwise become outstanding after the date hereof (an
"Increase"), the number of shares of Common Stock subject to the Option shall be
increased by a number of shares equal to the product of (A) a fraction, the
numerator of which is the number of shares of Common Stock for which the Option
was exercisable immediately prior to the Increase and the denominator of which
is the number of shares of Common Stock specified in Section 1 hereof and (B)
the product of (i) 11.68193% and (ii) the number of shares of Common Stock on a
fully diluted basis immediately after the Increase minus the number of shares of
Common Stock on a fully diluted basis immediately prior to the Increase;
provided
7
<PAGE>
that the number of shares of Common Stock subject to the Option shall in no
event exceed 19.9% of the issued and outstanding shares of Common Stock
immediately prior to exercise.
(b) In the event of any change in Common Stock by reason of stock
dividends, splits, mergers, recapitalization, combinations, subdivisions,
conversions, exchanges of shares or other similar transactions and no adjustment
is required pursuant to the terms of Section 5(a), then, the type and number of
shares of Common Stock purchasable upon exercise hereof shall be appropriately
adjusted so that Grantee shall receive upon exercise of the Option and payment
of the aggregate Option Price hereunder the number and class of shares or other
securities or property that Grantee would have received in respect of Common
Stock if the Option had been exercised in full immediately prior to such event,
or the record date therefor, as applicable.
(c) Whenever the number of shares of Common Stock on a fully
diluted basis changes after the date hereof, the Option Price shall be adjusted
by multiplying the Option Price by a fraction, the numerator of which shall be
equal to the aggregate number of shares of Common Stock purchasable prior to the
adjustment and the denominator of which shall be equal to the aggregate number
of shares of Common Stock purchasable immediately after the adjustment.
6. REGISTRATION RIGHTS. Upon the occurrence of a Triggering
Event that occurs prior to an Exercise Termination Event (or as otherwise
provided in the last sentence of Section 2(e)), Issuer shall, at the request of
Grantee delivered at any time on or prior to the Option Expiration Date (whether
on its own behalf or on behalf of any subsequent holder of this Option (or part
thereof) or any of the shares of Common Stock issued pursuant hereto), promptly
prepare, file and keep current a shelf registration statement under the
Securities Act covering any shares issued and issuable pursuant to this Option
and shall use its best efforts to cause such registration statement to become
effective and remain current in order to permit the sale or other disposition of
any shares of Common Stock issued upon total or partial exercise of this Option
("OPTION SHARES") in accordance with any plan of disposition requested by
Grantee.
8
<PAGE>
Issuer will use its best efforts to cause such registration statement first to
become effective and then to remain effective for such period not in excess of
360 days from the day such registration statement first becomes effective or
such shorter time as may be reasonably necessary to effect such sales or other
dispositions. Grantee for a period of 18 months following such first request
shall have the right to demand a second such registration if reasonably
necessary to effect such sales or dispositions. The foregoing notwithstanding,
if, at the time of any request by Grantee for registration of Option Shares as
provided above, Issuer is in registration with respect to an underwritten public
offering of shares of Common Stock, and if in the good faith judgment of the
managing underwriter or managing underwriters, or, if none, the sole underwriter
or underwriters, of such offering the inclusion of the Grantee's Option or
Option Shares would interfere with the successful marketing of the shares of
Common Stock offered by Issuer, the number of Option Shares otherwise to be
covered in the registration statement contemplated hereby may be reduced; and
PROVIDED, HOWEVER, that after any such required reduction the number of
Option Shares to be included in such offering for the account of Grantee shall
constitute at least 25% of the total number of shares to be sold by Grantee and
Issuer in the aggregate; and PROVIDED FURTHER, HOWEVER, that if such
reduction occurs, then the Issuer shall file a registration statement for the
balance as promptly as practicable and no reduction shall thereafter occur (and
such registration shall not be charged against Grantee). Grantee shall provide
all information reasonably requested by Issuer for inclusion in any registration
statement to be filed hereunder. If requested by any Grantee in connection with
such registration, Issuer shall become a party to any underwriting agreement
relating to the sale of such shares, but only to the extent of obligating itself
in respect of representations, warranties, indemnities and other agreements
customarily included in such underwriting agreements for the Issuer. Upon
receiving any request under this Section 6 from Grantee, Issuer agrees to send a
copy thereof to any other person known to Issuer to be entitled to registration
rights under this Section 6, in each case by promptly mailing the same, postage
prepaid, to the address of record of the persons entitled to receive such
copies.
9
<PAGE>
7. REPURCHASE OF OPTION AND OPTION SHARES. (a) Within ten
business days following the occurrence of a Repurchase Event (as defined below),
Issuer shall (i) deliver an offer (a "REPURCHASE OFFER") to repurchase the
Option from Grantee at a price (the "OPTION REPURCHASE PRICE") equal to the
amount by which (A) the Alternative Transaction Price (as defined below) exceeds
(B) the Option Price, multiplied by the number of shares for which the Option
may then be exercised, and (ii) deliver an offer (also, a "REPURCHASE OFFER")
to repurchase the Option Shares from each owner of Option Shares from time to
time (each, an "OWNER") at a price (the "OPTION SHARE REPURCHASE PRICE")
equal to the Alternative Transaction Price multiplied by the number of Option
Shares then held by such Owner. The term "ALTERNATIVE TRANSACTION PRICE"
shall mean, as of any date for the determination thereof, the price per share of
Common Stock paid pursuant to the Alternative Transaction or, in the event of a
sale of assets of Issuer, the last per-share sale price of Common Stock on the
fourth trading day following the announcement of such sale. If the
consideration paid or received in the Alternative Transaction shall be other
than in cash, the value of such consideration shall be determined by a
nationally recognized investment banking firm selected by Grantee, which
determination shall be conclusive for all purposes of this Agreement.
(b) Upon the occurrence of a Repurchase Event and whether or not
Issuer shall have made a Repurchase Offer under Section 7(a), (i) at the request
(the date of such request being the "OPTION REPURCHASE REQUEST DATE") of
Grantee delivered prior to an the Option Expiration Date, Issuer shall
repurchase the Option from Grantee at the Option Repurchase Price and (ii) at
the request (the date of such request being the "OPTION SHARE REPURCHASE
REQUEST DATE") of any Owner delivered prior to the Option Expiration Date,
Issuer shall repurchase such number of the Option Shares from the Owner as the
Owner shall designate at the Option Share Repurchase Price.
(c) Grantee and/or the Owner, as the case may be, may accept
Issuer's Repurchase Offer under Section 7(a) or may exercise its right to
require Issuer to repurchase the Option and/or any Option Shares pursuant to
Section 7(b) by a written notice or notices stating that Grantee or the Owner,
as the case may be, elects to accept such offer or to require Issuer to
repurchase the
10
<PAGE>
Option and/or the Option Shares in accordance with the provisions of this
Section 7. As promptly as practicable, and in any event within five business
days, after the surrender to it of this Agreement and/or Certificates for Option
Shares, as applicable, following receipt of a notice under this Section 7(c) and
the occurrence of a Repurchase Event, Issuer shall deliver or cause to be
delivered to Grantee the Option Repurchase Price and/or to the Owner the Option
Share Repurchase Price and/or the portion thereof that Issuer is not then
prohibited from so delivering under applicable Law.
(d) Issuer hereby undertakes to use its best efforts to obtain all
required regulatory and legal approvals and to file any required notices as
promptly as practicable in order to accomplish any repurchase contemplated by
this Section 7. Nonetheless, to the extent that Issuer is prohibited under
applicable Law, from repurchasing the Option and/or any Option Shares in full,
Issuer shall immediately so notify Grantee and/or the Owner and thereafter
deliver or cause to be delivered, from time to time, to Grantee and/or the
Owner, as appropriate, the portion of the Option Repurchase Price and the Option
Share Repurchase Price, respectively, that it is no longer prohibited from
delivering, within five business days after the date on which Issuer is no
longer so prohibited; provided, however, that if Issuer at any time after
delivery of a notice of repurchase pursuant to Section 7(b) is prohibited under
applicable Law, from delivering to Grantee and/or the Owner, as appropriate, the
Option Repurchase Price or the Option Share Repurchase Price, respectively, in
full, Grantee or the Owner, as appropriate, may revoke its notice of repurchase
of the Option or the Option Shares either in whole or in part whereupon, in the
case of a revocation in part, Issuer shall promptly (i) deliver to Grantee
and/or the Owner, as appropriate, that portion of the Option Repurchase Price or
the Option Share Repurchase Price that Issuer is not prohibited from delivering
after taking into account any such revocation and (ii) deliver, as appropriate,
either (a) to Grantee, a new Agreement evidencing the right of Grantee to
purchase that number of shares of Common Stock equal to the number of shares of
Common Stock purchasable immediately prior to the delivery of the notice of
repurchase less the number of shares of Common Stock covered by the portion of
the Option repurchased or (b) to the Owner, a certificate for
11
<PAGE>
the number of Option Shares covered by the revocation. If an Exercise
Termination Event shall have occurred prior to the date of the notice by Issuer
described in the first sentence of this subsection (c), or shall be scheduled to
occur at any time before the expiration of a period ending on the thirtieth day
after such date, Grantee shall nonetheless have the right to exercise the Option
until the expiration of such 30-day period.
(e) The term "REPURCHASE EVENT" shall mean a Triggering Event
followed by the consummation of any transaction included in the definition of
Alternative Transaction.
(f) Notwithstanding anything to the contrary in Sections 2(a) and
2(e), the delivery of a notice by Grantee under Section 7(b) specifying that
such notice relating to an anticipated Repurchase Event under Section 7(d) is
based on the Issuer's public announcement of the execution of an agreement
providing for an Alternative Transaction shall be deemed to constitute an
election to exercise the Option, as to the number of Option Shares not
heretofore purchased pursuant to one or more prior exercises of the Option, on
the fifth business day following the public announcement of the consummation of
the transaction contemplated by such agreement, in which event a closing shall
occur with respect to such unpurchased Option Shares in accordance with Section
2(e) on such fifth business day (or such later date as determined pursuant to
the proviso in the first sentence of Section 2(e)).
8. SUBSTITUTE OPTION IN THE EVENT OF CORPORATE CHANGE. (a) In
the event that prior to an Exercise Termination Event, Issuer shall enter into
an agreement (i)to consolidate with or merge into any person, other than Grantee
or one of its subsidiaries, and shall not be the continuing or surviving
corporation of such consolidation or merger, (ii) to permit any person, other
than Grantee or one of its subsidiaries, to merge into Issuer and Issuer shall
be the continuing or surviving corporation, but, in connection with such merger,
the then outstanding shares of Common Stock shall be changed into or exchanged
for stock or other securities of any other person or cash or any other property
or the then outstanding shares of Common Stock shall after such merger represent
less than 50% of the outstanding shares and
12
<PAGE>
share equivalents of the merged company, or (iii) to sell or otherwise transfer
all or substantially all of its assets to any person, other than Grantee or one
of its subsidiaries, then, and in each such case, the agreement governing such
transaction shall make proper provision so that the Option shall, upon the
consummation of any such transaction and upon the terms and conditions set forth
herein, be converted into, or exchanged for, an option (the "SUBSTITUTE
Option"), at the election of Grantee, of either (x) the Acquiring Corporation
(as hereinafter defined) or (y) any person that controls the Acquiring
Corporation.
(b) The following terms have the meanings indicated:
(1) "ACQUIRING CORPORATION" shall mean (i) the continuing
or surviving corporation of a consolidation or merger with Issuer
(if other than Issuer), (ii) Issuer in a merger in which Issuer is
the continuing or surviving person, and (iii) the transferee of all
or substantially all of Issuer's assets.
(2) "SUBSTITUTE COMMON STOCK" shall mean the common stock
issued by the issuer of the Substitute Option upon exercise of the
Substitute Option.
(3) "ASSIGNED VALUE" shall mean the Alternative Transaction
Price, as defined in Section 7.
(4) "AVERAGE PRICE" shall mean the average closing price of
a share of the Substitute Common Stock for the one year immediately
preceding the consolidation, merger or sale in question, but in no
event higher than the closing price of the shares of Substitute
Common Stock on the day preceding such consolidation, merger or
sale; PROVIDED that if Issuer is the issuer of the Substitute
Option, the Average Price shall be computed with respect to a share
of common stock issued by the person merging into Issuer or by any
company which controls or is controlled by such person, as Grantee
may elect.
13
<PAGE>
(c) The Substitute Option shall have the same terms as the Option,
PROVIDED, that if the terms of the Substitute Option cannot, for legal
reasons, be the same as the Option, such terms shall be as similar as possible
and in no event less advantageous to Grantee. The issuer of the Substitute
Option shall also enter into an agreement with Grantee in substantially the same
form as this Agreement, which agreement shall be applicable to the Substitute
Option.
(d) The Substitute Option shall be exercisable for such number of
shares of Substitute Common Stock as is equal to the Assigned Value multiplied
by the number of shares of Common Stock for which the Option is then
exercisable, divided by the Average Price. The exercise price of the Substitute
Option per share of Substitute Common Stock shall then be equal to the Option
Price multiplied by a fraction, the numerator of which shall be the number of
shares of Common Stock for which the Option is then exercisable and the
denominator of which shall be the number of shares of Substitute Common Stock
for which the Substitute Option is exercisable.
(e) In no event, pursuant to any of the foregoing paragraphs, shall
the Substitute Option be exercisable for more than 19.9% of the shares of
Substitute Common Stock outstanding prior to exercise of the Substitute Option.
In the event that the Substitute Option would be exercisable for more than 19.9%
of the shares of Substitute Common Stock outstanding prior to exercise but for
this clause (e), the issuer of the Substitute Option (the "SUBSTITUTE OPTION
Issuer") shall make a cash payment to Grantee equal to the excess of (i) the
value of the Substitute Option without giving effect to the limitation in this
clause (e) over (ii) the value of the Substitute Option after giving effect to
the limitation in this clause (e). This difference in value shall be determined
by a nationally recognized investment banking firm selected by Grantee.
(f) Issuer shall not enter into any transaction described in
subsection (a) of this Section 8 unless the Acquiring Corporation and any person
that controls the Acquiring Corporation assume in writing all the obligations of
Issuer hereunder.
14
<PAGE>
9. EXTENSION OF TIME FOR REGULATORY APPROVALS. The 18-month
period for exercise of certain rights under Sections 2, 6 and 11 shall be
extended: (i) to the extent necessary to obtain all regulatory approvals for
the exercise of such rights, and for the expiration of all statutory waiting
periods; and (ii) to the extent necessary to avoid liability under Section 10(b)
of the Exchange Act by reason of such exercise.
10. REPRESENTATIONS AND WARRANTIES OF THE ISSUER. Issuer hereby
represents and warrants to Grantee as follows:
(a) Issuer has full corporate power and authority to execute and
deliver this Agreement and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by the
Board of Directors of Issuer and no other corporate proceedings on the part of
Issuer are necessary to authorize this Agreement or to consummate the
transactions so contemplated. This Agreement has been duly and validly executed
and delivered by Issuer. This Agreement is the valid and legally binding
obligation of Issuer, enforceable against Issuer in accordance with its terms.
(b) Issuer has taken all necessary corporate action to authorize
and reserve and to permit it to issue, and at all times from the date hereof
through the termination of this Agreement in accordance with its terms will have
reserved for issuance upon the exercise of the Option, that number of shares of
Common Stock equal to the maximum number of shares of Common Stock at any time
and from time to time issuable hereunder, and all such shares, upon issuance
pursuant hereto, will be duly authorized, validly issued, fully paid,
nonassessable, and will be delivered free and clear of all claims, liens,
encumbrance and security interests and not subject to any preemptive rights.
(c) The execution and delivery of this Agreement does not, and the
consummation of the transactions contemplated hereby will not, conflict with, or
result in any violation pursuant to any provisions of the Articles of
Incorporation or by-laws of Issuer or any Issuer subsidiary, subject to
obtaining any approvals or con-
15
<PAGE>
sents contemplated hereby, result in any violation of any loan or credit
agreement, note, mortgage, indenture, lease, plan or other agreement,
obligation, instrument, permit, concession, franchise, license, judgment, order,
decree, statute, law, ordinance, rule or regulation applicable to Issuer or any
Issuer subsidiary or their respective properties or assets which violation would
have, individually or in the aggregate, a Parent Material Adverse Effect.
(d) The provisions of Sections 78.411-78.444 of the General
Corporation Law of Nevada will not, prior to the termination of this Agreement
(assuming that prior to the date hereof neither the Grantee nor any of its
affiliates or associates (as such terms are defined in the Exchange Act) (i)
beneficially owns, directly or indirectly, or (ii) are parties to any agreement,
arrangement or understanding for the purpose of acquiring, holding, voting or
disposing of, in each case, shares of capital stock of the Issuer, which in the
aggregate, represent 10% or more of the outstanding shares of capital stock of
the Issuer entitled to vote generally in the electing of directors (other than
shares held in a fiduciary capacity)), apply to this Agreement or the
transactions contemplated hereby and thereby. The Issuer has taken, and will in
the future take, all steps necessary to irrevocably exempt the transactions
contemplated by this Agreement from any other applicable state takeover law and
from any applicable charter or contractual provision containing change of
control or anti-takeover provisions.
11. ASSIGNMENT OF OPTION BY GRANTEE. Neither of the parties
hereto may assign any of its rights or obligations under this Option Agreement
or the Option created hereunder to any other person, without the express written
consent of the other party.
12. LIMITATION OF GRANTEE PROFIT. (a) Notwithstanding any other
provision of this Agreement, in no event shall the Grantee's Total Profit (as
hereinafter defined) exceed $55,000,000 and, if it otherwise would exceed such
amount, the Grantee, at its sole election, shall either (i) reduce the number of
shares of Common Stock subject to this Option, (ii) deliver to the Issuer for
cancellation Option Shares previously purchased by Grantee, (iii) pay cash to
the Issuer, or (iv) any combi-
16
<PAGE>
nation thereof, so that Grantee's actually realized Total Profit shall not
exceed $55,000,000 after taking into account the foregoing actions.
(b) As used herein, the term "TOTAL PROFIT" shall mean the amount
(before taxes) of the following: (a) the aggregate amount of (i) (x) the net
cash amounts received by Grantee pursuant to the sale of Option Shares (or any
other securities into which such Option Shares are converted or exchanged) to
any unaffiliated party within 12 months from the exercise of this Option with
respect to such Option Shares, less (y) the Grantee's purchase price of such
Option Shares, (ii) any amounts received by Grantee on the transfer of the
Option (or any portion thereof) to any unaffiliated party, if permitted
hereunder, (iii) any equivalent amount with respect to the Substitute Option,
and (iv) the amount received by Grantee pursuant to Section 9.3 of the Merger
Agreement; MINUS (b) the amount of cash paid to the Issuer pursuant to this
Section 12 plus the value of the Option Shares delivered to the Issuer for
cancellation.
(c) Notwithstanding any other provision of this Agreement, nothing
in this Agreement shall affect the ability of Grantee to receive nor relieve
Issuer's obligation to pay a fee pursuant to Section 9.3 of the Merger
Agreement; PROVIDED that if Total Profit received by Grantee would exceed
$55,000,000 following the receipt of such fee, Grantee shall be obligated to
comply with the terms of Section 12(a) within 30 days of the later of (i) the
date of receipt of such fee and (ii) the date of receipt of the net cash by
Grantee pursuant to the sale of Option Shares (or any other securities into
which such Option Shares are converted or exchanged) to any unaffiliated party
within 12 months of the exercise of this Option with respect to such Option
Shares.
13. FIRST REFUSAL. At any time after the first occurrence of a
Triggering Event and prior to the later of (a) the expiration of 18 months
immediately following the first purchase of shares of Issuer Common Stock
pursuant to the Option and (b) the Option Termination Date, if Grantee shall
desire to sell, assign, transfer or otherwise dispose of all or any of the
Option or the shares of Issuer Common Stock or other securities acquired by it
pursuant to the Option, it shall give Issuer written notice of the proposed
transaction (an
17
<PAGE>
"OFFEROR'S NOTICE"), identifying the proposed transferee, accompanied by a
copy of a binding offer to purchase the Option or such shares or other
securities signed by such transferee and setting forth the terms of the proposed
transaction. An Offeror's Notice shall be deemed an offer by Grantee to Issuer,
which may be accepted within 20 business days of the receipt of such Offeror's
Notice, on the same terms and conditions and at the same price at which Grantee
is proposing to transfer the Option or such shares or other securities to such
transferee. The purchase of the Option or any such shares or other securities
by Issuer shall be settled within 10 business days of the date of the acceptance
of the offer and the purchase price shall be paid to Grantee in immediately
available funds; provided that, if prior notification to or approval of any
regulatory authority is required in connection with such purchase, Issuer shall
promptly file the required notice or application for approval and shall
expeditiously process the same (and Grantee shall cooperate with Issuer in the
filing of any such notice or application and the obtaining of any such approval)
and the period of time that otherwise would run pursuant to this sentence shall
run instead from the date on which, as the case may be, (a) required
notification period has expired or been terminated or (b) such approval has been
obtained and, in either event, any requisite waiting period shall have passed.
In the event of the failure or refusal of Issuer to purchase all of the Option
or all of the shares or other securities covered by an Offeror's Notice or if
any regulatory authority disapproves Issuer's proposed purchase of any portion
of the Option or such shares or other securities, Grantee may, within 60 days
from the date of the Offeror's Notice (subject to any necessary extension for
regulatory notification, approval or waiting periods), sell all, but not less
than all, of such portion of the Option or such shares or other securities to
the proposed transferee at no less than the price specified and on terms no more
favorable than those set forth in the Offeror's Notice. The requirements of
this Section 11 shall not apply to (w) any disposition as a result of which the
proposed transferee would own beneficially not more than 2% of the outstanding
voting power of Issuer, (x) any disposition of Issuer Common Stock or other
securities by a person to whom grantee has assigned its rights under the Option
with the consent of Issuer, (y) any sale by means of a public offering
registered under the Securities Act in which
18
<PAGE>
steps are taken to reasonably assure that no purchaser will acquire securities
representing more than 2% of the outstanding voting power of Issuer or (z) any
transfer to a wholly owned subsidiary of Grantee which agrees in writing to be
bound by the terms hereof.
14. VOTING. For a period of 18 months from the date of exercise
of the Option, so long as Grantee beneficially owns any Option Shares, Grantee
agrees to (a) be present, in person or represented by proxy, at all stockholder
meetings of Issuer, so that all Option Shares beneficially owned by holder may
be counted for the purpose of determining the presence of a quorum at such
meetings, and (b) vote or cause to be voted all Option Shares beneficially owned
by it, with respect to all matters submitted to shareholders for a vote, in the
same proportion as shares of Common Stock are voted by shareholders unaffiliated
with Grantee.
15. APPLICATION FOR REGULATORY APPROVAL. Each of Grantee and
Issuer will use its best efforts to make all filings with, and to obtain
consents of, all third parties and governmental authorities necessary to the
consummation of the transactions contemplated by this Agreement, including
without limitation making application to list the shares of Common Stock
issuable hereunder on the New York Stock Exchange upon official notice of
issuance.
16. SPECIFIC PERFORMANCE. The parties hereto acknowledge that
damages would be an inadequate remedy for a breach of this Agreement by either
party hereto and that the obligations of the parties hereto shall be enforceable
by either party hereto through injunctive or other equitable relief.
17. SEPARABILITY OF PROVISIONS. If any term, provision, covenant
or restriction contained in this Agreement is held by a court or a federal or
state regulatory agency of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions and covenants and
restrictions contained in this Agreement shall remain in full force and effect,
and shall in no way be affected, impaired or invalidated.
18. NOTICES. All notices, claims, demands and other
communications hereunder shall be deemed to have
19
<PAGE>
been duly given or made when delivered in person, by registered or certified
mail (postage prepaid, return receipt requested), by overnight courier or by
facsimile at the respective addresses of the parties set forth in the Merger
Agreement.
19. GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, regardless of
the laws that might otherwise govern under applicable principles of conflicts of
laws thereof.
20. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which will be deemed to be an original, but all of which
shall constitute one and the same agreement.
21. EXPENSES. Except as otherwise expressly provided herein or
in the Merger Agreement, each of the parties hereto shall bear and pay all costs
and expenses incurred by it or on its behalf in connection with the transactions
contemplated hereunder, including fees and expenses of its own financial
consultants, investment bankers, accountants and counsel.
22. ENTIRE AGREEMENT. Except as otherwise expressly provided
herein or in the Merger Agreement, this Agreement contains the entire agreement
between the parties with respect to the transactions contemplated hereunder and
supersedes all prior arrangements or understandings with respect thereof,
written or oral. The terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective
successors and permitted assigns. Nothing in this Agreement, expressed or
implied, is intended to confer upon any party, other than the parties hereto,
and their respective successors except as assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein. Any provision of this Agreement may be waived only
in writing at any time by the party that is entitled to the benefits of such
provision. This Agreement may not be modified, amended, altered or supplemented
except upon the execution and delivery of a written agreement executed by the
parties hereto.
20
<PAGE>
23. FURTHER ASSURANCES. In the event of any exercise of the
Option by Grantee, Issuer and Grantee shall execute and deliver all other
documents and instruments and take all other action that may be reasonably
necessary in order to consummate the transactions provided for by such exercise.
Nothing contained in this Agreement shall be deemed to authorize Issuer or
Grantee to breach any provision of the Merger Agreement.
21
<PAGE>
IN WITNESS WHEREOF, OrNda Healthcorp and Tenet Healthcare
Corporation have caused this Agreement to be signed by their respective officers
thereunto duly authorized, all as of the date first written above.
ORNDA HEALTHCORP
By:
-----------------------------
Name:
----------------------------
Title:
---------------------------
Attest:
Name:
-------------------------
Title:-------------------------
TENET HEALTHCARE CORPORATION
By:
-----------------------------
Name:
----------------------------
Title:
---------------------------
Attest:
Name:
-------------------------
Title:------------------------
<PAGE>
EXHIBIT F-2
FORM OF
STOCK OPTION AGREEMENT
THIS STOCK OPTION AGREEMENT (this "AGREEMENT"), dated October 17,
1996, between OrNda Healthcorp, a Delaware corporation ("ISSUER"), and Tenet
Healthcare Corporation, a Nevada corporation ("GRANTEE"),
W I T N E S S E T H:
WHEREAS, Grantee and Issuer, among others, have entered into an
Agreement and Plan of Merger, dated as of October 16, 1996 (the "MERGER
AGREEMENT"), which agreement has been executed by the parties hereto prior to
this Agreement (capitalized terms used herein without definition shall have the
respective meanings specified in the Merger Agreement); and
WHEREAS, as a condition to Grantee's entering into the Merger
Agreement and in consideration therefor, Issuer has agreed to grant Grantee the
Option (as hereinafter defined);
NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth herein and in the Merger Agreement, the
parties hereto agree as follows:
1. GRANT OF OPTION. Issuer hereby grants to Grantee an
unconditional, irrevocable option (the "OPTION") to purchase, subject to the
terms hereof, 11,608,358 shares of fully paid and nonassessable common stock
of the Issuer, par value $.01 per share ("COMMON STOCK"), equal to 19.9% of
the number of shares of Common Stock issued and outstanding as of the date
hereof at a purchase price of $29.869 per share of Common Stock, as adjusted in
accordance with the provisions of Section 5 of this Agreement (such price, as
adjusted if applicable, the "OPTION PRICE").
2. (a) EXERCISE OF OPTION. Grantee may exercise the Option, in
whole or part, and from time to time, if, but only if, a Triggering Event (as
hereinafter defined) shall have occurred prior to the occurrence of an Option
Termination Event (as hereinafter defined),
<PAGE>
provided that Grantee shall have sent the written notice of such exercise (as
provided in subsection (e) of this Section 2 on or prior to the last date of the
18-month period following such Triggering Event (the "Option Expiration Date").
(b) OPTION TERMINATION EVENTS. The term "OPTION TERMINATION
EVENT" shall mean either of the following events: (i) immediately prior to the
Effective Time of the Merger; or (ii) termination of the Merger Agreement (A)
by either party pursuant to Section 9.1(c) of the Merger Agreement, whether or
not such termination occurs prior to the occurrence of a Triggering Event,
provided that the matter giving rise to the order, decree, ruling or other
action providing the basis for termination under Section 9.1(c) shall not have
been initiated by Issuer or any Bidder, (B) by Grantee pursuant to Section
9.1(d)(i) of the Merger Agreement because of a material adverse change in the
business, financial condition, results of operations, properties, assets or
liabilities of Issuer and its subsidiaries taken as a whole (other than any
change relating to the United States economy in general or to the United
States investor-owned hospital business in general) that is caused by the
matters described in Schedule 5.8(a) to the Company Disclosure Letter if such
termination occurs prior to the occurrence of a Triggering Event described in
clause (i) of Section 2(c) hereof or (iii) by either party pursuant to any
other provision of the Merger Agreement if such termination occurs prior to
the occurrence of a Triggering Event.
(c) TRIGGERING EVENTS. The term "TRIGGERING EVENT" shall mean
either of the following events occurring after the date hereof:
(i) Any event shall have occurred that would entitle either
party to terminate the Merger Agreement and permit Grantee to
receive any fee from Issuer pursuant to Section 9.3 of the Merger
Agreement (a "SECTION 9.3 EVENT"); or
(ii) Any person (the term "PERSON" for purposes of this
Agreement having the meaning assigned thereto in Sections 3(a)(9)
and 13(d)(3) of the Securities Exchange Act of
2
<PAGE>
1934, as amended (the "EXCHANGE ACT"), and the rules and
regulations thereunder), other than Grantee or any of its
subsidiaries or affiliates (such person, the "BIDDER"), shall make
an offer or proposal for, or an announcement of any intention with
respect to (including, without limitation, the filing of a statement
of beneficial ownership on Schedule 13D discussing the possibility
of, or reserving the right to engage in), an Alternative
Transaction.
(d) NOTICE OF TRIGGERING EVENT. Issuer shall notify Grantee
promptly in writing of the occurrence of any Triggering Event, it being
understood that the giving of such notice by Issuer shall not be a condition to
the right of Grantee to exercise the Option or for a Triggering Event to have
occurred.
(e) NOTICE OF EXERCISE; CLOSING. In the event Grantee is
entitled to and wishes to exercise the Option, it shall send to Issuer a written
notice (the date of which being herein referred to as the "NOTICE DATE")
specifying (i) the total number of shares it will purchase pursuant to such
exercise and (ii) a place and date not earlier than three business days nor
later than 60 business days from the Notice Date for the closing of such
purchase (the "CLOSING DATE"); PROVIDED, that if the closing of the purchase
and sale pursuant to the Option (the "CLOSING") cannot be consummated, in the
reasonable opinion of Grantee, by reason of any applicable judgment, decree,
order, law or regulation, the period of time that otherwise would run pursuant
to this sentence shall run instead from the date on which such restriction on
consummation has expired or been terminated; and PROVIDED FURTHER, without
limiting the foregoing, that if, in the reasonable opinion of Grantee, prior
notification to or approval of any regulatory agency is required in connection
with such purchase, Grantee shall promptly file the required notice or
application for approval and shall expeditiously process the same and the period
of time that otherwise would run pursuant to this sentence shall run instead
from the date on which any required notification periods have expired or been
terminated or such approvals have been obtained and any requisite waiting period
or periods shall have passed. Any exercise of the Option shall be deemed to
occur on the Notice Date relating thereto. Notwithstanding this subsection (e),
in no
3
<PAGE>
event shall any Closing Date be more than 18 months after the related Notice
Date, and if the Closing Date shall not have occurred within 18 months after the
related Notice Date due to the failure to obtain any such required approval, the
exercise of the Option effected on the Notice Date shall be deemed to have
expired. In the event (x) Grantee receives official notice that an approval of
any regulatory authority required for the purchase of Option Shares (as
hereinafter defined) would not be issued or granted, (y) a Closing Date shall
not have occurred within 18 months after the related Notice Date due to the
failure to obtain any such required approval or (z) Grantee shall have the right
pursuant to the last sentence of Section 8 (or Section 10) to exercise the
Option (or Substitute Option), Grantee shall nevertheless be entitled to
exercise its right as set forth in Section 8 and Grantee shall be entitled to
exercise the Option (or Substitute Option) in connection with the resale of
Issuer Common Stock or other securities pursuant to a registration statement as
provided in Section 6.
(f) PURCHASE PRICE. At the Closing referred to in subsection (e)
of this Section 2, Grantee shall pay to Issuer the aggregate purchase price for
the shares of Common Stock purchased pursuant to the exercise of the Option in
immediately available funds by wire transfer to a bank account designated by
Issuer, PROVIDED that failure or refusal of Issuer to designate such a bank
account shall not preclude Grantee from exercising the Option.
(g) ISSUANCE OF COMMON STOCK. At such Closing, simultaneously
with the delivery of immediately available funds as provided in subsection (f)
of this Section 2, Issuer shall deliver to Grantee a certificate or certificates
representing the number of shares of Common Stock purchased by the Grantee and,
if the Option should be exercised in part only, a new Option evidencing the
rights of Grantee thereof to purchase the balance of the shares purchasable
hereunder, and the Grantee shall deliver to Issuer a copy of this Agreement and
a letter agreeing that Grantee will not offer to sell or otherwise dispose of
such shares in violation of applicable law or the provisions of this Agreement.
If at the time of issuance of any Option Shares pursuant to an exercise of all
or part of the Option hereunder, Issuer shall not have redeemed the Parent
Rights, or shall have issued any
4
<PAGE>
similar securities, then each Option Share issued pursuant to such exercise
shall also represent rights or new rights with terms substantially the same as
and at least as favorable to Grantee as are provided under Issuer's shareholder
rights agreement or any similar agreement then in effect.
(h) LEGEND. Certificates for Common Stock delivered at a closing
hereunder may be endorsed with a restrictive legend that shall read
substantially as follows:
"The transfer and voting of the shares represented by this
certificate is subject to certain provisions of an agreement between
the registered holder hereof and Issuer and to resale restrictions
arising under the Securities Act of 1933, as amended. A copy of
such agreement is on file at the principal office of Issuer and will
be provided to the holder hereof without charge upon receipt by
Issuer of a written request therefor."
It is understood and agreed that: (i) the reference to the resale restrictions
of the Securities Act of 1933, as amended (the "SECURITIES ACT"), in the above
legend shall be removed by delivery of substitute certificate(s) without such
reference if Grantee shall have delivered to Issuer a copy of a letter from the
staff of the SEC, or an opinion of counsel, in form and substance reasonably
satisfactory to Issuer, to the effect that such legend is not required for
purposes of the Securities Act; (ii) the reference to the provisions of this
Agreement in the above legend shall be removed by delivery of substitute
certificate(s) without such reference if the shares have been sold or
transferred in compliance with the provisions of this Agreement and under
circumstances that do not require the retention of such reference; and (iii) the
legend shall be removed in its entirety if the conditions in the preceding
clauses (i) and (ii) are both satisfied. In addition, such certificates shall
bear any other legend as may be required by law.
(i) RECORD GRANTEE; EXPENSES. Upon the giving by Grantee to
Issuer of the written notice of exercise of the Option provided for under
subsection (e) of this Section 2 and the tender of the applicable purchase price
5
<PAGE>
in immediately available funds, Grantee shall be deemed to be the holder of
record of the shares of Common Stock issuable upon such exercise,
notwithstanding that the stock transfer books of Issuer shall then be closed or
that certificates representing such shares of Common Stock shall not then be
actually delivered to Grantee or the Issuer shall have failed or refused to
designate the bank account described in subsection (f) of this Section 2.
Issuer shall pay all expenses, and any and all United States federal, state and
local taxes and other charges that may be payable in connection with the
preparation, issuance and delivery of stock certificates under this Section 2 in
the name of Grantee or its assignee, transferee or designee.
3. RESERVATION OF SHARES. Issuer agrees: (i) that it shall at
all times maintain, free from preemptive rights, sufficient authorized but
unissued or treasury shares of Common Stock (and other securities issuable
pursuant to Section 5(a)) so that the Option may be exercised without additional
authorization of Common Stock (or such other securities) after giving effect to
all other options, warrants, convertible securities and other rights to purchase
Common Stock (or such other securities); (ii) that it will not, by charter
amendment or through reorganization, consolidation, merger, dissolution or sale
of assets, or by any other voluntary act, avoid or seek to avoid the observance
or performance of any of the covenants, stipulations or conditions to be
observed or performed hereunder by Issuer; (iii) promptly to take all action as
may from time to time be required (including without limitation complying with
all premerger notification, reporting and waiting periods in 15 U.S.C.
Section 18a and the rules and regulations thereunder) in order to permit
Grantee to exercise the Option and the Issuer duly and effectively to issue
shares of Common Stock pursuant hereto; and (iv) promptly to take all action
provided herein to protect the rights of Grantee against dilution.
4. DIVISION OF OPTION; LOST OPTIONS. This Agreement (and the
Option granted hereby) are exchangeable, without expense, at the option of
Grantee, upon presentation and surrender of this Agreement at the principal
office of Issuer, for other Agreements providing for Options of different
denominations entitling the holder thereof to purchase, on the same terms and
subject
6
<PAGE>
to the same conditions as are set forth herein, in the aggregate the same number
of shares of Common Stock purchasable hereunder. The terms "Agreement" and
"Option" as used herein include any Stock Option Agreements and related Options
for which this Agreement (and the Option granted hereby) may be exchanged. Upon
receipt by Issuer of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Agreement, and (in the case of loss, theft or
destruction) of reasonably satisfactory indemnification, and upon surrender and
cancellation of this Agreement, if mutilated, Issuer will execute and deliver a
new Agreement of like tenor and date. Any such new Agreement executed and
delivered shall constitute an additional contractual obligation on the part of
Issuer, whether or not the Agreement so lost, stolen, destroyed or mutilated
shall at any time be enforceable by anyone.
5. ADJUSTMENT UPON CHANGES IN CAPITALIZATION. The number of
shares of Common Stock purchasable upon the exercise of the Option shall be
subject to adjustment from time to time as provided in this Section 5.
(a) In the event that any additional shares of Common Stock, or any
rights, options, warrants, subscriptions, calls, convertible securities or other
agreements or commitments obligating Issuer to issue any shares of Common Stock,
are issued or otherwise become outstanding after the date hereof (an
"INCREASE"), the number of shares of Common Stock subject to the Option shall
be increased so that the number of shares issuable upon exercise of the Option
shall be equal to the product of (A) the percentage of the outstanding Common
Stock for which the Option was exercisable immediately prior to the Increase and
(B) the number of shares of Common Stock outstanding immediately after the
Increase; provided that the number of shares of Common Stock subject to the
Option shall in no event exceed 19.9% of the issued and outstanding shares of
Common Stock immediately prior to exercise.
(b) In the event of any change in Common Stock by reason of stock
dividends, splits, mergers, recapitalization, combinations, subdivisions,
conversions, exchanges of shares or other similar transactions, and no
adjustment is required pursuant to the terms of Section 5(a), then the type and
number of shares of Common Stock
7
<PAGE>
purchasable upon exercise hereof shall be appropriately adjusted so that Grantee
shall receive upon exercise of the Option and payment of the aggregate Option
Price hereunder the number and class of shares or other securities or property
that Grantee would have received in respect of Common Stock if the Option had
been exercised in full immediately prior to such event, or the record date
therefor, as applicable.
(c) Whenever the number of shares of Common Stock on a fully
diluted basis changes after the date hereof, the Option Price shall be adjusted
by multiplying the Option Price by a fraction, the numerator of which shall be
equal to the aggregate number of shares of Common Stock purchasable prior to the
adjustment and the denominator of which shall be equal to the aggregate number
of shares of Common Stock purchasable immediately after the adjustment.
6. REGISTRATION RIGHTS. Upon the occurrence of a Triggering
Event that occurs prior to an Exercise Termination Event (or as otherwise
provided in the last sentence of Section 2(e)), Issuer shall, at the request of
Grantee delivered at any time on or prior to the Option Expiration Date (whether
on its own behalf or on behalf of any subsequent holder of this Option (or part
thereof) or any of the shares of Common Stock issued pursuant hereto), promptly
prepare, file and keep current a shelf registration statement under the
Securities Act covering any shares issued and issuable pursuant to this Option
and shall use its best efforts to cause such registration statement to become
effective and remain current in order to permit the sale or other disposition of
any shares of Common Stock issued upon total or partial exercise of this Option
("OPTION SHARES") in accordance with any plan of disposition requested by
Grantee. Issuer will use its best efforts to cause such registration statement
first to become effective and then to remain effective for such period not in
excess of 360 days from the day such registration statement first becomes
effective or such shorter time as may be reasonably necessary to effect such
sales or other dispositions. Grantee for a period of 18 months following such
first request shall have the right to demand a second such registration if
reasonably necessary to effect such sales or dispositions. The foregoing
notwithstanding, if, at the time of any request by Grantee for registr-
8
<PAGE>
ation of Option Shares as provided above, Issuer is in registration with respect
to an underwritten public offering of shares of Common Stock, and if in the good
faith judgment of the managing underwriter or managing underwriters, or, if
none, the sole underwriter or underwriters, of such offering the inclusion of
the Grantee's Option or Option Shares would interfere with the successful
marketing of the shares of Common Stock offered by Issuer, the number of Option
Shares otherwise to be covered in the registration statement contemplated hereby
may be reduced; and PROVIDED, HOWEVER, that after any such required reduction
the number of Option Shares to be included in such offering for the account of
Grantee shall constitute at least 25% of the total number of shares to be sold
by Grantee and Issuer in the aggregate; and PROVIDED FURTHER, HOWEVER,
that if such reduction occurs, then the Issuer shall file a registration
statement for the balance as promptly as practicable and no reduction shall
thereafter occur (and such registration shall not be charged against Grantee).
Grantee shall provide all information reasonably requested by Issuer for
inclusion in any registration statement to be filed hereunder. If requested by
any Grantee in connection with such registration, Issuer shall become a party to
any underwriting agreement relating to the sale of such shares, but only to the
extent of obligating itself in respect of representations, warranties,
indemnities and other agreements customarily included in such underwriting
agreements for the Issuer. Upon receiving any request under this Section 6 from
Grantee, Issuer agrees to send a copy thereof to any other person known to
Issuer to be entitled to registration rights under this Section 6, in each case
by promptly mailing the same, postage prepaid, to the address of record of the
persons entitled to receive such copies.
7. REPURCHASE OF OPTION AND OPTION SHARES. (a) Within ten
business days following the occurrence of a Repurchase Event (as defined below),
Issuer shall (i) deliver an offer (a "REPURCHASE OFFER") to repurchase the
Option from Grantee at a price (the "OPTION REPURCHASE PRICE") equal to the
amount by which (A) the Alternative Transaction Price (as defined below)
exceeds (B) the Option Price, multiplied by the number of shares for which the
Option may then be exercised, and (ii) deliver an offer (also, a "REPURCHASE
OFFER") to repurchase the Option Shares from each owner of Option Shares from
time
9
<PAGE>
to time (each, an "OWNER") at a price (the "OPTION SHARE REPURCHASE PRICE")
equal to the Alternative Transaction Price multiplied by the number of Option
Shares then held by such Owner. The term "ALTERNATIVE TRANSACTION PRICE"
shall mean, as of any date for the determination thereof, the price per share of
Common Stock paid pursuant to the Alternative Transaction or, in the event of a
sale of assets of Issuer, the last per-share sale price of Common Stock on the
fourth trading day following the announcement of such sale. If the
consideration paid or received in the Alternative Transaction shall be other
than in cash, the value of such consideration shall be determined by a
nationally recognized investment banking firm selected by Grantee, which
determination shall be conclusive for all purposes of this Agreement.
(b) Upon the occurrence of a Repurchase Event and whether or not
Issuer shall have made a Repurchase Offer under Section 7(a), (i) at the request
(the date of such request being the "OPTION REPURCHASE REQUEST DATE") of
Grantee delivered prior to an the Option Expiration Date, Issuer shall
repurchase the Option from Grantee at the Option Repurchase Price and (ii) at
the request (the date of such request being the "OPTION SHARE REPURCHASE
REQUEST DATE") of any Owner delivered prior to the Option Expiration Date,
Issuer shall repurchase such number of the Option Shares from the Owner as the
Owner shall designate at the Option Share Repurchase Price.
(c) Grantee and/or the Owner, as the case may be, may accept
Issuer's Repurchase Offer under Section 7(a) or may exercise its right to
require Issuer to repurchase the Option and/or any Option Shares pursuant to
Section 7(b) by a written notice or notices stating that Grantee or the Owner,
as the case may be, elects to accept such offer or to require Issuer to
repurchase the Option and/or the Option Shares in accordance with the provisions
of this Section 7. As promptly as practicable, and in any event within five
business days, after the surrender to it of this Agreement and/or Certificates
for Option Shares, as applicable, following receipt of a notice under this
Section 7(c) and the occurrence of a Repurchase Event, Issuer shall deliver or
cause to be delivered to Grantee the Option Repurchase Price and/or to the Owner
the Option Share Repurchase Price and/or the portion thereof that Issuer is not
then prohibited from so delivering under applicable Law.
10
<PAGE>
(d) Issuer hereby undertakes to use its best efforts to obtain all
required regulatory and legal approvals and to file any required notices as
promptly as practicable in order to accomplish any repurchase contemplated by
this Section 7. Nonetheless, to the extent that Issuer is prohibited under
applicable Law, from repurchasing the Option and/or any Option Shares in full,
Issuer shall immediately so notify Grantee and/or the Owner and thereafter
deliver or cause to be delivered, from time to time, to Grantee and/or the
Owner, as appropriate, the portion of the Option Repurchase Price and the Option
Share Repurchase Price, respectively, that it is no longer prohibited from
delivering, within five business days after the date on which Issuer is no
longer so prohibited; provided, however, that if Issuer at any time after
delivery of a notice of repurchase pursuant to Section 7(b) is prohibited under
applicable Law, from delivering to Grantee and/or the Owner, as appropriate, the
Option Repurchase Price or the Option Share Repurchase Price, respectively, in
full, Grantee or the Owner, as appropriate, may revoke its notice of repurchase
of the Option or the Option Shares either in whole or in part whereupon, in the
case of a revocation in part, Issuer shall promptly (i) deliver to Grantee
and/or the Owner, as appropriate, that portion of the Option Repurchase Price or
the Option Share Repurchase Price that Issuer is not prohibited from delivering
after taking into account any such revocation and (ii) deliver, as appropriate,
either (a) to Grantee, a new Agreement evidencing the right of Grantee to
purchase that number of shares of Common Stock equal to the number of shares of
Common Stock purchasable immediately prior to the delivery of the notice of
repurchase less the number of shares of Common Stock covered by the portion of
the Option repurchased or (b) to the Owner, a certificate for the number of
Option Shares covered by the revocation. If an Exercise Termination Event shall
have occurred prior to the date of the notice by Issuer described in the first
sentence of this subsection (c), or shall be scheduled to occur at any time
before the expiration of a period ending on the thirtieth day after such date,
Grantee shall nonetheless have the right to exercise the Option until the
expiration of such 30-day period.
(e) The term "REPURCHASE EVENT" shall mean a Triggering Event
followed by the consummation of any
11
<PAGE>
transaction included in the definition of Alternative Transaction.
(f) Notwithstanding anything to the contrary in Sections 2(a) and
2(e), the delivery of a notice by Grantee under Section 7(b) specifying that
such notice relating to an anticipated Repurchase Event under Section 7(d) is
based on the Issuer's public announcement of the execution of an agreement
providing for an Alternative Transaction shall be deemed to constitute an
election to exercise the Option, as to the number of Option Shares not
heretofore purchased pursuant to one or more prior exercises of the Option, on
the fifth business day following the public announcement of the consummation of
the transaction contemplated by such agreement, in which event a closing shall
occur with respect to such unpurchased Option Shares in accordance with Section
2(e) on such fifth business day (or such later date as determined pursuant to
the proviso in the first sentence of Section 2(e)).
8. SUBSTITUTE OPTION IN THE EVENT OF CORPORATE CHANGE. (a) In
the event that prior to an Exercise Termination Event, Issuer shall enter into
an agreement (i)to consolidate with or merge into any person, other than Grantee
or one of its subsidiaries, and shall not be the continuing or surviving
corporation of such consolidation or merger, (ii) to permit any person, other
than Grantee or one of its subsidiaries, to merge into Issuer and Issuer shall
be the continuing or surviving corporation, but, in connection with such merger,
the then outstanding shares of Common Stock shall be changed into or exchanged
for stock or other securities of any other person or cash or any other property
or the then outstanding shares of Common Stock shall after such merger represent
less than 50% of the outstanding shares and share equivalents of the merged
company, or (iii) to sell or otherwise transfer all or substantially all of its
assets to any person, other than Grantee or one of its subsidiaries, then, and
in each such case, the agreement governing such transaction shall make proper
provision so that the Option shall, upon the consummation of any such
transaction and upon the terms and conditions set forth herein, be converted
into, or exchanged for, an option (the "SUBSTITUTE OPTION"), at the election
of Grantee, of either (x) the Acquiring Corporation (as hereinafter
12
<PAGE>
defined) or (y) any person that controls the Acquiring Corporation.
(b) The following terms have the meanings indicated:
(1) "ACQUIRING CORPORATION" shall mean (i) the continuing
or surviving corporation of a consolidation or merger with Issuer
(if other than Issuer), (ii) Issuer in a merger in which Issuer is
the continuing or surviving person, and (iii) the transferee of all
or substantially all of Issuer's assets.
(2) "SUBSTITUTE COMMON STOCK" shall mean the common stock
issued by the issuer of the Substitute Option upon exercise of the
Substitute Option.
(3) "ASSIGNED VALUE" shall mean the Alternative Transaction
Price, as defined in Section 7.
(4) "AVERAGE PRICE" shall mean the average closing price of
a share of the Substitute Common Stock for the one year immediately
preceding the consolidation, merger or sale in question, but in no
event higher than the closing price of the shares of Substitute
Common Stock on the day preceding such consolidation, merger or
sale; PROVIDED that if Issuer is the issuer of the Substitute
Option, the Average Price shall be computed with respect to a share
of common stock issued by the person merging into Issuer or by any
company which controls or is controlled by such person, as Grantee
may elect.
(c) The Substitute Option shall have the same terms as the Option,
PROVIDED, that if the terms of the Substitute Option cannot, for legal
reasons, be the same as the Option, such terms shall be as similar as possible
and in no event less advantageous to Grantee. The issuer of the Substitute
Option shall also enter into an agreement with Grantee in substantially the same
form as this Agreement, which agreement shall be applicable to the Substitute
Option.
13
<PAGE>
(d) The Substitute Option shall be exercisable for such number of
shares of Substitute Common Stock as is equal to the Assigned Value multiplied
by the number of shares of Common Stock for which the Option is then
exercisable, divided by the Average Price. The exercise price of the Substitute
Option per share of Substitute Common Stock shall then be equal to the Option
Price multiplied by a fraction, the numerator of which shall be the number of
shares of Common Stock for which the Option is then exercisable and the
denominator of which shall be the number of shares of Substitute Common Stock
for which the Substitute Option is exercisable.
(e) In no event, pursuant to any of the foregoing paragraphs, shall
the Substitute Option be exercisable for more than 19.9% of the shares of
Substitute Common Stock outstanding prior to exercise of the Substitute Option.
In the event that the Substitute Option would be exercisable for more than 19.9%
of the shares of Substitute Common Stock outstanding prior to exercise but for
this clause (e), the issuer of the Substitute Option (the "SUBSTITUTE OPTION
ISSUER") shall make a cash payment to Grantee equal to the excess of (i) the
value of the Substitute Option without giving effect to the limitation in this
clause (e) over (ii) the value of the Substitute Option after giving effect to
the limitation in this clause (e). This difference in value shall be determined
by a nationally recognized investment banking firm selected by Grantee.
(f) Issuer shall not enter into any transaction described in
subsection (a) of this Section 8 unless the Acquiring Corporation and any person
that controls the Acquiring Corporation assume in writing all the obligations of
Issuer hereunder.
9. EXTENSION OF TIME FOR REGULATORY APPROVALS. The 18-month
period for exercise of certain rights under Sections 2, 6 and 11 shall be
extended: (i) to the extent necessary to obtain all regulatory approvals for
the exercise of such rights, and for the expiration of all statutory waiting
periods; and (ii) to the extent necessary to avoid liability under Section 10(b)
of the Exchange Act by reason of such exercise.
14
<PAGE>
10. REPRESENTATIONS AND WARRANTIES OF THE ISSUER. Issuer hereby
represents and warrants to Grantee as follows:
(a) Issuer has full corporate power and authority to execute and
deliver this Agreement and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by the
Board of Directors of Issuer and no other corporate proceedings on the part of
Issuer are necessary to authorize this Agreement or to consummate the
transactions so contemplated. This Agreement has been duly and validly executed
and delivered by Issuer. This Agreement is the valid and legally binding
obligation of Issuer, enforceable against Issuer in accordance with its terms.
(b) Issuer has taken all necessary corporate action to authorize
and reserve and to permit it to issue, and at all times from the date hereof
through the termination of this Agreement in accordance with its terms will have
reserved for issuance upon the exercise of the Option, that number of shares of
Common Stock equal to the maximum number of shares of Common Stock at any time
and from time to time issuable hereunder, and all such shares, upon issuance
pursuant hereto, will be duly authorized, validly issued, fully paid,
nonassessable, and will be delivered free and clear of all claims, liens,
encumbrance and security interests and not subject to any preemptive rights.
(c) The execution and delivery of this Agreement does not, and the
consummation of the transactions contemplated hereby will not, conflict with, or
result in any violation pursuant to any provisions of the Articles of
Incorporation or by-laws of Issuer or any Issuer subsidiary, subject to
obtaining any approvals or consents contemplated hereby, result in any violation
of any loan or credit agreement, note, mortgage, indenture, lease, plan or other
agreement, obligation, instrument, permit, concession, franchise, license,
judgment, order, decree, statute, law, ordinance, rule or regulation applicable
to Issuer or any Issuer subsidiary or their respective properties or assets
which violation would have, individually or in the aggregate, a Parent Material
Adverse Effect.
15
<PAGE>
(d) The Board of Directors of Issuer having approved this Agreement
and the consummation of the transactions contemplated thereby, the provisions of
Section 203 of the Delaware General Corporation Law do not and will not apply to
this Agreement or the purchase of shares of Common Stock pursuant to this
Agreement. The Issuer has taken, and will in the future take, all steps
necessary to irrevocably exempt the transactions contemplated by this Agreement
from any other applicable state takeover law and from any applicable charter or
contractual provision containing change of control or anti-takeover provisions.
11. ASSIGNMENT OF OPTION BY GRANTEE. Neither of the parties
hereto may assign any of its rights or obligations under this Option Agreement
or the Option created hereunder to any other person, without the express written
consent of the other party.
12. LIMITATION OF GRANTEE PROFIT. (a) Notwithstanding any other
provision of this Agreement, in no event shall the Grantee's Total Profit (as
hereinafter defined) exceed $55,000,000 and, if it otherwise would exceed such
amount, the Grantee, at its sole election, shall either (i) reduce the number of
shares of Common Stock subject to this Option, (ii) deliver to the Issuer for
cancellation Option Shares previously purchased by Grantee, (iii) pay cash to
the Issuer, or (iv) any combination thereof, so that Grantee's actually realized
Total Profit shall not exceed $55,000,000 after taking into account the
foregoing actions.
(b) As used herein, the term "TOTAL PROFIT" shall mean the amount
(before taxes) of the following: (a) the aggregate amount of (i) (x) the net
cash amounts received by Grantee pursuant to the sale of Option Shares (or any
other securities into which such Option Shares are converted or exchanged) to
any unaffiliated party within 12 months from the exercise of this Option with
respect to such Option Shares, less (y) the Grantee's purchase price of such
Option Shares, (ii) any amounts received by Grantee on the transfer of the
Option (or any portion thereof) to any unaffiliated party, if permitted
hereunder, (iii) any equivalent amount with respect to the Substitute Option,
and (iv) the amount received by Grantee pursuant to Section 9.3 of the Merger
Agreement; MINUS (b) the amount of cash paid to the Issuer pursuant
16
<PAGE>
to this Section 12 plus the value of the Option Shares delivered to the Issuer
for cancellation.
(c) Notwithstanding any other provision of this Agreement, nothing
in this Agreement shall affect the ability of Grantee to receive nor relieve
Issuer's obligation to pay a fee pursuant to Section 9.3 of the Merger
Agreement; PROVIDED that if Total Profit received by Grantee would exceed
$55,000,000 following the receipt of such fee, Grantee shall be obligated to
comply with the terms of Section 12(a) within 30 days of the later of (i) the
date of receipt of such fee and (ii) the date of receipt of the net cash by
Grantee pursuant to the sale of Option Shares (or any other securities into
which such Option Shares are converted or exchanged) to any unaffiliated party
within 12 months of the exercise of this Option with respect to such Option
Shares.
13. FIRST REFUSAL. At any time after the first occurrence of a
Triggering Event and prior to the later of (a) the expiration of 18 months
immediately following the first purchase of shares of Issuer Common Stock
pursuant to the Option and (b) the Option Termination Date, if Grantee shall
desire to sell, assign, transfer or otherwise dispose of all or any of the
Option or the shares of Issuer Common Stock or other securities acquired by it
pursuant to the Option, it shall give Issuer written notice of the proposed
transaction (an "OFFEROR'S NOTICE"), identifying the proposed transferee,
accompanied by a copy of a binding offer to purchase the Option or such shares
or other securities signed by such transferee and setting forth the terms of the
proposed transaction. An Offeror's Notice shall be deemed an offer by Grantee
to Issuer, which may be accepted within 20 business days of the receipt of such
Offeror's Notice, on the same terms and conditions and at the same price at
which Grantee is proposing to transfer the Option or such shares or other
securities to such transferee. The purchase of the Option or any such shares or
other securities by Issuer shall be settled within 10 business days of the date
of the acceptance of the offer and the purchase price shall be paid to Grantee
in immediately available funds; provided that, if prior notification to or
approval of any regulatory authority is required in connection with such
purchase, Issuer shall promptly file the required notice or application for
approval and shall expeditiously process the same (and Grantee shall cooper-
17
<PAGE>
ate with Issuer in the filing of any such notice or application and the
obtaining of any such approval) and the period of time that otherwise would run
pursuant to this sentence shall run instead from the date on which, as the case
may be, (a) required notification period has expired or been terminated or (b)
such approval has been obtained and, in either event, any requisite waiting
period shall have passed. In the event of the failure or refusal of Issuer to
purchase all of the Option or all of the shares or other securities covered by
an Offeror's Notice or if any regulatory authority disapproves Issuer's proposed
purchase of any portion of the Option or such shares or other securities,
Grantee may, within 60 days from the date of the Offeror's Notice (subject to
any necessary extension for regulatory notification, approval or waiting
periods), sell all, but not less than all, of such portion of the Option or such
shares or other securities to the proposed transferee at no less than the price
specified and on terms no more favorable than those set forth in the Offeror's
Notice. The requirements of this Section 11 shall not apply to (w) any
disposition as a result of which the proposed transferee would own beneficially
not more than 2% of the outstanding voting power of Issuer, (x) any disposition
of Issuer Common Stock or other securities by a person to whom grantee has
assigned its rights under the Option with the consent of Issuer, (y) any sale by
means of a public offering registered under the Securities Act in which steps
are taken to reasonably assure that no purchaser will acquire securities
representing more than 2% of the outstanding voting power of Issuer or (z) any
transfer to a wholly owned subsidiary of Grantee which agrees in writing to be
bound by the terms hereof.
14. VOTING. For a period of 18 months from the date of exercise
of the Option, so long as Grantee beneficially owns any Option Shares, Grantee
agrees to (a) be present, in person or represented by proxy, at all stockholder
meetings of Issuer, so that all Option Shares beneficially owned by holder may
be counted for the purpose of determining the presence of a quorum at such
meetings, and (b) vote or cause to be voted all Option Shares beneficially owned
by it, with respect to all matters submitted to shareholders for a vote, in the
same proportion as shares of Common Stock are voted by shareholders unaffiliated
with Grantee.
18
<PAGE>
15. APPLICATION FOR REGULATORY APPROVAL. Each of Grantee and
Issuer will use its best efforts to make all filings with, and to obtain
consents of, all third parties and governmental authorities necessary to the
consummation of the transactions contemplated by this Agreement, including
without limitation making application to list the shares of Common Stock
issuable hereunder on the New York Stock Exchange upon official notice of
issuance.
16. SPECIFIC PERFORMANCE. The parties hereto acknowledge that
damages would be an inadequate remedy for a breach of this Agreement by either
party hereto and that the obligations of the parties hereto shall be enforceable
by either party hereto through injunctive or other equitable relief.
17. SEPARABILITY OF PROVISIONS. If any term, provision, covenant
or restriction contained in this Agreement is held by a court or a federal or
state regulatory agency of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions and covenants and
restrictions contained in this Agreement shall remain in full force and effect,
and shall in no way be affected, impaired or invalidated.
18. NOTICES. All notices, claims, demands and other
communications hereunder shall be deemed to have been duly given or made when
delivered in person, by registered or certified mail (postage prepaid, return
receipt requested), by overnight courier or by facsimile at the respective
addresses of the parties set forth in the Merger Agreement.
19. GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, regardless of
the laws that might otherwise govern under applicable principles of conflicts of
laws thereof.
20. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which will be deemed to be an original, but all of which
shall constitute one and the same agreement.
21. EXPENSES. Except as otherwise expressly provided herein or
in the Merger Agreement, each of the
19
<PAGE>
parties hereto shall bear and pay all costs and expenses incurred by it or on
its behalf in connection with the transactions contemplated hereunder, including
fees and expenses of its own financial consultants, investment bankers,
accountants and counsel.
22. ENTIRE AGREEMENT. Except as otherwise expressly provided
herein or in the Merger Agreement, this Agreement contains the entire agreement
between the parties with respect to the transactions contemplated hereunder and
supersedes all prior arrangements or understandings with respect thereof,
written or oral. The terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective
successors and permitted assigns. Nothing in this Agreement, expressed or
implied, is intended to confer upon any party, other than the parties hereto,
and their respective successors except as assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein. Any provision of this Agreement may be waived only
in writing at any time by the party that is entitled to the benefits of such
provision. This Agreement may not be modified, amended, altered or supplemented
except upon the execution and delivery of a written agreement executed by the
parties hereto.
23. FURTHER ASSURANCES. In the event of any exercise of the
Option by Grantee, Issuer and Grantee shall execute and deliver all other
documents and instruments and take all other action that may be reasonably
necessary in order to consummate the transactions provided for by such exercise.
Nothing contained in this Agreement shall be deemed to authorize Issuer or
Grantee to breach any provision of the Merger Agreement.
20
<PAGE>
IN WITNESS WHEREOF, OrNda Healthcorp and Tenet Healthcare
Corporation have caused this Agreement to be signed by their respective officers
thereunto duly authorized, all as of the date first written above.
ORNDA HEALTHCORP
By:
-----------------------------
Name:
----------------------------
Title:
---------------------------
Attest:
Name:
---------------------------
Title:
--------------------------
TENET HEALTHCARE CORPORATION
By:
-----------------------------
Name:
----------------------------
Title:
---------------------------
Attest:
Name:
---------------------------
Title:
--------------------------
<PAGE>
EXHIBIT A-1
FORM OF
STOCKHOLDER VOTING AGREEMENT
THIS STOCKHOLDER VOTING AGREEMENT (this "Agreement") is made and
entered into as of this 17th day of October, 1996, by and among Tenet Healthcare
Corporation, a Nevada corporation ("Acquiror"), and the stockholder named on the
signature page hereto ("Stockholder"). On the date hereof the Stockholder
Beneficially Owns (as defined in Section 11(a) hereof) the number of shares of
common stock, par value $.01 per share (the "Company Shares"), of OrNda
Healthcorp, a Delaware corporation ("Company"), set forth next to the
Stockholder's name on the signature page hereto.
WHEREAS, Acquiror and the Company concurrently herewith are entering
into an Agreement and Plan of Merger, dated as of the 16th day of October, 1996
(the "Merger Agreement"), providing for, among other things, the merger (the
"Merger") of a wholly owned subsidiary of Acquiror with and into the Company,
with the Company as the surviving corporation; and
WHEREAS, as an essential condition and inducement to Acquiror's
execution of the Merger Agreement, Acquiror has requested that the Stockholder
agree, and the Stockholder has agreed, to vote (or consent with regard to) all
Company Shares as to which the Stockholder has voting power in favor of the
Merger as provided herein.
NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements contained herein and in
the Merger Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto, intending
to be legally bound hereby, agree as follows:
1. VOTING RIGHTS.
VOTING AGREEMENT. The Stockholder agrees that, at any time the
Merger Agreement remains in effect, it will vote all Stockholder Shares (as
defined below) on matters as to which the Stockholder is entitled to vote
1
<PAGE>
at any annual, special or other meeting of the Stockholders of the Company, and
at any adjournment or adjournments thereof, or by written consent without a
meeting with respect to all Stockholder Shares as follows: (i) in favor of
approval and adoption of the Merger Agreement, the terms thereof and each of the
other transactions contemplated by the Merger Agreement; and (ii) against any
action or agreement (other than the Merger Agreement or the transactions
contemplated thereby) that would impede, interfere with, delay, postpone or
attempt to discourage the Merger, including without limitation: (A) any
extraordinary corporate transaction, such as a merger, consolidation or other
business combination involving the Company and its subsidiaries; or (B) a sale
or transfer of a material amount of assets of the Company and its subsidiaries
or a reorganization, recapitalization or liquidation of the Company and its
subsidiaries.
"Stockholder Shares" shall mean the shares of Company capital stock
(including without limitation the Company Shares) Beneficially Owned by such
Stockholder as of the date hereof, or Beneficially Owned by such Stockholder at
any time hereafter (including, without limitation, by way of exercise of options
or by way of dividend, distribution, exchange, merger, consolidation,
recapitalization, reorganization, stock split, grant of proxy or otherwise) by
such Stockholder (as adjusted as set forth herein). The Stockholder hereby
agrees to promptly notify Acquiror of the number of any new Stockholder Shares
acquired by the Stockholder, if any, after the date hereof. In the event of any
change in the Company Shares by reason of a stock dividend, stock split, split
up, recapitalization, combination, exchange of shares or similar transaction,
the type and number of shares or securities that constitute Stockholder Shares
hereunder shall be adjusted appropriately.
2. TERMINATION.
a. This Agreement shall terminate upon the earlier to occur of
(i) the termination of the Merger Agreement in accordance with its terms
pursuant to Section 9.1 thereof, or (ii) the Effective Time (as defined in the
Merger Agreement).
b. Upon termination, this Agreement shall have no further force
or effect, except for Section 7
2
<PAGE>
which shall continue to apply to any case, action or proceeding relating to the
enforcement of this Agreement.
3. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER. The
Stockholder hereby represents and warrants to Acquiror as follows:
a. DUE AUTHORIZATION. The Stockholder has the legal capacity
and all necessary power and authority to execute and deliver this Agreement and
to consummate the transactions contemplated hereby. As of the date hereof, the
Stockholder Beneficially Owns the number of the Stockholder Shares listed on the
signature page hereof and specified as so owned with no restrictions on the
voting rights (except as specified in this Agreement) or rights of disposition
pertaining thereto, which constitute all Company Shares Beneficially Owned by
such Stockholder. Assuming this Agreement has been duly and validly authorized,
executed and delivered by Acquiror, this Agreement constitutes a valid and
binding agreement of the Stockholder, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency, moratorium or
other similar laws affecting creditors' rights generally or by the principles
governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by the Stockholder of the transactions
contemplated hereby will conflict with or constitute a violation of or default
under any contract, commitment, agreement, arrangement or restriction of any
kind to which the Stockholder is a party or by which the Stockholder is bound.
4. REPRESENTATIONS AND WARRANTIES OF ACQUIROR. Acquiror hereby
represents and warrants to the Stockholder as follows:
a. DUE AUTHORIZATION. Acquiror has the requisite corporate
power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly
authorized by all necessary corporate action on the part of Acquiror and this
Agreement has been duly executed by a duly authorized officer of Acquiror.
Assuming this Agreement has been duly and
3
<PAGE>
validly executed and delivered by the Stockholder, this Agreement constitutes a
valid and binding agreement of Acquiror, enforceable against it in accordance
with its terms, except as enforceability may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting creditors' rights
generally or by the principles governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by Acquiror of the transactions contemplated
hereby will conflict with or constitute a violation of or default under any
contract, commitment, agreement, arrangement or restriction of any kind to which
Acquiror is a party or by which Acquiror is bound.
5. NO TRANSFER. Except as provided in this Agreement or the
Merger Agreement, the Stockholder hereby agrees, without the prior written
consent of Acquiror, except pursuant to the terms hereof, not to (i) sell,
transfer, assign, pledge or otherwise dispose of or hypothecate any of his
Stockholder Shares other than to a "Permitted Transferee" (as defined below) and
except that the Stockholder may transfer Stockholder Shares to Company in order
to pay the exercise price or withholding taxes applicable in connection with the
exercise of employee stock options ; (ii) grant any proxies, deposit any
Stockholder Shares into a voting trust or enter into a voting agreement with
respect to any Stockholder Shares; (iii) take any action that would make any
representation or warranty of the Stockholder contained herein untrue or
incorrect or have the effect of preventing or disabling the Stockholder from
performing his obligations under this Agreement; or (iv) take any action which
would jeopardize the treatment of Acquiror's acquisition of Company as a pooling
of interests for accounting purposes. For purposes of this Agreement,
"Permitted Transferee" shall mean an organization that qualifies for treatment
under section 501(c)(3) of the Internal Revenue Code of 1986, as amended. Any
Permitted Transferee of Stockholder Shares must become a party to this Agreement
and any purported transfer of Stockholder Shares to a person or entity that has
not become a party hereto shall be null and void. In furtherance of this
Agreement, concurrently herewith the Stockholder shall and hereby does authorize
the Company's counsel to notify the Company's transfer agent that there is a
stop transfer order with
4
<PAGE>
respect to all of the Stockholder Shares (and that this Agreement places limits
on the voting and transfer of such shares).
6. ENTIRE AGREEMENT. Other than the Merger Agreement
(including the exhibits, schedules and other documents and instruments referred
to therein), this Agreement (including the documents and instruments referred to
herein) (a) constitutes the entire agreement among the parties hereto with
respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties, or any of them,
with respect to the subject matter hereof; (b) shall not be assigned by
operation of law or otherwise without the prior written consent of the other
parties hereto, except that Acquiror may assign, in its sole discretion, all or
any of its rights, interests and obligations hereunder to any direct or indirect
wholly owned subsidiary of Acquiror; (c) shall not be amended, altered or
modified in any manner whatsoever, except by a written instrument executed by
the parties hereto; and (d) shall be governed in all respects, including
validity, interpretation and effect, by the laws of the State of Delaware
(without giving effect to the provisions thereof relating to conflicts of law).
7. REMEDIES. The parties acknowledge that it would be
impossible to fix money damages for violations of this Agreement and that such
violations will cause irreparable injury for which adequate remedy at law is not
available and, therefore, this Agreement must be enforced by specific
performance or injunctive relief. The parties hereto agree that any party may,
in its sole discretion, apply to any court of competent jurisdiction for
specific performance or injunctive or such other relief as such court may deem
just and proper in order to enforce this Agreement or prevent any violation
hereof and, to the extent permitted by applicable law, each party waives any
objection or defense to the imposition of such relief. Nothing herein shall be
construed to prohibit any party from bringing any action for damages in addition
to an action for specific performance or an injunction for a breach of this
Agreement.
8. LEGENDS ON CERTIFICATES. Until such time as this Agreement
shall terminate pursuant to Section 2
5
<PAGE>
hereof, all certificates representing Stockholder Shares shall bear the
following legend:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
OF A STOCKHOLDER VOTING AGREEMENT, DATED AS OF OCTOBER 17, 1996, BY AND
BETWEEN TENET HEALTHCARE CORPORATION AND THE STOCKHOLDER. ANY TRANSFEREE
OF THESE SHARES TAKES SUBJECT TO THE TERMS OF SUCH AGREEMENT, COPIES OF
WHICH ARE ON FILE AT THE OFFICES OF TENET HEALTHCARE CORPORATION.
9. PARTIES IN INTEREST. Subject to the provisions of Sections
5 and 6(b) hereof, this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors,
permitted assigns, heirs, executors, administrators and other legal
representatives, and nothing in this Agreement, express or implied, is intended
to confer upon any other person any rights or remedies of any nature whatsoever
under or by reason of this Agreement.
10. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same agreement.
11. DEFINITIONS. The following terms shall have the following
respective meanings:
a. "Beneficial Owner" has the meaning set forth in Rule 13d-3 of
the Rules and Regulations to the Exchange Act, and "Beneficially Owned" and
"Beneficially Owns" shall have correlative meanings; PROVIDED, HOWEVER, that
for purposes of this Agreement a person shall be deemed to be the Beneficial
Owner of Company Shares that may be acquired pursuant to the exercise of an
option or other right regardless of when such option is exercisable.
b. A "person" means a corporation, association, partnership,
joint venture, organization, business, individual, trust, estate or any other
entity or group (within the meaning of Section 13(d)(3) of the Exchange Act).
6
<PAGE>
12. NOTICES. All notices and other communications hereunder
shall be in writing and shall be deemed given if delivered personally,
telecopied (which is confirmed) or mailed by registered or certified mail
(return receipt requested) to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):
(a) If to Acquiror to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue, Suite 3400
Los Angeles, California 90071
Telecopy No. (213) 687-5600
Attention: Brian J. McCarthy
(b) If to the Stockholder, to the address set forth on the
signature page, hereto.
13. INTERPRETATION. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
14. SEVERABILITY. Any term or provision of this Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction. If any provision of
this Agreement is so broad as to be unenforceable, the provision shall be
interpreted to be only so broad as is enforceable.
15. FURTHER ASSURANCES. The Stockholder further agrees to
execute all additional writings, con-
7
<PAGE>
sents and authorizations as may be reasonably requested by Acquiror to evidence
the agreements herein.
8
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
TENET HEALTHCARE CORPORATION
By
------------------------------------
Name:
Title:
CHARLES N. MARTIN
By
------------------------------------
Name:
Title:
---------------------------------------
No. of Shares Beneficially Owned:
Address for Notices:
3401 West End Avenue
Nashville, Tennessee 37203
<PAGE>
EXHIBIT A-2
FORM OF
STOCKHOLDER VOTING AGREEMENT
THIS STOCKHOLDER VOTING AGREEMENT (this "Agreement") is made and
entered into as of this 17th day of October, 1996, by and among Tenet Healthcare
Corporation, a Nevada corporation ("Acquiror"), and the stockholder named on the
signature page hereto ("Stockholder"). On the date hereof the Stockholder
Beneficially Owns (as defined in Section 11(a) hereof) the number of shares of
common stock, par value $.01 per share (the "Company Shares"), of OrNda
Healthcorp, a Delaware corporation ("Company"), set forth next to the
Stockholder's name on the signature page hereto.
WHEREAS, Acquiror and the Company concurrently herewith are entering
into an Agreement and Plan of Merger, dated as of the 16th day of October, 1996
(the "Merger Agreement"), providing for, among other things, the merger (the
"Merger") of a wholly owned subsidiary of Acquiror with and into the Company,
with the Company as the surviving corporation; and
WHEREAS, as an essential condition and inducement to Acquiror's
execution of the Merger Agreement, Acquiror has requested that the Stockholder
agree, and the Stockholder has agreed, to vote (or consent with regard to) all
Company Shares as to which the Stockholder has voting power in favor of the
Merger as provided herein.
NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements contained herein and in
the Merger Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto, intending
to be legally bound hereby, agree as follows:
1. VOTING RIGHTS.
VOTING AGREEMENT. The Stockholder agrees that, at any time the
Merger Agreement remains in effect, it will vote all Stockholder Shares (as
defined below) on matters as to which the Stockholder is entitled to vote
1
<PAGE>
at any annual, special or other meeting of the Stockholders of the Company, and
at any adjournment or adjournments thereof, or by written consent without a
meeting with respect to all Stockholder Shares as follows: (i) in favor of
approval and adoption of the Merger Agreement, the terms thereof and each of the
other transactions contemplated by the Merger Agreement; and (ii) against any
action or agreement (other than the Merger Agreement or the transactions
contemplated thereby) that would impede, interfere with, delay, postpone or
attempt to discourage the Merger, including without limitation: (a) any
extraordinary corporate transaction, such as a merger, consolidation or other
business combination involving the Company and its subsidiaries; or (b) a sale
or transfer of a material amount of assets of the Company and its subsidiaries
or a reorganization, recapitalization or liquidation of the Company and its
subsidiaries.
"Stockholder Shares" shall mean the shares of Company capital stock
(including without limitation the Company Shares) Beneficially Owned by such
Stockholder as of the date hereof, or Beneficially Owned by such Stockholder at
any time hereafter (including, without limitation, by way of exercise of options
or by way of dividend, distribution, exchange, merger, consolidation,
recapitalization, reorganization, stock split, grant of proxy or otherwise) by
such Stockholder (as adjusted as set forth herein). The Stockholder hereby
agrees to promptly notify Acquiror of the number of any new Stockholder Shares
acquired by the Stockholder, if any, after the date hereof. In the event of any
change in the Company Shares by reason of a stock dividend, stock split, split
up, recapitalization, combination, exchange of shares or similar transaction,
the type and number of shares or securities that constitute Stockholder Shares
hereunder shall be adjusted appropriately.
2. TERMINATION.
a. This Agreement shall terminate upon the earlier to occur of
(i) the termination of the Merger Agreement in accordance with its terms
pursuant to Section 9.1 thereof, or (ii) the Effective Time (as defined in the
Merger Agreement).
b. Upon termination, this Agreement shall have no further force
or effect, except for Section 7
2
<PAGE>
which shall continue to apply to any case, action or proceeding relating to the
enforcement of this Agreement.
3. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER. The
Stockholder hereby represents and warrants to Acquiror as follows:
a. DUE AUTHORIZATION. The Stockholder has the legal capacity
and all necessary power and authority to execute and deliver this Agreement and
to consummate the transactions contemplated hereby. As of the date hereof, the
Stockholder Beneficially Owns the number of the Stockholder Shares listed on the
signature page hereof and specified as so owned with no restrictions on the
voting rights (except as specified in this Agreement) or rights of disposition
pertaining thereto, which constitute all Company Shares Beneficially Owned by
such Stockholder. Assuming this Agreement has been duly and validly authorized,
executed and delivered by Acquiror, this Agreement constitutes a valid and
binding agreement of the Stockholder, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency, moratorium or
other similar laws affecting creditors' rights generally or by the principles
governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by the Stockholder of the transactions
contemplated hereby will conflict with or constitute a violation of or default
under any contract, commitment, agreement, arrangement or restriction of any
kind to which the Stockholder is a party or by which the Stockholder is bound.
4. REPRESENTATIONS AND WARRANTIES OF ACQUIROR. Acquiror hereby
represents and warrants to the Stockholder as follows:
a. DUE AUTHORIZATION. Acquiror has the requisite corporate
power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly
authorized by all necessary corporate action on the part of Acquiror and this
Agreement has been duly executed by a duly authorized officer of Acquiror.
Assuming this Agreement has been duly and
3
<PAGE>
validly executed and delivered by the Stockholder, this Agreement constitutes a
valid and binding agreement of Acquiror, enforceable against it in accordance
with its terms, except as enforceability may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting creditors' rights
generally or by the principles governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by Acquiror of the transactions contemplated
hereby will conflict with or constitute a violation of or default under any
contract, commitment, agreement, arrangement or restriction of any kind to which
Acquiror is a party or by which Acquiror is bound.
5. NO TRANSFER. Except as provided in this Agreement or the
Merger Agreement, the Stockholder hereby agrees, without the prior written
consent of Acquiror, except pursuant to the terms hereof, not to (i) sell,
transfer, assign, pledge or otherwise dispose of or hypothecate any of his
Stockholder Shares; (ii) grant any proxies, deposit any Stockholder Shares
into a voting trust or enter into a voting agreement with respect to any
Stockholder Shares; or (iii) take any action that would make any representation
or warranty of the Stockholder contained herein untrue or incorrect or have
the effect of preventing or disabling the Stockholder from performing his
obligations under this Agreement. Any permitted transferee of Stockholder
Shares must become a party to this Agreement and any purported transfer of
Stockholder Shares to a person or entity that has not become a party hereto
shall be null and void. In furtherance of this Agreement, concurrently
herewith the Stockholder shall and hereby does authorize the Company's counsel
to notify the Company's transfer agent that there is a stop transfer order
with respect to all of the Stockholder Shares (and that this Agreement places
limits on the voting and transfer of such shares).
6. ENTIRE AGREEMENT. Other than the Merger Agreement
(including the exhibits, schedules and other documents and instruments referred
to therein), this
4
<PAGE>
Agreement (including the documents and instruments referred to
herein) (a) constitutes the entire agreement among the parties hereto with
respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties, or any of them,
with respect to the subject matter hereof; (b) shall not be assigned by
operation of law or otherwise without the prior written consent of the other
parties hereto, except that Acquiror may assign, in its sole discretion, all or
any of its rights, interests and obligations hereunder to any direct or indirect
wholly owned subsidiary of Acquiror; (c) shall not be amended, altered or
modified in any manner whatsoever, except by a written instrument executed by
the parties hereto; and (d) shall be governed in all respects, including
validity, interpretation and effect, by the laws of the State of Delaware
(without giving effect to the provisions thereof relating to conflicts of law).
7. REMEDIES. The parties acknowledge that it would be
impossible to fix money damages for violations of this Agreement and that such
violations will cause irreparable injury for which adequate remedy at law is not
available and, therefore, this Agreement must be enforced by specific
performance or injunctive relief. The parties hereto agree that any party may,
in its sole discretion, apply to any court of competent jurisdiction for
specific performance or injunctive or such other relief as such court may deem
just and proper in order to enforce this Agreement or prevent any violation
hereof and, to the extent permitted by applicable law, each party waives any
objection or defense to the imposition of such relief. Nothing herein shall be
construed to prohibit any party from bringing any action for damages in addition
to an action for specific performance or an injunction for a breach of this
Agreement.
8. LEGENDS ON CERTIFICATES. Until such time as this Agreement
shall terminate pursuant to Section 2 hereof, all certificates representing
Stockholder Shares shall bear the following legend:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
OF A STOCKHOLDER VOTING AGREEMENT, DATED AS OF OCTOBER 17, 1996, BY AND
BETWEEN TENET HEALTHCARE CORPORATION AND THE STOCKHOLDER. ANY TRANSFEREE
OF THESE
5
<PAGE>
SHARES TAKES SUBJECT TO THE TERMS OF SUCH AGREEMENT, COPIES OF
WHICH ARE ON FILE AT THE OFFICES OF TENET HEALTHCARE CORPORATION.
9. PARTIES IN INTEREST. Subject to the provisions of Sections
5 and 6(b) hereof, this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors,
permitted assigns, heirs, executors, administrators and other legal
representatives, and nothing in this Agreement, express or implied, is intended
to confer upon any other person any rights or remedies of any nature whatsoever
under or by reason of this Agreement.
10. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same agreement.
11. DEFINITIONS. The following terms shall have the following
respective meanings:
a. "Beneficial Owner" has the meaning set forth in Rule 13d-3 of
the Rules and Regulations to the Exchange Act, and "Beneficially Owned" and
"Beneficially Owns" shall have correlative meanings; PROVIDED, HOWEVER, that
for purposes of this Agreement a person shall be deemed to be the Beneficial
Owner of Company Shares that may be acquired pursuant to the exercise of an
option or other right regardless of when such option is exercisable.
b. A "person" means a corporation, association, partnership,
joint venture, organization, business, individual, trust, estate or any other
entity or group (within the meaning of Section 13(d)(3) of the Exchange Act).
12. NOTICES. All notices and other communications hereunder
shall be in writing and shall be deemed given if delivered personally,
telecopied (which is confirmed) or mailed by registered or certified mail
(return receipt requested) to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):
6
<PAGE>
(a) If to Acquiror to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue, Suite 3400
Los Angeles, California 90071
Telecopy No. (213) 687-5600
Attention: Brian J. McCarthy
(b) If to the Stockholder, to the address set forth on the
signature page, hereto.
13. INTERPRETATION. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
14. SEVERABILITY. Any term or provision of this Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction. If any provision of
this Agreement is so broad as to be unenforceable, the provision shall be
interpreted to be only so broad as is enforceable.
15. FURTHER ASSURANCES. The Stockholder further agrees to
execute all additional writings, consents and authorizations as may be
reasonably requested by Acquiror to evidence the agreements herein.
7
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
TENET HEALTHCARE CORPORATION
By
-----------------------------------
Name:
Title:
JOSEPH, LITTLEJOHN & LEVY FUND, L.P.
By
-----------------------------------
Name:
Title:
No. of Shares Beneficially Owned:
-----------------------------------
Address for Notices:
50 Main Street, Suite 1000
White Plains, New York 10606
<PAGE>
EXHIBIT 10.1
STOCK OPTION AGREEMENT
THIS STOCK OPTION AGREEMENT (this "AGREEMENT"), dated October 17,
1996, between OrNda Healthcorp, a Delaware corporation ("GRANTEE"), and Tenet
Healthcare Corporation, a Nevada corporation ("ISSUER"),
W I T N E S S E T H:
WHEREAS, Grantee and Issuer, among others, have entered into an
Agreement and Plan of Merger, dated as of October 16, 1996 (the "MERGER
AGREEMENT"), which agreement has been executed by the parties hereto prior to
this Agreement (capitalized terms used herein without definition shall have the
respective meanings specified in the Merger Agreement); and
WHEREAS, as a condition to Grantee's entering into the Merger
Agreement and in consideration therefor, Issuer has agreed to grant Grantee the
Option (as hereinafter defined);
NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth herein and in the Merger Agreement, the
parties hereto agree as follows:
1. GRANT OF OPTION. Issuer hereby grants to Grantee an
unconditional, irrevocable option (the "OPTION") to purchase, subject to the
terms hereof, 28,388,098 shares of fully paid and nonassessable common stock of
the Issuer, par value $.075 per share ("COMMON STOCK"), equal to 10.46% of
the number of shares of Common Stock (on a fully diluted basis after giving
effect to the exercise of the Option), together with any associated purchase
rights (the "Rights") under the Rights Agreement, dated as of December 7,
1988, as amended from time to time, between Issuer and Bank of America, NTS
as successor trustee to Bankers Trust Company (references to shares
purchasable upon exercise of the Option shall be deemed to include the
associated Rights), as of the date hereof at a purchase price of $22.125 per
share of Common Stock, as adjusted in accordance with the provisions of
<PAGE>
Section 5 of this Agreement (such price, as adjusted if applicable, the "OPTION
PRICE").
2. (a) EXERCISE OF OPTION. Grantee may exercise the Option, in
whole or part, and from time to time, if, but only if, a Triggering Event (as
hereinafter defined) shall have occurred prior to the occurrence of an Option
Termination Event (as hereinafter defined), provided that Grantee shall have
sent the written notice of such exercise (as provided in subsection (f) of this
Section 2 on or prior to the last date of the 18-month period following such
Triggering Event (the "Option Expiration Date").
(b) OPTION TERMINATION EVENTS. The term "OPTION TERMINATION
EVENT" shall mean either of the following events: (i) immediately prior to the
Effective Time of the Merger; or (ii) termination of the Merger Agreement (A) by
either party pursuant to Section 9.1(c) of the Merger Agreement, whether or not
such termination occurs prior to the occurrence of a Triggering Event, provided
that the matter giving rise to the order, decree, ruling or other action
providing the basis for termination under Section 9.1(c) shall not have been
initiated by Issuer or any Bidder, (B) by Issuer pursuant to Section 9.1(d)(i)
of the Merger Agreement because of a material adverse change after the date
hereof in the business, financial condition, results of operations, properties,
assets or liabilities of Grantee and its subsidiaries taken as a whole (other
than any change relating to the United States economy in general or to the
United States investor-owned hospital business in general) that is caused by the
matters described in Schedule 5.8(a) to the Company Disclosure Letter if such
termination occurs prior to the occurrence of a Triggering Event described in
clause (i) of Section 2(c) hereof or (iii) by either party pursuant to any other
provision of the Merger Agreement if such termination occurs prior to the
occurrence of a Triggering Event.
(c) TRIGGERING EVENTS. The term "TRIGGERING EVENT" shall mean
either of the following events occurring after the date hereof:
(i) Any event shall have occurred that would entitle either
party to terminate the Merger Agreement and permit Grantee to
receive
2
<PAGE>
any fee from Issuer pursuant to Section 9.3 of the Merger Agreement
(a "SECTION 9.3 EVENT"); or
(ii) Any person (the term "PERSON" for purposes of this
Agreement having the meaning assigned thereto in Sections 3(a)(9)
and 13(d)(3) of the Securities Exchange Act of 1934, as amended (the
"EXCHANGE ACT"), and the rules and regulations thereunder), other
than Grantee or any of its subsidiaries or affiliates (such person,
the "BIDDER"), shall make an offer or proposal for, or an
announcement of any intention with respect to (including, without
limitation, the filing of a statement of beneficial ownership on
Schedule 13D discussing the possibility of, or reserving the right
to engage in), an Alternative Transaction.
(d) NOTICE OF TRIGGERING EVENT. Issuer shall notify Grantee
promptly in writing of the occurrence of any Triggering Event, it being
understood that the giving of such notice by Issuer shall not be a condition to
the right of Grantee to exercise the Option or for a Triggering Event to have
occurred.
(e) NOTICE OF EXERCISE; CLOSING. In the event Grantee is
entitled to and wishes to exercise the Option, it shall send to Issuer a written
notice (the date of which being herein referred to as the "NOTICE DATE")
specifying (i) the total number of shares it will purchase pursuant to such
exercise and (ii) a place and date not earlier than three business days nor
later than 60 business days from the Notice Date for the closing of such
purchase (the "CLOSING DATE"); PROVIDED, that if the closing of the purchase
and sale pursuant to the Option (the "CLOSING") cannot be consummated, in the
reasonable opinion of Grantee, by reason of any applicable judgment, decree,
order, law or regulation, the period of time that otherwise would run pursuant
to this sentence shall run instead from the date on which such restriction on
consummation has expired or been terminated; and PROVIDED FURTHER, without
limiting the foregoing, that if, in the reasonable opinion of Grantee, prior
notification to or approval of any regulatory agency is required in connection
with such purchase, Grantee shall promptly file the required notice or
application for approval and shall
3
<PAGE>
expeditiously process the same and the period of time that otherwise would run
pursuant to this sentence shall run instead from the date on which any required
notification periods have expired or been terminated or such approvals have been
obtained and any requisite waiting period or periods shall have passed. Any
exercise of the Option shall be deemed to occur on the Notice Date relating
thereto. Notwithstanding this subsection (e), in no event shall any Closing
Date be more than 18 months after the related Notice Date, and if the Closing
Date shall not have occurred within 18 months after the related Notice Date due
to the failure to obtain any such required approval, the exercise of the Option
effected on the Notice Date shall be deemed to have expired. In the event (x)
Grantee receives official notice that an approval of any regulatory authority
required for the purchase of Option Shares (as hereinafter defined) would not be
issued or granted, (y) a Closing Date shall not have occurred within 18 months
after the related Notice Date due to the failure to obtain any such required
approval or (z) Grantee shall have the right pursuant to the last sentence of
Section 8 (or Section 10) to exercise the Option (or Substitute Option), Grantee
shall nevertheless be entitled to exercise its right as set forth in Section 8
and Grantee shall be entitled to exercise the Option (or Substitute Option) in
connection with the resale of Issuer Common Stock or other securities pursuant
to a registration statement as provided in Section 6.
(f) PURCHASE PRICE. At the Closing referred to in subsection (e)
of this Section 2, Grantee shall pay to Issuer the aggregate purchase price for
the shares of Common Stock purchased pursuant to the exercise of the Option in
immediately available funds by wire transfer to a bank account designated by
Issuer, PROVIDED that failure or refusal of Issuer to designate such a bank
account shall not preclude Grantee from exercising the Option.
(g) ISSUANCE OF COMMON STOCK. At such Closing, simultaneously
with the delivery of immediately available funds as provided in subsection (f)
of this Section 2, Issuer shall deliver to Grantee a certificate or certificates
representing the number of shares of Common Stock purchased by the Grantee and,
if the Option should be exercised in part only, a new Option evidencing the
rights of Grantee thereof to purchase the balance of
4
<PAGE>
the shares purchasable hereunder, and the Grantee shall deliver to Issuer a copy
of this Agreement and a letter agreeing that Grantee will not offer to sell or
otherwise dispose of such shares in violation of applicable law or the
provisions of this Agreement. If at the time of issuance of any Option Shares
pursuant to an exercise of all or part of the Option hereunder, Issuer shall not
have redeemed the Parent Rights, or shall have issued any similar securities,
then each Option Share issued pursuant to such exercise shall also represent
rights or new rights with terms substantially the same as and at least as
favorable to Grantee as are provided under Issuer's shareholder rights agreement
or any similar agreement then in effect.
(h) LEGEND. Certificates for Common Stock delivered at a closing
hereunder may be endorsed with a restrictive legend that shall read
substantially as follows:
"The transfer and voting of the shares represented by this
certificate is subject to certain provisions of an agreement between
the registered holder hereof and Issuer and to resale restrictions
arising under the Securities Act of 1933, as amended. A copy of
such agreement is on file at the principal office of Issuer and will
be provided to the holder hereof without charge upon receipt by
Issuer of a written request therefor."
It is understood and agreed that: (i) the reference to the resale restrictions
of the Securities Act of 1933, as amended (the "SECURITIES ACT"), in the above
legend shall be removed by delivery of substitute certificate(s) without such
reference if Grantee shall have delivered to Issuer a copy of a letter from the
staff of the SEC, or an opinion of counsel, in form and substance reasonably
satisfactory to Issuer, to the effect that such legend is not required for
purposes of the Securities Act; (ii) the reference to the provisions of this
Agreement in the above legend shall be removed by delivery of substitute
certificate(s) without such reference if the shares have been sold or
transferred in compliance with the provisions of this Agreement and under
circumstances that do not require the retention of such reference; and (iii) the
legend shall be removed in its entirety if the condi-
5
<PAGE>
tions in the preceding clauses (i) and (ii) are both satisfied. In addition,
such certificates shall bear any other legend as may be required by law.
(i) RECORD GRANTEE; EXPENSES. Upon the giving by Grantee to
Issuer of the written notice of exercise of the Option provided for under
subsection (e) of this Section 2 and the tender of the applicable purchase price
in immediately available funds, Grantee shall be deemed to be the holder of
record of the shares of Common Stock issuable upon such exercise,
notwithstanding that the stock transfer books of Issuer shall then be closed or
that certificates representing such shares of Common Stock shall not then be
actually delivered to Grantee or the Issuer shall have failed or refused to
designate the bank account described in subsection (f) of this Section 2.
Issuer shall pay all expenses, and any and all United States federal, state and
local taxes and other charges that may be payable in connection with the
preparation, issuance and delivery of stock certificates under this Section 2 in
the name of Grantee or its assignee, transferee or designee.
3. RESERVATION OF SHARES. Issuer agrees: (i) that it shall at
all times maintain, free from preemptive rights, sufficient authorized but
unissued or treasury shares of Common Stock (and other securities issuable
pursuant to Section 5(a)) so that the Option may be exercised without additional
authorization of Common Stock (or such other securities) after giving effect to
all other options, warrants, convertible securities and other rights to purchase
Common Stock (or such other securities); (ii) that it will not, by charter
amendment or through reorganization, consolidation, merger, dissolution or sale
of assets, or by any other voluntary act, avoid or seek to avoid the observance
or performance of any of the covenants, stipulations or conditions to be
observed or performed hereunder by Issuer; (iii) promptly to take all action as
may from time to time be required (including without limitation complying with
all premerger notification, reporting and waiting periods in 15 U.S.C.
Section 18a the rules and regulations thereunder) in order to permit Grantee
to exercise the Option and the Issuer duly and effectively to issue shares of
Common Stock pursuant hereto; and (iv) promptly to take all action provided
herein to protect the rights of Grantee against dilution.
6
<PAGE>
4. DIVISION OF OPTION; LOST OPTIONS. This Agreement (and the
Option granted hereby) are exchangeable, without expense, at the option of
Grantee, upon presentation and surrender of this Agreement at the principal
office of Issuer, for other Agreements providing for Options of different
denominations entitling the holder thereof to purchase, on the same terms and
subject to the same conditions as are set forth herein, in the aggregate the
same number of shares of Common Stock purchasable hereunder. The terms
"Agreement" and "Option" as used herein include any Stock Option Agreements and
related Options for which this Agreement (and the Option granted hereby) may be
exchanged. Upon receipt by Issuer of evidence reasonably satisfactory to it of
the loss, theft, destruction or mutilation of this Agreement, and (in the case
of loss, theft or destruction) of reasonably satisfactory indemnification, and
upon surrender and cancellation of this Agreement, if mutilated, Issuer will
execute and deliver a new Agreement of like tenor and date. Any such new
Agreement executed and delivered shall constitute an additional contractual
obligation on the part of Issuer, whether or not the Agreement so lost, stolen,
destroyed or mutilated shall at any time be enforceable by anyone.
5. ADJUSTMENT UPON CHANGES IN CAPITALIZATION. The number of
shares of Common Stock purchasable upon the exercise of the Option shall be
subject to adjustment from time to time as provided in this Section 5.
(a) In the event that any additional shares of Common Stock, or any
rights, options, warrants, subscriptions, calls, convertible securities or other
agreements or commitments obligating Issuer to issue any shares of Common Stock,
are issued or otherwise become outstanding after the date hereof (an
"Increase"), the number of shares of Common Stock subject to the Option shall be
increased by a number of shares equal to the product of (A) a fraction, the
numerator of which is the number of shares of Common Stock for which the Option
was exercisable immediately prior to the Increase and the denominator of which
is the number of shares of Common Stock specified in Section 1 hereof and (B)
the product of (i) 11.68193% and (ii) the number of shares of Common Stock on a
fully diluted basis immediately after the Increase minus the number of shares of
Common Stock on a fully diluted basis immediately prior to the Increase;
provided
7
<PAGE>
that the number of shares of Common Stock subject to the Option shall in no
event exceed 19.9% of the issued and outstanding shares of Common Stock
immediately prior to exercise.
(b) In the event of any change in Common Stock by reason of stock
dividends, splits, mergers, recapitalization, combinations, subdivisions,
conversions, exchanges of shares or other similar transactions and no adjustment
is required pursuant to the terms of Section 5(a), then, the type and number of
shares of Common Stock purchasable upon exercise hereof shall be appropriately
adjusted so that Grantee shall receive upon exercise of the Option and payment
of the aggregate Option Price hereunder the number and class of shares or other
securities or property that Grantee would have received in respect of Common
Stock if the Option had been exercised in full immediately prior to such event,
or the record date therefor, as applicable.
(c) Whenever the number of shares of Common Stock on a fully
diluted basis changes after the date hereof, the Option Price shall be adjusted
by multiplying the Option Price by a fraction, the numerator of which shall be
equal to the aggregate number of shares of Common Stock purchasable prior to the
adjustment and the denominator of which shall be equal to the aggregate number
of shares of Common Stock purchasable immediately after the adjustment.
6. REGISTRATION RIGHTS. Upon the occurrence of a Triggering
Event that occurs prior to an Exercise Termination Event (or as otherwise
provided in the last sentence of Section 2(e)), Issuer shall, at the request of
Grantee delivered at any time on or prior to the Option Expiration Date (whether
on its own behalf or on behalf of any subsequent holder of this Option (or part
thereof) or any of the shares of Common Stock issued pursuant hereto), promptly
prepare, file and keep current a shelf registration statement under the
Securities Act covering any shares issued and issuable pursuant to this Option
and shall use its best efforts to cause such registration statement to become
effective and remain current in order to permit the sale or other disposition of
any shares of Common Stock issued upon total or partial exercise of this Option
("OPTION SHARES") in accordance with any plan of disposition requested by
Grantee.
8
<PAGE>
Issuer will use its best efforts to cause such registration statement first to
become effective and then to remain effective for such period not in excess of
360 days from the day such registration statement first becomes effective or
such shorter time as may be reasonably necessary to effect such sales or other
dispositions. Grantee for a period of 18 months following such first request
shall have the right to demand a second such registration if reasonably
necessary to effect such sales or dispositions. The foregoing notwithstanding,
if, at the time of any request by Grantee for registration of Option Shares as
provided above, Issuer is in registration with respect to an underwritten public
offering of shares of Common Stock, and if in the good faith judgment of the
managing underwriter or managing underwriters, or, if none, the sole underwriter
or underwriters, of such offering the inclusion of the Grantee's Option or
Option Shares would interfere with the successful marketing of the shares of
Common Stock offered by Issuer, the number of Option Shares otherwise to be
covered in the registration statement contemplated hereby may be reduced; and
PROVIDED, HOWEVER, that after any such required reduction the number of
Option Shares to be included in such offering for the account of Grantee shall
constitute at least 25% of the total number of shares to be sold by Grantee and
Issuer in the aggregate; and PROVIDED FURTHER, HOWEVER, that if such
reduction occurs, then the Issuer shall file a registration statement for the
balance as promptly as practicable and no reduction shall thereafter occur (and
such registration shall not be charged against Grantee). Grantee shall provide
all information reasonably requested by Issuer for inclusion in any registration
statement to be filed hereunder. If requested by any Grantee in connection with
such registration, Issuer shall become a party to any underwriting agreement
relating to the sale of such shares, but only to the extent of obligating itself
in respect of representations, warranties, indemnities and other agreements
customarily included in such underwriting agreements for the Issuer. Upon
receiving any request under this Section 6 from Grantee, Issuer agrees to send a
copy thereof to any other person known to Issuer to be entitled to registration
rights under this Section 6, in each case by promptly mailing the same, postage
prepaid, to the address of record of the persons entitled to receive such
copies.
9
<PAGE>
7. REPURCHASE OF OPTION AND OPTION SHARES. (a) Within ten
business days following the occurrence of a Repurchase Event (as defined below),
Issuer shall (i) deliver an offer (a "REPURCHASE OFFER") to repurchase the
Option from Grantee at a price (the "OPTION REPURCHASE PRICE") equal to the
amount by which (A) the Alternative Transaction Price (as defined below) exceeds
(B) the Option Price, multiplied by the number of shares for which the Option
may then be exercised, and (ii) deliver an offer (also, a "REPURCHASE OFFER")
to repurchase the Option Shares from each owner of Option Shares from time to
time (each, an "OWNER") at a price (the "OPTION SHARE REPURCHASE PRICE")
equal to the Alternative Transaction Price multiplied by the number of Option
Shares then held by such Owner. The term "ALTERNATIVE TRANSACTION PRICE"
shall mean, as of any date for the determination thereof, the price per share of
Common Stock paid pursuant to the Alternative Transaction or, in the event of a
sale of assets of Issuer, the last per-share sale price of Common Stock on the
fourth trading day following the announcement of such sale. If the
consideration paid or received in the Alternative Transaction shall be other
than in cash, the value of such consideration shall be determined by a
nationally recognized investment banking firm selected by Grantee, which
determination shall be conclusive for all purposes of this Agreement.
(b) Upon the occurrence of a Repurchase Event and whether or not
Issuer shall have made a Repurchase Offer under Section 7(a), (i) at the request
(the date of such request being the "OPTION REPURCHASE REQUEST DATE") of
Grantee delivered prior to the Option Expiration Date, Issuer shall
repurchase the Option from Grantee at the Option Repurchase Price and (ii) at
the request (the date of such request being the "OPTION SHARE REPURCHASE
REQUEST DATE") of any Owner delivered prior to the Option Expiration Date,
Issuer shall repurchase such number of the Option Shares from the Owner as the
Owner shall designate at the Option Share Repurchase Price.
(c) Grantee and/or the Owner, as the case may be, may accept
Issuer's Repurchase Offer under Section 7(a) or may exercise its right to
require Issuer to repurchase the Option and/or any Option Shares pursuant to
Section 7(b) by a written notice or notices stating that Grantee or the Owner,
as the case may be, elects to accept such offer or to require Issuer to
repurchase the
10
<PAGE>
Option and/or the Option Shares in accordance with the provisions of this
Section 7. As promptly as practicable, and in any event within five business
days, after the surrender to it of this Agreement and/or Certificates for Option
Shares, as applicable, following receipt of a notice under this Section 7(c) and
the occurrence of a Repurchase Event, Issuer shall deliver or cause to be
delivered to Grantee the Option Repurchase Price and/or to the Owner the Option
Share Repurchase Price and/or the portion thereof that Issuer is not then
prohibited from so delivering under applicable Law.
(d) Issuer hereby undertakes to use its best efforts to obtain all
required regulatory and legal approvals and to file any required notices as
promptly as practicable in order to accomplish any repurchase contemplated by
this Section 7. Nonetheless, to the extent that Issuer is prohibited under
applicable Law, from repurchasing the Option and/or any Option Shares in full,
Issuer shall immediately so notify Grantee and/or the Owner and thereafter
deliver or cause to be delivered, from time to time, to Grantee and/or the
Owner, as appropriate, the portion of the Option Repurchase Price and the Option
Share Repurchase Price, respectively, that it is no longer prohibited from
delivering, within five business days after the date on which Issuer is no
longer so prohibited; provided, however, that if Issuer at any time after
delivery of a notice of repurchase pursuant to Section 7(b) is prohibited under
applicable Law, from delivering to Grantee and/or the Owner, as appropriate, the
Option Repurchase Price or the Option Share Repurchase Price, respectively, in
full, Grantee or the Owner, as appropriate, may revoke its notice of repurchase
of the Option or the Option Shares either in whole or in part whereupon, in the
case of a revocation in part, Issuer shall promptly (i) deliver to Grantee
and/or the Owner, as appropriate, that portion of the Option Repurchase Price or
the Option Share Repurchase Price that Issuer is not prohibited from delivering
after taking into account any such revocation and (ii) deliver, as appropriate,
either (a) to Grantee, a new Agreement evidencing the right of Grantee to
purchase that number of shares of Common Stock equal to the number of shares of
Common Stock purchasable immediately prior to the delivery of the notice of
repurchase less the number of shares of Common Stock covered by the portion of
the Option repurchased or (b) to the Owner, a certificate for
11
<PAGE>
the number of Option Shares covered by the revocation. If an Exercise
Termination Event shall have occurred prior to the date of the notice by Issuer
described in the first sentence of this subsection (c), or shall be scheduled to
occur at any time before the expiration of a period ending on the thirtieth day
after such date, Grantee shall nonetheless have the right to exercise the Option
until the expiration of such 30-day period.
(e) The term "REPURCHASE EVENT" shall mean a Triggering Event
followed by the consummation of any transaction included in the definition of
Alternative Transaction.
(f) Notwithstanding anything to the contrary in Sections 2(a) and
2(e), the delivery of a notice by Grantee under Section 7(b) specifying that
such notice relating to an anticipated Repurchase Event under Section 7(d) is
based on the Issuer's public announcement of the execution of an agreement
providing for an Alternative Transaction shall be deemed to constitute an
election to exercise the Option, as to the number of Option Shares not
heretofore purchased pursuant to one or more prior exercises of the Option, on
the fifth business day following the public announcement of the consummation of
the transaction contemplated by such agreement, in which event a closing shall
occur with respect to such unpurchased Option Shares in accordance with Section
2(e) on such fifth business day (or such later date as determined pursuant to
the proviso in the first sentence of Section 2(e)).
8. SUBSTITUTE OPTION IN THE EVENT OF CORPORATE CHANGE. (a) In
the event that prior to an Exercise Termination Event, Issuer shall enter into
an agreement (i)to consolidate with or merge into any person, other than Grantee
or one of its subsidiaries, and shall not be the continuing or surviving
corporation of such consolidation or merger, (ii) to permit any person, other
than Grantee or one of its subsidiaries, to merge into Issuer and Issuer shall
be the continuing or surviving corporation, but, in connection with such merger,
the then outstanding shares of Common Stock shall be changed into or exchanged
for stock or other securities of any other person or cash or any other property
or the then outstanding shares of Common Stock shall after such merger represent
less than 50% of the outstanding shares and
12
<PAGE>
share equivalents of the merged company, or (iii) to sell or otherwise transfer
all or substantially all of its assets to any person, other than Grantee or one
of its subsidiaries, then, and in each such case, the agreement governing such
transaction shall make proper provision so that the Option shall, upon the
consummation of any such transaction and upon the terms and conditions set forth
herein, be converted into, or exchanged for, an option (the "SUBSTITUTE
Option"), at the election of Grantee, of either (x) the Acquiring Corporation
(as hereinafter defined) or (y) any person that controls the Acquiring
Corporation.
(b) The following terms have the meanings indicated:
(1) "ACQUIRING CORPORATION" shall mean (i) the continuing
or surviving corporation of a consolidation or merger with Issuer
(if other than Issuer), (ii) Issuer in a merger in which Issuer is
the continuing or surviving person, and (iii) the transferee of all
or substantially all of Issuer's assets.
(2) "SUBSTITUTE COMMON STOCK" shall mean the common stock
issued by the issuer of the Substitute Option upon exercise of the
Substitute Option.
(3) "ASSIGNED VALUE" shall mean the Alternative Transaction
Price, as defined in Section 7.
(4) "AVERAGE PRICE" shall mean the average closing price of
a share of the Substitute Common Stock for the one year immediately
preceding the consolidation, merger or sale in question, but in no
event higher than the closing price of the shares of Substitute
Common Stock on the day preceding such consolidation, merger or
sale; PROVIDED that if Issuer is the issuer of the Substitute
Option, the Average Price shall be computed with respect to a share
of common stock issued by the person merging into Issuer or by any
company which controls or is controlled by such person, as Grantee
may elect.
13
<PAGE>
(c) The Substitute Option shall have the same terms as the Option,
PROVIDED, that if the terms of the Substitute Option cannot, for legal
reasons, be the same as the Option, such terms shall be as similar as possible
and in no event less advantageous to Grantee. The issuer of the Substitute
Option shall also enter into an agreement with Grantee in substantially the same
form as this Agreement, which agreement shall be applicable to the Substitute
Option.
(d) The Substitute Option shall be exercisable for such number of
shares of Substitute Common Stock as is equal to the Assigned Value multiplied
by the number of shares of Common Stock for which the Option is then
exercisable, divided by the Average Price. The exercise price of the Substitute
Option per share of Substitute Common Stock shall then be equal to the Option
Price multiplied by a fraction, the numerator of which shall be the number of
shares of Common Stock for which the Option is then exercisable and the
denominator of which shall be the number of shares of Substitute Common Stock
for which the Substitute Option is exercisable.
(e) In no event, pursuant to any of the foregoing paragraphs, shall
the Substitute Option be exercisable for more than 19.9% of the shares of
Substitute Common Stock outstanding prior to exercise of the Substitute Option.
In the event that the Substitute Option would be exercisable for more than 19.9%
of the shares of Substitute Common Stock outstanding prior to exercise but for
this clause (e), the issuer of the Substitute Option (the "SUBSTITUTE OPTION
Issuer") shall make a cash payment to Grantee equal to the excess of (i) the
value of the Substitute Option without giving effect to the limitation in this
clause (e) over (ii) the value of the Substitute Option after giving effect to
the limitation in this clause (e). This difference in value shall be determined
by a nationally recognized investment banking firm selected by Grantee.
(f) Issuer shall not enter into any transaction described in
subsection (a) of this Section 8 unless the Acquiring Corporation and any person
that controls the Acquiring Corporation assume in writing all the obligations of
Issuer hereunder.
14
<PAGE>
9. EXTENSION OF TIME FOR REGULATORY APPROVALS. The 18-month
period for exercise of certain rights under Sections 2, 6 and 11 shall be
extended: (i) to the extent necessary to obtain all regulatory approvals for
the exercise of such rights, and for the expiration of all statutory waiting
periods; and (ii) to the extent necessary to avoid liability under Section 10(b)
of the Exchange Act by reason of such exercise.
10. REPRESENTATIONS AND WARRANTIES OF THE ISSUER. Issuer hereby
represents and warrants to Grantee as follows:
(a) Issuer has full corporate power and authority to execute and
deliver this Agreement and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by the
Board of Directors of Issuer and no other corporate proceedings on the part of
Issuer are necessary to authorize this Agreement or to consummate the
transactions so contemplated. This Agreement has been duly and validly executed
and delivered by Issuer. This Agreement is the valid and legally binding
obligation of Issuer, enforceable against Issuer in accordance with its terms.
(b) Issuer has taken all necessary corporate action to authorize
and reserve and to permit it to issue, and at all times from the date hereof
through the termination of this Agreement in accordance with its terms will have
reserved for issuance upon the exercise of the Option, that number of shares of
Common Stock equal to the maximum number of shares of Common Stock at any time
and from time to time issuable hereunder, and all such shares, upon issuance
pursuant hereto, will be duly authorized, validly issued, fully paid,
nonassessable, and will be delivered free and clear of all claims, liens,
encumbrance and security interests and not subject to any preemptive rights.
(c) The execution and delivery of this Agreement does not, and the
consummation of the transactions contemplated hereby will not, conflict with, or
result in any violation pursuant to any provisions of the Articles of
Incorporation or by-laws of Issuer or any Issuer subsidiary, subject to
obtaining any approvals or con-
15
<PAGE>
sents contemplated hereby, result in any violation of any loan or credit
agreement, note, mortgage, indenture, lease, plan or other agreement,
obligation, instrument, permit, concession, franchise, license, judgment, order,
decree, statute, law, ordinance, rule or regulation applicable to Issuer or any
Issuer subsidiary or their respective properties or assets which violation would
have, individually or in the aggregate, a Parent Material Adverse Effect.
(d) The provisions of Sections 78.411-78.444 of the General
Corporation Law of Nevada will not, prior to the termination of this Agreement
(assuming that prior to the date hereof neither the Grantee nor any of its
affiliates or associates (as such terms are defined in the Exchange Act) (i)
beneficially owns, directly or indirectly, or (ii) are parties to any agreement,
arrangement or understanding for the purpose of acquiring, holding, voting or
disposing of, in each case, shares of capital stock of the Issuer, which in the
aggregate, represent 10% or more of the outstanding shares of capital stock of
the Issuer entitled to vote generally in the electing of directors (other than
shares held in a fiduciary capacity)), apply to this Agreement or the
transactions contemplated hereby and thereby. The Issuer has taken, and will in
the future take, all steps necessary to irrevocably exempt the transactions
contemplated by this Agreement from any other applicable state takeover law and
from any applicable charter or contractual provision containing change of
control or anti-takeover provisions.
11. ASSIGNMENT OF OPTION BY GRANTEE. Neither of the parties
hereto may assign any of its rights or obligations under this Option Agreement
or the Option created hereunder to any other person, without the express written
consent of the other party.
12. LIMITATION OF GRANTEE PROFIT. (a) Notwithstanding any other
provision of this Agreement, in no event shall the Grantee's Total Profit (as
hereinafter defined) exceed $55,000,000 and, if it otherwise would exceed such
amount, the Grantee, at its sole election, shall either (i) reduce the number of
shares of Common Stock subject to this Option, (ii) deliver to the Issuer for
cancellation Option Shares previously purchased by Grantee, (iii) pay cash to
the Issuer, or (iv) any combi-
16
<PAGE>
nation thereof, so that Grantee's actually realized Total Profit shall not
exceed $55,000,000 after taking into account the foregoing actions.
(b) As used herein, the term "TOTAL PROFIT" shall mean the amount
(before taxes) of the following: (a) the aggregate amount of (i) (x) the net
cash amounts received by Grantee pursuant to the sale of Option Shares (or any
other securities into which such Option Shares are converted or exchanged) to
any unaffiliated party within 12 months from the exercise of this Option with
respect to such Option Shares, less (y) the Grantee's purchase price of such
Option Shares, (ii) any amounts received by Grantee on the transfer of the
Option (or any portion thereof) to any unaffiliated party, if permitted
hereunder, (iii) any equivalent amount with respect to the Substitute Option,
and (iv) the amount received by Grantee pursuant to Section 9.3 of the Merger
Agreement; MINUS (b) the amount of cash paid to the Issuer pursuant to this
Section 12 plus the value of the Option Shares delivered to the Issuer for
cancellation.
(c) Notwithstanding any other provision of this Agreement, nothing
in this Agreement shall affect the ability of Grantee to receive nor relieve
Issuer's obligation to pay a fee pursuant to Section 9.3 of the Merger
Agreement; PROVIDED that if Total Profit received by Grantee would exceed
$55,000,000 following the receipt of such fee, Grantee shall be obligated to
comply with the terms of Section 12(a) within 30 days of the later of (i) the
date of receipt of such fee and (ii) the date of receipt of the net cash by
Grantee pursuant to the sale of Option Shares (or any other securities into
which such Option Shares are converted or exchanged) to any unaffiliated party
within 12 months of the exercise of this Option with respect to such Option
Shares.
13. FIRST REFUSAL. At any time after the first occurrence of a
Triggering Event and prior to the later of (a) the expiration of 18 months
immediately following the first purchase of shares of Issuer Common Stock
pursuant to the Option and (b) the Option Termination Date, if Grantee shall
desire to sell, assign, transfer or otherwise dispose of all or any of the
Option or the shares of Issuer Common Stock or other securities acquired by it
pursuant to the Option, it shall give Issuer written notice of the proposed
transaction (an
17
<PAGE>
"OFFEROR'S NOTICE"), identifying the proposed transferee, accompanied by a
copy of a binding offer to purchase the Option or such shares or other
securities signed by such transferee and setting forth the terms of the proposed
transaction. An Offeror's Notice shall be deemed an offer by Grantee to Issuer,
which may be accepted within 20 business days of the receipt of such Offeror's
Notice, on the same terms and conditions and at the same price at which Grantee
is proposing to transfer the Option or such shares or other securities to such
transferee. The purchase of the Option or any such shares or other securities
by Issuer shall be settled within 10 business days of the date of the acceptance
of the offer and the purchase price shall be paid to Grantee in immediately
available funds; provided that, if prior notification to or approval of any
regulatory authority is required in connection with such purchase, Issuer shall
promptly file the required notice or application for approval and shall
expeditiously process the same (and Grantee shall cooperate with Issuer in the
filing of any such notice or application and the obtaining of any such approval)
and the period of time that otherwise would run pursuant to this sentence shall
run instead from the date on which, as the case may be, (a) required
notification period has expired or been terminated or (b) such approval has been
obtained and, in either event, any requisite waiting period shall have passed.
In the event of the failure or refusal of Issuer to purchase all of the Option
or all of the shares or other securities covered by an Offeror's Notice or if
any regulatory authority disapproves Issuer's proposed purchase of any portion
of the Option or such shares or other securities, Grantee may, within 60 days
from the date of the Offeror's Notice (subject to any necessary extension for
regulatory notification, approval or waiting periods), sell all, but not less
than all, of such portion of the Option or such shares or other securities to
the proposed transferee at no less than the price specified and on terms no more
favorable than those set forth in the Offeror's Notice. The requirements of
this Section 11 shall not apply to (w) any disposition as a result of which the
proposed transferee would own beneficially not more than 2% of the outstanding
voting power of Issuer, (x) any disposition of Issuer Common Stock or other
securities by a person to whom grantee has assigned its rights under the Option
with the consent of Issuer, (y) any sale by means of a public offering
registered under the Securities Act in which
18
<PAGE>
steps are taken to reasonably assure that no purchaser will acquire securities
representing more than 2% of the outstanding voting power of Issuer or (z) any
transfer to a wholly owned subsidiary of Grantee which agrees in writing to be
bound by the terms hereof.
14. VOTING. For a period of 18 months from the date of exercise
of the Option, so long as Grantee beneficially owns any Option Shares, Grantee
agrees to (a) be present, in person or represented by proxy, at all stockholder
meetings of Issuer, so that all Option Shares beneficially owned by holder may
be counted for the purpose of determining the presence of a quorum at such
meetings, and (b) vote or cause to be voted all Option Shares beneficially owned
by it, with respect to all matters submitted to shareholders for a vote, in the
same proportion as shares of Common Stock are voted by shareholders unaffiliated
with Grantee.
15. APPLICATION FOR REGULATORY APPROVAL. Each of Grantee and
Issuer will use its best efforts to make all filings with, and to obtain
consents of, all third parties and governmental authorities necessary to the
consummation of the transactions contemplated by this Agreement, including
without limitation making application to list the shares of Common Stock
issuable hereunder on the New York Stock Exchange upon official notice of
issuance.
16. SPECIFIC PERFORMANCE. The parties hereto acknowledge that
damages would be an inadequate remedy for a breach of this Agreement by either
party hereto and that the obligations of the parties hereto shall be enforceable
by either party hereto through injunctive or other equitable relief.
17. SEPARABILITY OF PROVISIONS. If any term, provision, covenant
or restriction contained in this Agreement is held by a court or a federal or
state regulatory agency of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions and covenants and
restrictions contained in this Agreement shall remain in full force and effect,
and shall in no way be affected, impaired or invalidated.
18. NOTICES. All notices, claims, demands and other
communications hereunder shall be deemed to have
19
<PAGE>
been duly given or made when delivered in person, by registered or certified
mail (postage prepaid, return receipt requested), by overnight courier or by
facsimile at the respective addresses of the parties set forth in the Merger
Agreement.
19. GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, regardless of
the laws that might otherwise govern under applicable principles of conflicts of
laws thereof.
20. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which will be deemed to be an original, but all of which
shall constitute one and the same agreement.
21. EXPENSES. Except as otherwise expressly provided herein or
in the Merger Agreement, each of the parties hereto shall bear and pay all costs
and expenses incurred by it or on its behalf in connection with the transactions
contemplated hereunder, including fees and expenses of its own financial
consultants, investment bankers, accountants and counsel.
22. ENTIRE AGREEMENT. Except as otherwise expressly provided
herein or in the Merger Agreement, this Agreement contains the entire agreement
between the parties with respect to the transactions contemplated hereunder and
supersedes all prior arrangements or understandings with respect thereof,
written or oral. The terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective
successors and permitted assigns. Nothing in this Agreement, expressed or
implied, is intended to confer upon any party, other than the parties hereto,
and their respective successors except as assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein. Any provision of this Agreement may be waived only
in writing at any time by the party that is entitled to the benefits of such
provision. This Agreement may not be modified, amended, altered or supplemented
except upon the execution and delivery of a written agreement executed by the
parties hereto.
20
<PAGE>
23. FURTHER ASSURANCES. In the event of any exercise of the
Option by Grantee, Issuer and Grantee shall execute and deliver all other
documents and instruments and take all other action that may be reasonably
necessary in order to consummate the transactions provided for by such exercise.
Nothing contained in this Agreement shall be deemed to authorize Issuer or
Grantee to breach any provision of the Merger Agreement.
21
<PAGE>
IN WITNESS WHEREOF, OrNda Healthcorp and Tenet Healthcare
Corporation have caused this Agreement to be signed by their respective officers
thereunto duly authorized, all as of the date first written above.
ORNDA HEALTHCORP
By: /s/ Ronald P. Soltman
---------------------------------------
Name: Ronald P. Soltman
--------------------------------------
Title: Senior Vice President
-------------------------------------
Attest: /s/ James H. Spalding
Name: James H. Spalding
-----------------------------
Title: Vice President
----------------------------
TENET HEALTHCARE CORPORATION
By: /s/ Jeffrey C. Barbakow
---------------------------------------
Name: Jeffrey C. Barbakow
--------------------------------------
Title: Chairman and Chief Executive Officer
-------------------------------------
Attest: /s/ Patricia Campana
Name: Patricia Campana
-----------------------------
Title: Senior Executive Assistant
----------------------------
<PAGE>
EXHIBIT 10.2
STOCK OPTION AGREEMENT
THIS STOCK OPTION AGREEMENT (this "AGREEMENT"), dated October 17,
1996, between OrNda Healthcorp, a Delaware corporation ("ISSUER"), and Tenet
Healthcare Corporation, a Nevada corporation ("GRANTEE"),
W I T N E S S E T H:
WHEREAS, Grantee and Issuer, among others, have entered into an
Agreement and Plan of Merger, dated as of October 16, 1996 (the "MERGER
AGREEMENT"), which agreement has been executed by the parties hereto prior to
this Agreement (capitalized terms used herein without definition shall have the
respective meanings specified in the Merger Agreement); and
WHEREAS, as a condition to Grantee's entering into the Merger
Agreement and in consideration therefor, Issuer has agreed to grant Grantee the
Option (as hereinafter defined);
NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth herein and in the Merger Agreement, the
parties hereto agree as follows:
1. GRANT OF OPTION. Issuer hereby grants to Grantee an
unconditional, irrevocable option (the "OPTION") to purchase, subject to the
terms hereof, 11,608,358 shares of fully paid and nonassessable common stock
of the Issuer, par value $.01 per share ("COMMON STOCK"), equal to 19.9% of
the number of shares of Common Stock issued and outstanding as of the date
hereof at a purchase price of $29.869 per share of Common Stock, as adjusted in
accordance with the provisions of Section 5 of this Agreement (such price, as
adjusted if applicable, the "OPTION PRICE").
2. (a) EXERCISE OF OPTION. Grantee may exercise the Option, in
whole or part, and from time to time, if, but only if, a Triggering Event (as
hereinafter defined) shall have occurred prior to the occurrence of an Option
Termination Event (as hereinafter defined),
<PAGE>
provided that Grantee shall have sent the written notice of such exercise (as
provided in subsection (e) of this Section 2 on or prior to the last date of the
18-month period following such Triggering Event (the "Option Expiration Date").
(b) OPTION TERMINATION EVENTS. The term "OPTION TERMINATION
EVENT" shall mean either of the following events: (i) immediately prior to the
Effective Time of the Merger; or (ii) termination of the Merger Agreement (A)
by either party pursuant to Section 9.1(c) of the Merger Agreement, whether or
not such termination occurs prior to the occurrence of a Triggering Event,
provided that the matter giving rise to the order, decree, ruling or other
action providing the basis for termination under Section 9.1(c) shall not have
been initiated by Issuer or any Bidder, (B) by Grantee pursuant to Section
9.1(d)(i) of the Merger Agreement because of a material adverse change in the
business, financial condition, results of operations, properties, assets or
liabilities of Issuer and its subsidiaries taken as a whole (other than any
change relating to the United States economy in general or to the United
States investor-owned hospital business in general) that is caused by the
matters described in Schedule 5.8(a) to the Company Disclosure Letter if such
termination occurs prior to the occurrence of a Triggering Event described in
clause (i) of Section 2(c) hereof or (iii) by either party pursuant to any
other provision of the Merger Agreement if such termination occurs prior to
the occurrence of a Triggering Event.
(c) TRIGGERING EVENTS. The term "TRIGGERING EVENT" shall mean
either of the following events occurring after the date hereof:
(i) Any event shall have occurred that would entitle either
party to terminate the Merger Agreement and permit Grantee to
receive any fee from Issuer pursuant to Section 9.3 of the Merger
Agreement (a "SECTION 9.3 EVENT"); or
(ii) Any person (the term "PERSON" for purposes of this
Agreement having the meaning assigned thereto in Sections 3(a)(9)
and 13(d)(3) of the Securities Exchange Act of
2
<PAGE>
1934, as amended (the "EXCHANGE ACT"), and the rules and
regulations thereunder), other than Grantee or any of its
subsidiaries or affiliates (such person, the "BIDDER"), shall make
an offer or proposal for, or an announcement of any intention with
respect to (including, without limitation, the filing of a statement
of beneficial ownership on Schedule 13D discussing the possibility
of, or reserving the right to engage in), an Alternative
Transaction.
(d) NOTICE OF TRIGGERING EVENT. Issuer shall notify Grantee
promptly in writing of the occurrence of any Triggering Event, it being
understood that the giving of such notice by Issuer shall not be a condition to
the right of Grantee to exercise the Option or for a Triggering Event to have
occurred.
(e) NOTICE OF EXERCISE; CLOSING. In the event Grantee is
entitled to and wishes to exercise the Option, it shall send to Issuer a written
notice (the date of which being herein referred to as the "NOTICE DATE")
specifying (i) the total number of shares it will purchase pursuant to such
exercise and (ii) a place and date not earlier than three business days nor
later than 60 business days from the Notice Date for the closing of such
purchase (the "CLOSING DATE"); PROVIDED, that if the closing of the purchase
and sale pursuant to the Option (the "CLOSING") cannot be consummated, in the
reasonable opinion of Grantee, by reason of any applicable judgment, decree,
order, law or regulation, the period of time that otherwise would run pursuant
to this sentence shall run instead from the date on which such restriction on
consummation has expired or been terminated; and PROVIDED FURTHER, without
limiting the foregoing, that if, in the reasonable opinion of Grantee, prior
notification to or approval of any regulatory agency is required in connection
with such purchase, Grantee shall promptly file the required notice or
application for approval and shall expeditiously process the same and the period
of time that otherwise would run pursuant to this sentence shall run instead
from the date on which any required notification periods have expired or been
terminated or such approvals have been obtained and any requisite waiting period
or periods shall have passed. Any exercise of the Option shall be deemed to
occur on the Notice Date relating thereto. Notwithstanding this subsection (e),
in no
3
<PAGE>
event shall any Closing Date be more than 18 months after the related Notice
Date, and if the Closing Date shall not have occurred within 18 months after the
related Notice Date due to the failure to obtain any such required approval, the
exercise of the Option effected on the Notice Date shall be deemed to have
expired. In the event (x) Grantee receives official notice that an approval of
any regulatory authority required for the purchase of Option Shares (as
hereinafter defined) would not be issued or granted, (y) a Closing Date shall
not have occurred within 18 months after the related Notice Date due to the
failure to obtain any such required approval or (z) Grantee shall have the right
pursuant to the last sentence of Section 8 (or Section 10) to exercise the
Option (or Substitute Option), Grantee shall nevertheless be entitled to
exercise its right as set forth in Section 8 and Grantee shall be entitled to
exercise the Option (or Substitute Option) in connection with the resale of
Issuer Common Stock or other securities pursuant to a registration statement as
provided in Section 6.
(f) PURCHASE PRICE. At the Closing referred to in subsection (e)
of this Section 2, Grantee shall pay to Issuer the aggregate purchase price for
the shares of Common Stock purchased pursuant to the exercise of the Option in
immediately available funds by wire transfer to a bank account designated by
Issuer, PROVIDED that failure or refusal of Issuer to designate such a bank
account shall not preclude Grantee from exercising the Option.
(g) ISSUANCE OF COMMON STOCK. At such Closing, simultaneously
with the delivery of immediately available funds as provided in subsection (f)
of this Section 2, Issuer shall deliver to Grantee a certificate or certificates
representing the number of shares of Common Stock purchased by the Grantee and,
if the Option should be exercised in part only, a new Option evidencing the
rights of Grantee thereof to purchase the balance of the shares purchasable
hereunder, and the Grantee shall deliver to Issuer a copy of this Agreement and
a letter agreeing that Grantee will not offer to sell or otherwise dispose of
such shares in violation of applicable law or the provisions of this Agreement.
If at the time of issuance of any Option Shares pursuant to an exercise of all
or part of the Option hereunder, Issuer shall not have redeemed the Parent
Rights, or shall have issued any
4
<PAGE>
similar securities, then each Option Share issued pursuant to such exercise
shall also represent rights or new rights with terms substantially the same as
and at least as favorable to Grantee as are provided under Issuer's shareholder
rights agreement or any similar agreement then in effect.
(h) LEGEND. Certificates for Common Stock delivered at a closing
hereunder may be endorsed with a restrictive legend that shall read
substantially as follows:
"The transfer and voting of the shares represented by this
certificate is subject to certain provisions of an agreement between
the registered holder hereof and Issuer and to resale restrictions
arising under the Securities Act of 1933, as amended. A copy of
such agreement is on file at the principal office of Issuer and will
be provided to the holder hereof without charge upon receipt by
Issuer of a written request therefor."
It is understood and agreed that: (i) the reference to the resale restrictions
of the Securities Act of 1933, as amended (the "SECURITIES ACT"), in the above
legend shall be removed by delivery of substitute certificate(s) without such
reference if Grantee shall have delivered to Issuer a copy of a letter from the
staff of the SEC, or an opinion of counsel, in form and substance reasonably
satisfactory to Issuer, to the effect that such legend is not required for
purposes of the Securities Act; (ii) the reference to the provisions of this
Agreement in the above legend shall be removed by delivery of substitute
certificate(s) without such reference if the shares have been sold or
transferred in compliance with the provisions of this Agreement and under
circumstances that do not require the retention of such reference; and (iii) the
legend shall be removed in its entirety if the conditions in the preceding
clauses (i) and (ii) are both satisfied. In addition, such certificates shall
bear any other legend as may be required by law.
(i) RECORD GRANTEE; EXPENSES. Upon the giving by Grantee to
Issuer of the written notice of exercise of the Option provided for under
subsection (e) of this Section 2 and the tender of the applicable purchase price
5
<PAGE>
in immediately available funds, Grantee shall be deemed to be the holder of
record of the shares of Common Stock issuable upon such exercise,
notwithstanding that the stock transfer books of Issuer shall then be closed or
that certificates representing such shares of Common Stock shall not then be
actually delivered to Grantee or the Issuer shall have failed or refused to
designate the bank account described in subsection (f) of this Section 2.
Issuer shall pay all expenses, and any and all United States federal, state and
local taxes and other charges that may be payable in connection with the
preparation, issuance and delivery of stock certificates under this Section 2 in
the name of Grantee or its assignee, transferee or designee.
3. RESERVATION OF SHARES. Issuer agrees: (i) that it shall at
all times maintain, free from preemptive rights, sufficient authorized but
unissued or treasury shares of Common Stock (and other securities issuable
pursuant to Section 5(a)) so that the Option may be exercised without additional
authorization of Common Stock (or such other securities) after giving effect to
all other options, warrants, convertible securities and other rights to purchase
Common Stock (or such other securities); (ii) that it will not, by charter
amendment or through reorganization, consolidation, merger, dissolution or sale
of assets, or by any other voluntary act, avoid or seek to avoid the observance
or performance of any of the covenants, stipulations or conditions to be
observed or performed hereunder by Issuer; (iii) promptly to take all action as
may from time to time be required (including without limitation complying with
all premerger notification, reporting and waiting periods in 15 U.S.C.
Section 18a and the rules and regulations thereunder) in order to permit
Grantee to exercise the Option and the Issuer duly and effectively to issue
shares of Common Stock pursuant hereto; and (iv) promptly to take all action
provided herein to protect the rights of Grantee against dilution.
4. DIVISION OF OPTION; LOST OPTIONS. This Agreement (and the
Option granted hereby) are exchangeable, without expense, at the option of
Grantee, upon presentation and surrender of this Agreement at the principal
office of Issuer, for other Agreements providing for Options of different
denominations entitling the holder thereof to purchase, on the same terms and
subject
6
<PAGE>
to the same conditions as are set forth herein, in the aggregate the same number
of shares of Common Stock purchasable hereunder. The terms "Agreement" and
"Option" as used herein include any Stock Option Agreements and related Options
for which this Agreement (and the Option granted hereby) may be exchanged. Upon
receipt by Issuer of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of this Agreement, and (in the case of loss, theft or
destruction) of reasonably satisfactory indemnification, and upon surrender and
cancellation of this Agreement, if mutilated, Issuer will execute and deliver a
new Agreement of like tenor and date. Any such new Agreement executed and
delivered shall constitute an additional contractual obligation on the part of
Issuer, whether or not the Agreement so lost, stolen, destroyed or mutilated
shall at any time be enforceable by anyone.
5. ADJUSTMENT UPON CHANGES IN CAPITALIZATION. The number of
shares of Common Stock purchasable upon the exercise of the Option shall be
subject to adjustment from time to time as provided in this Section 5.
(a) In the event that any additional shares of Common Stock, or any
rights, options, warrants, subscriptions, calls, convertible securities or other
agreements or commitments obligating Issuer to issue any shares of Common Stock,
are issued or otherwise become outstanding after the date hereof (an
"INCREASE"), the number of shares of Common Stock subject to the Option shall
be increased so that the number of shares issuable upon exercise of the Option
shall be equal to the product of (A) the percentage of the outstanding Common
Stock for which the Option was exercisable immediately prior to the Increase and
(B) the number of shares of Common Stock outstanding immediately after the
Increase; provided that the number of shares of Common Stock subject to the
Option shall in no event exceed 19.9% of the issued and outstanding shares of
Common Stock immediately prior to exercise.
(b) In the event of any change in Common Stock by reason of stock
dividends, splits, mergers, recapitalization, combinations, subdivisions,
conversions, exchanges of shares or other similar transactions, and no
adjustment is required pursuant to the terms of Section 5(a), then the type and
number of shares of Common Stock
7
<PAGE>
purchasable upon exercise hereof shall be appropriately adjusted so that Grantee
shall receive upon exercise of the Option and payment of the aggregate Option
Price hereunder the number and class of shares or other securities or property
that Grantee would have received in respect of Common Stock if the Option had
been exercised in full immediately prior to such event, or the record date
therefor, as applicable.
(c) Whenever the number of shares of Common Stock on a fully
diluted basis changes after the date hereof, the Option Price shall be adjusted
by multiplying the Option Price by a fraction, the numerator of which shall be
equal to the aggregate number of shares of Common Stock purchasable prior to the
adjustment and the denominator of which shall be equal to the aggregate number
of shares of Common Stock purchasable immediately after the adjustment.
6. REGISTRATION RIGHTS. Upon the occurrence of a Triggering
Event that occurs prior to an Exercise Termination Event (or as otherwise
provided in the last sentence of Section 2(e)), Issuer shall, at the request of
Grantee delivered at any time on or prior to the Option Expiration Date (whether
on its own behalf or on behalf of any subsequent holder of this Option (or part
thereof) or any of the shares of Common Stock issued pursuant hereto), promptly
prepare, file and keep current a shelf registration statement under the
Securities Act covering any shares issued and issuable pursuant to this Option
and shall use its best efforts to cause such registration statement to become
effective and remain current in order to permit the sale or other disposition of
any shares of Common Stock issued upon total or partial exercise of this Option
("OPTION SHARES") in accordance with any plan of disposition requested by
Grantee. Issuer will use its best efforts to cause such registration statement
first to become effective and then to remain effective for such period not in
excess of 360 days from the day such registration statement first becomes
effective or such shorter time as may be reasonably necessary to effect such
sales or other dispositions. Grantee for a period of 18 months following such
first request shall have the right to demand a second such registration if
reasonably necessary to effect such sales or dispositions. The foregoing
notwithstanding, if, at the time of any request by Grantee for registr-
8
<PAGE>
ation of Option Shares as provided above, Issuer is in registration with respect
to an underwritten public offering of shares of Common Stock, and if in the good
faith judgment of the managing underwriter or managing underwriters, or, if
none, the sole underwriter or underwriters, of such offering the inclusion of
the Grantee's Option or Option Shares would interfere with the successful
marketing of the shares of Common Stock offered by Issuer, the number of Option
Shares otherwise to be covered in the registration statement contemplated hereby
may be reduced; and PROVIDED, HOWEVER, that after any such required reduction
the number of Option Shares to be included in such offering for the account of
Grantee shall constitute at least 25% of the total number of shares to be sold
by Grantee and Issuer in the aggregate; and PROVIDED FURTHER, HOWEVER,
that if such reduction occurs, then the Issuer shall file a registration
statement for the balance as promptly as practicable and no reduction shall
thereafter occur (and such registration shall not be charged against Grantee).
Grantee shall provide all information reasonably requested by Issuer for
inclusion in any registration statement to be filed hereunder. If requested by
any Grantee in connection with such registration, Issuer shall become a party to
any underwriting agreement relating to the sale of such shares, but only to the
extent of obligating itself in respect of representations, warranties,
indemnities and other agreements customarily included in such underwriting
agreements for the Issuer. Upon receiving any request under this Section 6 from
Grantee, Issuer agrees to send a copy thereof to any other person known to
Issuer to be entitled to registration rights under this Section 6, in each case
by promptly mailing the same, postage prepaid, to the address of record of the
persons entitled to receive such copies.
7. REPURCHASE OF OPTION AND OPTION SHARES. (a) Within ten
business days following the occurrence of a Repurchase Event (as defined below),
Issuer shall (i) deliver an offer (a "REPURCHASE OFFER") to repurchase the
Option from Grantee at a price (the "OPTION REPURCHASE PRICE") equal to the
amount by which (A) the Alternative Transaction Price (as defined below)
exceeds (B) the Option Price, multiplied by the number of shares for which the
Option may then be exercised, and (ii) deliver an offer (also, a "REPURCHASE
OFFER") to repurchase the Option Shares from each owner of Option Shares from
time
9
<PAGE>
to time (each, an "OWNER") at a price (the "OPTION SHARE REPURCHASE PRICE")
equal to the Alternative Transaction Price multiplied by the number of Option
Shares then held by such Owner. The term "ALTERNATIVE TRANSACTION PRICE"
shall mean, as of any date for the determination thereof, the price per share of
Common Stock paid pursuant to the Alternative Transaction or, in the event of a
sale of assets of Issuer, the last per-share sale price of Common Stock on the
fourth trading day following the announcement of such sale. If the
consideration paid or received in the Alternative Transaction shall be other
than in cash, the value of such consideration shall be determined by a
nationally recognized investment banking firm selected by Grantee, which
determination shall be conclusive for all purposes of this Agreement.
(b) Upon the occurrence of a Repurchase Event and whether or not
Issuer shall have made a Repurchase Offer under Section 7(a), (i) at the request
(the date of such request being the "OPTION REPURCHASE REQUEST DATE") of
Grantee delivered prior to an the Option Expiration Date, Issuer shall
repurchase the Option from Grantee at the Option Repurchase Price and (ii) at
the request (the date of such request being the "OPTION SHARE REPURCHASE
REQUEST DATE") of any Owner delivered prior to the Option Expiration Date,
Issuer shall repurchase such number of the Option Shares from the Owner as the
Owner shall designate at the Option Share Repurchase Price.
(c) Grantee and/or the Owner, as the case may be, may accept
Issuer's Repurchase Offer under Section 7(a) or may exercise its right to
require Issuer to repurchase the Option and/or any Option Shares pursuant to
Section 7(b) by a written notice or notices stating that Grantee or the Owner,
as the case may be, elects to accept such offer or to require Issuer to
repurchase the Option and/or the Option Shares in accordance with the provisions
of this Section 7. As promptly as practicable, and in any event within five
business days, after the surrender to it of this Agreement and/or Certificates
for Option Shares, as applicable, following receipt of a notice under this
Section 7(c) and the occurrence of a Repurchase Event, Issuer shall deliver or
cause to be delivered to Grantee the Option Repurchase Price and/or to the Owner
the Option Share Repurchase Price and/or the portion thereof that Issuer is not
then prohibited from so delivering under applicable Law.
10
<PAGE>
(d) Issuer hereby undertakes to use its best efforts to obtain all
required regulatory and legal approvals and to file any required notices as
promptly as practicable in order to accomplish any repurchase contemplated by
this Section 7. Nonetheless, to the extent that Issuer is prohibited under
applicable Law, from repurchasing the Option and/or any Option Shares in full,
Issuer shall immediately so notify Grantee and/or the Owner and thereafter
deliver or cause to be delivered, from time to time, to Grantee and/or the
Owner, as appropriate, the portion of the Option Repurchase Price and the Option
Share Repurchase Price, respectively, that it is no longer prohibited from
delivering, within five business days after the date on which Issuer is no
longer so prohibited; provided, however, that if Issuer at any time after
delivery of a notice of repurchase pursuant to Section 7(b) is prohibited under
applicable Law, from delivering to Grantee and/or the Owner, as appropriate, the
Option Repurchase Price or the Option Share Repurchase Price, respectively, in
full, Grantee or the Owner, as appropriate, may revoke its notice of repurchase
of the Option or the Option Shares either in whole or in part whereupon, in the
case of a revocation in part, Issuer shall promptly (i) deliver to Grantee
and/or the Owner, as appropriate, that portion of the Option Repurchase Price or
the Option Share Repurchase Price that Issuer is not prohibited from delivering
after taking into account any such revocation and (ii) deliver, as appropriate,
either (a) to Grantee, a new Agreement evidencing the right of Grantee to
purchase that number of shares of Common Stock equal to the number of shares of
Common Stock purchasable immediately prior to the delivery of the notice of
repurchase less the number of shares of Common Stock covered by the portion of
the Option repurchased or (b) to the Owner, a certificate for the number of
Option Shares covered by the revocation. If an Exercise Termination Event shall
have occurred prior to the date of the notice by Issuer described in the first
sentence of this subsection (c), or shall be scheduled to occur at any time
before the expiration of a period ending on the thirtieth day after such date,
Grantee shall nonetheless have the right to exercise the Option until the
expiration of such 30-day period.
(e) The term "REPURCHASE EVENT" shall mean a Triggering Event
followed by the consummation of any
11
<PAGE>
transaction included in the definition of Alternative Transaction.
(f) Notwithstanding anything to the contrary in Sections 2(a) and
2(e), the delivery of a notice by Grantee under Section 7(b) specifying that
such notice relating to an anticipated Repurchase Event under Section 7(d) is
based on the Issuer's public announcement of the execution of an agreement
providing for an Alternative Transaction shall be deemed to constitute an
election to exercise the Option, as to the number of Option Shares not
heretofore purchased pursuant to one or more prior exercises of the Option, on
the fifth business day following the public announcement of the consummation of
the transaction contemplated by such agreement, in which event a closing shall
occur with respect to such unpurchased Option Shares in accordance with Section
2(e) on such fifth business day (or such later date as determined pursuant to
the proviso in the first sentence of Section 2(e)).
8. SUBSTITUTE OPTION IN THE EVENT OF CORPORATE CHANGE. (a) In
the event that prior to an Exercise Termination Event, Issuer shall enter into
an agreement (i)to consolidate with or merge into any person, other than Grantee
or one of its subsidiaries, and shall not be the continuing or surviving
corporation of such consolidation or merger, (ii) to permit any person, other
than Grantee or one of its subsidiaries, to merge into Issuer and Issuer shall
be the continuing or surviving corporation, but, in connection with such merger,
the then outstanding shares of Common Stock shall be changed into or exchanged
for stock or other securities of any other person or cash or any other property
or the then outstanding shares of Common Stock shall after such merger represent
less than 50% of the outstanding shares and share equivalents of the merged
company, or (iii) to sell or otherwise transfer all or substantially all of its
assets to any person, other than Grantee or one of its subsidiaries, then, and
in each such case, the agreement governing such transaction shall make proper
provision so that the Option shall, upon the consummation of any such
transaction and upon the terms and conditions set forth herein, be converted
into, or exchanged for, an option (the "SUBSTITUTE OPTION"), at the election
of Grantee, of either (x) the Acquiring Corporation (as hereinafter
12
<PAGE>
defined) or (y) any person that controls the Acquiring Corporation.
(b) The following terms have the meanings indicated:
(1) "ACQUIRING CORPORATION" shall mean (i) the continuing
or surviving corporation of a consolidation or merger with Issuer
(if other than Issuer), (ii) Issuer in a merger in which Issuer is
the continuing or surviving person, and (iii) the transferee of all
or substantially all of Issuer's assets.
(2) "SUBSTITUTE COMMON STOCK" shall mean the common stock
issued by the issuer of the Substitute Option upon exercise of the
Substitute Option.
(3) "ASSIGNED VALUE" shall mean the Alternative Transaction
Price, as defined in Section 7.
(4) "AVERAGE PRICE" shall mean the average closing price of
a share of the Substitute Common Stock for the one year immediately
preceding the consolidation, merger or sale in question, but in no
event higher than the closing price of the shares of Substitute
Common Stock on the day preceding such consolidation, merger or
sale; PROVIDED that if Issuer is the issuer of the Substitute
Option, the Average Price shall be computed with respect to a share
of common stock issued by the person merging into Issuer or by any
company which controls or is controlled by such person, as Grantee
may elect.
(c) The Substitute Option shall have the same terms as the Option,
PROVIDED, that if the terms of the Substitute Option cannot, for legal
reasons, be the same as the Option, such terms shall be as similar as possible
and in no event less advantageous to Grantee. The issuer of the Substitute
Option shall also enter into an agreement with Grantee in substantially the same
form as this Agreement, which agreement shall be applicable to the Substitute
Option.
13
<PAGE>
(d) The Substitute Option shall be exercisable for such number of
shares of Substitute Common Stock as is equal to the Assigned Value multiplied
by the number of shares of Common Stock for which the Option is then
exercisable, divided by the Average Price. The exercise price of the Substitute
Option per share of Substitute Common Stock shall then be equal to the Option
Price multiplied by a fraction, the numerator of which shall be the number of
shares of Common Stock for which the Option is then exercisable and the
denominator of which shall be the number of shares of Substitute Common Stock
for which the Substitute Option is exercisable.
(e) In no event, pursuant to any of the foregoing paragraphs, shall
the Substitute Option be exercisable for more than 19.9% of the shares of
Substitute Common Stock outstanding prior to exercise of the Substitute Option.
In the event that the Substitute Option would be exercisable for more than 19.9%
of the shares of Substitute Common Stock outstanding prior to exercise but for
this clause (e), the issuer of the Substitute Option (the "SUBSTITUTE OPTION
ISSUER") shall make a cash payment to Grantee equal to the excess of (i) the
value of the Substitute Option without giving effect to the limitation in this
clause (e) over (ii) the value of the Substitute Option after giving effect to
the limitation in this clause (e). This difference in value shall be determined
by a nationally recognized investment banking firm selected by Grantee.
(f) Issuer shall not enter into any transaction described in
subsection (a) of this Section 8 unless the Acquiring Corporation and any person
that controls the Acquiring Corporation assume in writing all the obligations of
Issuer hereunder.
9. EXTENSION OF TIME FOR REGULATORY APPROVALS. The 18-month
period for exercise of certain rights under Sections 2, 6 and 11 shall be
extended: (i) to the extent necessary to obtain all regulatory approvals for
the exercise of such rights, and for the expiration of all statutory waiting
periods; and (ii) to the extent necessary to avoid liability under Section 10(b)
of the Exchange Act by reason of such exercise.
14
<PAGE>
10. REPRESENTATIONS AND WARRANTIES OF THE ISSUER. Issuer hereby
represents and warrants to Grantee as follows:
(a) Issuer has full corporate power and authority to execute and
deliver this Agreement and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by the
Board of Directors of Issuer and no other corporate proceedings on the part of
Issuer are necessary to authorize this Agreement or to consummate the
transactions so contemplated. This Agreement has been duly and validly executed
and delivered by Issuer. This Agreement is the valid and legally binding
obligation of Issuer, enforceable against Issuer in accordance with its terms.
(b) Issuer has taken all necessary corporate action to authorize
and reserve and to permit it to issue, and at all times from the date hereof
through the termination of this Agreement in accordance with its terms will have
reserved for issuance upon the exercise of the Option, that number of shares of
Common Stock equal to the maximum number of shares of Common Stock at any time
and from time to time issuable hereunder, and all such shares, upon issuance
pursuant hereto, will be duly authorized, validly issued, fully paid,
nonassessable, and will be delivered free and clear of all claims, liens,
encumbrance and security interests and not subject to any preemptive rights.
(c) The execution and delivery of this Agreement does not, and the
consummation of the transactions contemplated hereby will not, conflict with, or
result in any violation pursuant to any provisions of the Articles of
Incorporation or by-laws of Issuer or any Issuer subsidiary, subject to
obtaining any approvals or consents contemplated hereby, result in any violation
of any loan or credit agreement, note, mortgage, indenture, lease, plan or other
agreement, obligation, instrument, permit, concession, franchise, license,
judgment, order, decree, statute, law, ordinance, rule or regulation applicable
to Issuer or any Issuer subsidiary or their respective properties or assets
which violation would have, individually or in the aggregate, a Parent Material
Adverse Effect.
15
<PAGE>
(d) The Board of Directors of Issuer having approved this Agreement
and the consummation of the transactions contemplated thereby, the provisions of
Section 203 of the Delaware General Corporation Law do not and will not apply to
this Agreement or the purchase of shares of Common Stock pursuant to this
Agreement. The Issuer has taken, and will in the future take, all steps
necessary to irrevocably exempt the transactions contemplated by this Agreement
from any other applicable state takeover law and from any applicable charter or
contractual provision containing change of control or anti-takeover provisions.
11. ASSIGNMENT OF OPTION BY GRANTEE. Neither of the parties
hereto may assign any of its rights or obligations under this Option Agreement
or the Option created hereunder to any other person, without the express written
consent of the other party.
12. LIMITATION OF GRANTEE PROFIT. (a) Notwithstanding any other
provision of this Agreement, in no event shall the Grantee's Total Profit (as
hereinafter defined) exceed $55,000,000 and, if it otherwise would exceed such
amount, the Grantee, at its sole election, shall either (i) reduce the number of
shares of Common Stock subject to this Option, (ii) deliver to the Issuer for
cancellation Option Shares previously purchased by Grantee, (iii) pay cash to
the Issuer, or (iv) any combination thereof, so that Grantee's actually realized
Total Profit shall not exceed $55,000,000 after taking into account the
foregoing actions.
(b) As used herein, the term "TOTAL PROFIT" shall mean the amount
(before taxes) of the following: (a) the aggregate amount of (i) (x) the net
cash amounts received by Grantee pursuant to the sale of Option Shares (or any
other securities into which such Option Shares are converted or exchanged) to
any unaffiliated party within 12 months from the exercise of this Option with
respect to such Option Shares, less (y) the Grantee's purchase price of such
Option Shares, (ii) any amounts received by Grantee on the transfer of the
Option (or any portion thereof) to any unaffiliated party, if permitted
hereunder, (iii) any equivalent amount with respect to the Substitute Option,
and (iv) the amount received by Grantee pursuant to Section 9.3 of the Merger
Agreement; MINUS (b) the amount of cash paid to the Issuer pursuant
16
<PAGE>
to this Section 12 plus the value of the Option Shares delivered to the Issuer
for cancellation.
(c) Notwithstanding any other provision of this Agreement, nothing
in this Agreement shall affect the ability of Grantee to receive nor relieve
Issuer's obligation to pay a fee pursuant to Section 9.3 of the Merger
Agreement; PROVIDED that if Total Profit received by Grantee would exceed
$55,000,000 following the receipt of such fee, Grantee shall be obligated to
comply with the terms of Section 12(a) within 30 days of the later of (i) the
date of receipt of such fee and (ii) the date of receipt of the net cash by
Grantee pursuant to the sale of Option Shares (or any other securities into
which such Option Shares are converted or exchanged) to any unaffiliated party
within 12 months of the exercise of this Option with respect to such Option
Shares.
13. FIRST REFUSAL. At any time after the first occurrence of a
Triggering Event and prior to the later of (a) the expiration of 18 months
immediately following the first purchase of shares of Issuer Common Stock
pursuant to the Option and (b) the Option Termination Date, if Grantee shall
desire to sell, assign, transfer or otherwise dispose of all or any of the
Option or the shares of Issuer Common Stock or other securities acquired by it
pursuant to the Option, it shall give Issuer written notice of the proposed
transaction (an "OFFEROR'S NOTICE"), identifying the proposed transferee,
accompanied by a copy of a binding offer to purchase the Option or such shares
or other securities signed by such transferee and setting forth the terms of the
proposed transaction. An Offeror's Notice shall be deemed an offer by Grantee
to Issuer, which may be accepted within 20 business days of the receipt of such
Offeror's Notice, on the same terms and conditions and at the same price at
which Grantee is proposing to transfer the Option or such shares or other
securities to such transferee. The purchase of the Option or any such shares or
other securities by Issuer shall be settled within 10 business days of the date
of the acceptance of the offer and the purchase price shall be paid to Grantee
in immediately available funds; provided that, if prior notification to or
approval of any regulatory authority is required in connection with such
purchase, Issuer shall promptly file the required notice or application for
approval and shall expeditiously process the same (and Grantee shall cooper-
17
<PAGE>
ate with Issuer in the filing of any such notice or application and the
obtaining of any such approval) and the period of time that otherwise would run
pursuant to this sentence shall run instead from the date on which, as the case
may be, (a) required notification period has expired or been terminated or (b)
such approval has been obtained and, in either event, any requisite waiting
period shall have passed. In the event of the failure or refusal of Issuer to
purchase all of the Option or all of the shares or other securities covered by
an Offeror's Notice or if any regulatory authority disapproves Issuer's proposed
purchase of any portion of the Option or such shares or other securities,
Grantee may, within 60 days from the date of the Offeror's Notice (subject to
any necessary extension for regulatory notification, approval or waiting
periods), sell all, but not less than all, of such portion of the Option or such
shares or other securities to the proposed transferee at no less than the price
specified and on terms no more favorable than those set forth in the Offeror's
Notice. The requirements of this Section 11 shall not apply to (w) any
disposition as a result of which the proposed transferee would own beneficially
not more than 2% of the outstanding voting power of Issuer, (x) any disposition
of Issuer Common Stock or other securities by a person to whom grantee has
assigned its rights under the Option with the consent of Issuer, (y) any sale by
means of a public offering registered under the Securities Act in which steps
are taken to reasonably assure that no purchaser will acquire securities
representing more than 2% of the outstanding voting power of Issuer or (z) any
transfer to a wholly owned subsidiary of Grantee which agrees in writing to be
bound by the terms hereof.
14. VOTING. For a period of 18 months from the date of exercise
of the Option, so long as Grantee beneficially owns any Option Shares, Grantee
agrees to (a) be present, in person or represented by proxy, at all stockholder
meetings of Issuer, so that all Option Shares beneficially owned by holder may
be counted for the purpose of determining the presence of a quorum at such
meetings, and (b) vote or cause to be voted all Option Shares beneficially owned
by it, with respect to all matters submitted to shareholders for a vote, in the
same proportion as shares of Common Stock are voted by shareholders unaffiliated
with Grantee.
18
<PAGE>
15. APPLICATION FOR REGULATORY APPROVAL. Each of Grantee and
Issuer will use its best efforts to make all filings with, and to obtain
consents of, all third parties and governmental authorities necessary to the
consummation of the transactions contemplated by this Agreement, including
without limitation making application to list the shares of Common Stock
issuable hereunder on the New York Stock Exchange upon official notice of
issuance.
16. SPECIFIC PERFORMANCE. The parties hereto acknowledge that
damages would be an inadequate remedy for a breach of this Agreement by either
party hereto and that the obligations of the parties hereto shall be enforceable
by either party hereto through injunctive or other equitable relief.
17. SEPARABILITY OF PROVISIONS. If any term, provision, covenant
or restriction contained in this Agreement is held by a court or a federal or
state regulatory agency of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions and covenants and
restrictions contained in this Agreement shall remain in full force and effect,
and shall in no way be affected, impaired or invalidated.
18. NOTICES. All notices, claims, demands and other
communications hereunder shall be deemed to have been duly given or made when
delivered in person, by registered or certified mail (postage prepaid, return
receipt requested), by overnight courier or by facsimile at the respective
addresses of the parties set forth in the Merger Agreement.
19. GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, regardless of
the laws that might otherwise govern under applicable principles of conflicts of
laws thereof.
20. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which will be deemed to be an original, but all of which
shall constitute one and the same agreement.
21. EXPENSES. Except as otherwise expressly provided herein or
in the Merger Agreement, each of the
19
<PAGE>
parties hereto shall bear and pay all costs and expenses incurred by it or on
its behalf in connection with the transactions contemplated hereunder, including
fees and expenses of its own financial consultants, investment bankers,
accountants and counsel.
22. ENTIRE AGREEMENT. Except as otherwise expressly provided
herein or in the Merger Agreement, this Agreement contains the entire agreement
between the parties with respect to the transactions contemplated hereunder and
supersedes all prior arrangements or understandings with respect thereof,
written or oral. The terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective
successors and permitted assigns. Nothing in this Agreement, expressed or
implied, is intended to confer upon any party, other than the parties hereto,
and their respective successors except as assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein. Any provision of this Agreement may be waived only
in writing at any time by the party that is entitled to the benefits of such
provision. This Agreement may not be modified, amended, altered or supplemented
except upon the execution and delivery of a written agreement executed by the
parties hereto.
23. FURTHER ASSURANCES. In the event of any exercise of the
Option by Grantee, Issuer and Grantee shall execute and deliver all other
documents and instruments and take all other action that may be reasonably
necessary in order to consummate the transactions provided for by such exercise.
Nothing contained in this Agreement shall be deemed to authorize Issuer or
Grantee to breach any provision of the Merger Agreement.
20
<PAGE>
IN WITNESS WHEREOF, OrNda Healthcorp and Tenet Healthcare
Corporation have caused this Agreement to be signed by their respective officers
thereunto duly authorized, all as of the date first written above.
ORNDA HEALTHCORP
By: /s/ Ronald P. Soltman
-----------------------------
Name: Ronald P. Soltman
----------------------------
Title: Senior Vice President
---------------------------
Attest: /s/ James H. Spalding
Name: James H. Spalding
---------------------------
Title: Vice President
--------------------------
TENET HEALTHCARE CORPORATION
By: /s/ Jeffrey C. Barbakow
-----------------------------
Name: Jeffrey C. Barbakow
-----------------------------
Title: Chairman and Chief
-----------------------------
Executive Officer
-----------------------------
Attest: /s/ Patricia Campana
Name: Patricia Campana
-----------------------------
Title: Senior Executive Assistant
----------------------------
<PAGE>
EXHIBIT 99.1
STOCKHOLDER VOTING AGREEMENT
THIS STOCKHOLDER VOTING AGREEMENT (this "Agreement") is made and
entered into as of this 17th day of October, 1996, by and among Tenet Healthcare
Corporation, a Nevada corporation ("Acquiror"), and the stockholder named on the
signature page hereto ("Stockholder"). On the date hereof the Stockholder
Beneficially Owns (as defined in Section 11(a) hereof) the number of shares of
common stock, par value $.01 per share (the "Company Shares"), of OrNda
Healthcorp, a Delaware corporation ("Company"), set forth next to the
Stockholder's name on the signature page hereto.
WHEREAS, Acquiror and the Company concurrently herewith are entering
into an Agreement and Plan of Merger, dated as of the 16th day of October, 1996
(the "Merger Agreement"), providing for, among other things, the merger (the
"Merger") of a wholly owned subsidiary of Acquiror with and into the Company,
with the Company as the surviving corporation; and
WHEREAS, as an essential condition and inducement to Acquiror's
execution of the Merger Agreement, Acquiror has requested that the Stockholder
agree, and the Stockholder has agreed, to vote (or consent with regard to) all
Company Shares as to which the Stockholder has voting power in favor of the
Merger as provided herein.
NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements contained herein and in
the Merger Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto, intending
to be legally bound hereby, agree as follows:
1. VOTING RIGHTS.
VOTING AGREEMENT. The Stockholder agrees that, at any time the
Merger Agreement remains in effect, it will vote all Stockholder Shares (as
defined below) on matters as to which the Stockholder is entitled to vote
1
<PAGE>
at any annual, special or other meeting of the Stockholders of the Company, and
at any adjournment or adjournments thereof, or by written consent without a
meeting with respect to all Stockholder Shares as follows: (i) in favor of
approval and adoption of the Merger Agreement, the terms thereof and each of the
other transactions contemplated by the Merger Agreement; and (ii) against any
action or agreement (other than the Merger Agreement or the transactions
contemplated thereby) that would impede, interfere with, delay, postpone or
attempt to discourage the Merger, including without limitation: (A) any
extraordinary corporate transaction, such as a merger, consolidation or other
business combination involving the Company and its subsidiaries; or (B) a sale
or transfer of a material amount of assets of the Company and its subsidiaries
or a reorganization, recapitalization or liquidation of the Company and its
subsidiaries.
"Stockholder Shares" shall mean the shares of Company capital stock
(including without limitation the Company Shares) Beneficially Owned by such
Stockholder as of the date hereof, or Beneficially Owned by such Stockholder at
any time hereafter (including, without limitation, by way of exercise of options
or by way of dividend, distribution, exchange, merger, consolidation,
recapitalization, reorganization, stock split, grant of proxy or otherwise) by
such Stockholder (as adjusted as set forth herein). The Stockholder hereby
agrees to promptly notify Acquiror of the number of any new Stockholder Shares
acquired by the Stockholder, if any, after the date hereof. In the event of any
change in the Company Shares by reason of a stock dividend, stock split, split
up, recapitalization, combination, exchange of shares or similar transaction,
the type and number of shares or securities that constitute Stockholder Shares
hereunder shall be adjusted appropriately.
2. TERMINATION.
a. This Agreement shall terminate upon the earlier to occur of
(i) the termination of the Merger Agreement in accordance with its terms
pursuant to Section 9.1 thereof, or (ii) the Effective Time (as defined in the
Merger Agreement).
b. Upon termination, this Agreement shall have no further force
or effect, except for Section 7
2
<PAGE>
which shall continue to apply to any case, action or proceeding relating to the
enforcement of this Agreement.
3. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER. The
Stockholder hereby represents and warrants to Acquiror as follows:
a. DUE AUTHORIZATION. The Stockholder has the legal capacity
and all necessary power and authority to execute and deliver this Agreement and
to consummate the transactions contemplated hereby. As of the date hereof, the
Stockholder Beneficially Owns the number of the Stockholder Shares listed on the
signature page hereof and specified as so owned with no restrictions on the
voting rights (except as specified in this Agreement) or rights of disposition
pertaining thereto, which constitute all Company Shares Beneficially Owned by
such Stockholder. Assuming this Agreement has been duly and validly authorized,
executed and delivered by Acquiror, this Agreement constitutes a valid and
binding agreement of the Stockholder, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency, moratorium or
other similar laws affecting creditors' rights generally or by the principles
governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by the Stockholder of the transactions
contemplated hereby will conflict with or constitute a violation of or default
under any contract, commitment, agreement, arrangement or restriction of any
kind to which the Stockholder is a party or by which the Stockholder is bound.
4. REPRESENTATIONS AND WARRANTIES OF ACQUIROR. Acquiror hereby
represents and warrants to the Stockholder as follows:
a. DUE AUTHORIZATION. Acquiror has the requisite corporate
power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly
authorized by all necessary corporate action on the part of Acquiror and this
Agreement has been duly executed by a duly authorized officer of Acquiror.
Assuming this Agreement has been duly and
3
<PAGE>
validly executed and delivered by the Stockholder, this Agreement constitutes a
valid and binding agreement of Acquiror, enforceable against it in accordance
with its terms, except as enforceability may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting creditors' rights
generally or by the principles governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by Acquiror of the transactions contemplated
hereby will conflict with or constitute a violation of or default under any
contract, commitment, agreement, arrangement or restriction of any kind to which
Acquiror is a party or by which Acquiror is bound.
5. NO TRANSFER. Except as provided in this Agreement or the
Merger Agreement, the Stockholder hereby agrees, without the prior written
consent of Acquiror, except pursuant to the terms hereof, not to (i) sell,
transfer, assign, pledge or otherwise dispose of or hypothecate any of his
Stockholder Shares other than to a "Permitted Transferee" (as defined below) and
except that the Stockholder may transfer Stockholder Shares to Company in order
to pay the exercise price or withholding taxes applicable in connection with the
exercise of employee stock options ; (ii) grant any proxies, deposit any
Stockholder Shares into a voting trust or enter into a voting agreement with
respect to any Stockholder Shares; (iii) take any action that would make any
representation or warranty of the Stockholder contained herein untrue or
incorrect or have the effect of preventing or disabling the Stockholder from
performing his obligations under this Agreement; or (iv) take any action which
would jeopardize the treatment of Acquiror's acquisition of Company as a pooling
of interests for accounting purposes. For purposes of this Agreement,
"Permitted Transferee" shall mean an organization that qualifies for treatment
under section 501(c)(3) of the Internal Revenue Code of 1986, as amended. Any
Permitted Transferee of Stockholder Shares must become a party to this Agreement
and any purported transfer of Stockholder Shares to a person or entity that has
not become a party hereto shall be null and void. In furtherance of this
Agreement, concurrently herewith the Stockholder shall and hereby does authorize
the Company's counsel to notify the Company's transfer agent that there is a
stop transfer order with
4
<PAGE>
respect to all of the Stockholder Shares (and that this Agreement places limits
on the voting and transfer of such shares).
6. ENTIRE AGREEMENT. Other than the Merger Agreement
(including the exhibits, schedules and other documents and instruments referred
to therein), this Agreement (including the documents and instruments referred to
herein) (a) constitutes the entire agreement among the parties hereto with
respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties, or any of them,
with respect to the subject matter hereof; (b) shall not be assigned by
operation of law or otherwise without the prior written consent of the other
parties hereto, except that Acquiror may assign, in its sole discretion, all or
any of its rights, interests and obligations hereunder to any direct or indirect
wholly owned subsidiary of Acquiror; (c) shall not be amended, altered or
modified in any manner whatsoever, except by a written instrument executed by
the parties hereto; and (d) shall be governed in all respects, including
validity, interpretation and effect, by the laws of the State of Delaware
(without giving effect to the provisions thereof relating to conflicts of law).
7. REMEDIES. The parties acknowledge that it would be
impossible to fix money damages for violations of this Agreement and that such
violations will cause irreparable injury for which adequate remedy at law is not
available and, therefore, this Agreement must be enforced by specific
performance or injunctive relief. The parties hereto agree that any party may,
in its sole discretion, apply to any court of competent jurisdiction for
specific performance or injunctive or such other relief as such court may deem
just and proper in order to enforce this Agreement or prevent any violation
hereof and, to the extent permitted by applicable law, each party waives any
objection or defense to the imposition of such relief. Nothing herein shall be
construed to prohibit any party from bringing any action for damages in addition
to an action for specific performance or an injunction for a breach of this
Agreement.
8. LEGENDS ON CERTIFICATES. Until such time as this Agreement
shall terminate pursuant to Section 2
5
<PAGE>
hereof, all certificates representing Stockholder Shares shall bear the
following legend:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
OF A STOCKHOLDER VOTING AGREEMENT, DATED AS OF OCTOBER 17, 1996, BY AND
BETWEEN TENET HEALTHCARE CORPORATION AND THE STOCKHOLDER. ANY TRANSFEREE
OF THESE SHARES TAKES SUBJECT TO THE TERMS OF SUCH AGREEMENT, COPIES OF
WHICH ARE ON FILE AT THE OFFICES OF TENET HEALTHCARE CORPORATION.
9. PARTIES IN INTEREST. Subject to the provisions of Sections
5 and 6(b) hereof, this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors,
permitted assigns, heirs, executors, administrators and other legal
representatives, and nothing in this Agreement, express or implied, is intended
to confer upon any other person any rights or remedies of any nature whatsoever
under or by reason of this Agreement.
10. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same agreement.
11. DEFINITIONS. The following terms shall have the following
respective meanings:
a. "Beneficial Owner" has the meaning set forth in Rule 13d-3 of
the Rules and Regulations to the Exchange Act, and "Beneficially Owned" and
"Beneficially Owns" shall have correlative meanings; PROVIDED, HOWEVER, that
for purposes of this Agreement a person shall be deemed to be the Beneficial
Owner of Company Shares that may be acquired pursuant to the exercise of an
option or other right regardless of when such option is exercisable.
b. A "person" means a corporation, association, partnership,
joint venture, organization, business, individual, trust, estate or any other
entity or group (within the meaning of Section 13(d)(3) of the Exchange Act).
6
<PAGE>
12. NOTICES. All notices and other communications hereunder
shall be in writing and shall be deemed given if delivered personally,
telecopied (which is confirmed) or mailed by registered or certified mail
(return receipt requested) to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):
(a) If to Acquiror to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue, Suite 3400
Los Angeles, California 90071
Telecopy No. (213) 687-5600
Attention: Brian J. McCarthy
(b) If to the Stockholder, to the address set forth on the
signature page, hereto.
13. INTERPRETATION. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
14. SEVERABILITY. Any term or provision of this Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction. If any provision of
this Agreement is so broad as to be unenforceable, the provision shall be
interpreted to be only so broad as is enforceable.
15. FURTHER ASSURANCES. The Stockholder further agrees to
execute all additional writings, con-
7
<PAGE>
sents and authorizations as may be reasonably requested by Acquiror to evidence
the agreements herein.
8
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
TENET HEALTHCARE CORPORATION
By /s/ Jeffrey C. Barbakow
------------------------------------
Name: Jeffrey C. Barbakow
Title: Chairman and Chief Executive Officer
CHARLES N. MARTIN, Jr.
By /s/ Charles N. Martin, Jr.
------------------------------------
Name: Charles N. Martin, Jr.
Title: President and Chief Executive Officer
No. of Shares Beneficially Owned:
Common shares owned: 985,000
Options vested: 1,590,000
Options unvested: 560,000
Address for Notices:
3401 West End Avenue
Nashville, Tennessee 37203
<PAGE>
EXHIBIT 99.2
STOCKHOLDER VOTING AGREEMENT
THIS STOCKHOLDER VOTING AGREEMENT (this "Agreement") is made and
entered into as of this 17th day of October, 1996, by and among Tenet Healthcare
Corporation, a Nevada corporation ("Acquiror"), and the stockholder named on the
signature page hereto ("Stockholder"). On the date hereof the Stockholder
Beneficially Owns (as defined in Section 11(a) hereof) the number of shares of
common stock, par value $.01 per share (the "Company Shares"), of OrNda
Healthcorp, a Delaware corporation ("Company"), set forth next to the
Stockholder's name on the signature page hereto.
WHEREAS, Acquiror and the Company concurrently herewith are entering
into an Agreement and Plan of Merger, dated as of the 16th day of October, 1996
(the "Merger Agreement"), providing for, among other things, the merger (the
"Merger") of a wholly owned subsidiary of Acquiror with and into the Company,
with the Company as the surviving corporation; and
WHEREAS, as an essential condition and inducement to Acquiror's
execution of the Merger Agreement, Acquiror has requested that the Stockholder
agree, and the Stockholder has agreed, to vote (or consent with regard to) all
Company Shares as to which the Stockholder has voting power in favor of the
Merger as provided herein.
NOW, THEREFORE, in consideration of the premises and the
representations, warranties, covenants and agreements contained herein and in
the Merger Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto, intending
to be legally bound hereby, agree as follows:
1. VOTING RIGHTS.
VOTING AGREEMENT. The Stockholder agrees that, at any time the
Merger Agreement remains in effect, it will vote all Stockholder Shares (as
defined below) on matters as to which the Stockholder is entitled to vote
1
<PAGE>
at any annual, special or other meeting of the Stockholders of the Company, and
at any adjournment or adjournments thereof, or by written consent without a
meeting with respect to all Stockholder Shares as follows: (i) in favor of
approval and adoption of the Merger Agreement, the terms thereof and each of the
other transactions contemplated by the Merger Agreement; and (ii) against any
action or agreement (other than the Merger Agreement or the transactions
contemplated thereby) that would impede, interfere with, delay, postpone or
attempt to discourage the Merger, including without limitation: (a) any
extraordinary corporate transaction, such as a merger, consolidation or other
business combination involving the Company and its subsidiaries; or (b) a sale
or transfer of a material amount of assets of the Company and its subsidiaries
or a reorganization, recapitalization or liquidation of the Company and its
subsidiaries.
"Stockholder Shares" shall mean the shares of Company capital stock
(including without limitation the Company Shares) Beneficially Owned by such
Stockholder as of the date hereof, or Beneficially Owned by such Stockholder at
any time hereafter (including, without limitation, by way of exercise of options
or by way of dividend, distribution, exchange, merger, consolidation,
recapitalization, reorganization, stock split, grant of proxy or otherwise) by
such Stockholder (as adjusted as set forth herein). The Stockholder hereby
agrees to promptly notify Acquiror of the number of any new Stockholder Shares
acquired by the Stockholder, if any, after the date hereof. In the event of any
change in the Company Shares by reason of a stock dividend, stock split, split
up, recapitalization, combination, exchange of shares or similar transaction,
the type and number of shares or securities that constitute Stockholder Shares
hereunder shall be adjusted appropriately.
2. TERMINATION.
a. This Agreement shall terminate upon the earlier to occur of
(i) the termination of the Merger Agreement in accordance with its terms
pursuant to Section 9.1 thereof, or (ii) the Effective Time (as defined in the
Merger Agreement).
b. Upon termination, this Agreement shall have no further force
or effect, except for Section 7
2
<PAGE>
which shall continue to apply to any case, action or proceeding relating to the
enforcement of this Agreement.
3. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER. The
Stockholder hereby represents and warrants to Acquiror as follows:
a. DUE AUTHORIZATION. The Stockholder has the legal capacity
and all necessary power and authority to execute and deliver this Agreement and
to consummate the transactions contemplated hereby. As of the date hereof, the
Stockholder Beneficially Owns the number of the Stockholder Shares listed on the
signature page hereof and specified as so owned with no restrictions on the
voting rights (except as specified in this Agreement) or rights of disposition
pertaining thereto, which constitute all Company Shares Beneficially Owned by
such Stockholder. Assuming this Agreement has been duly and validly authorized,
executed and delivered by Acquiror, this Agreement constitutes a valid and
binding agreement of the Stockholder, enforceable in accordance with its terms,
except as enforceability may be limited by bankruptcy, insolvency, moratorium or
other similar laws affecting creditors' rights generally or by the principles
governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by the Stockholder of the transactions
contemplated hereby will conflict with or constitute a violation of or default
under any contract, commitment, agreement, arrangement or restriction of any
kind to which the Stockholder is a party or by which the Stockholder is bound.
4. REPRESENTATIONS AND WARRANTIES OF ACQUIROR. Acquiror hereby
represents and warrants to the Stockholder as follows:
a. DUE AUTHORIZATION. Acquiror has the requisite corporate
power and authority to enter into this Agreement and to consummate the
transactions contemplated hereby. The execution and delivery of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly
authorized by all necessary corporate action on the part of Acquiror and this
Agreement has been duly executed by a duly authorized officer of Acquiror.
Assuming this Agreement has been duly and
3
<PAGE>
validly executed and delivered by the Stockholder, this Agreement constitutes a
valid and binding agreement of Acquiror, enforceable against it in accordance
with its terms, except as enforceability may be limited by bankruptcy,
insolvency, moratorium or other similar laws affecting creditors' rights
generally or by the principles governing the availability of equitable remedies.
b. NO CONFLICTS. Neither the execution and delivery of this
Agreement nor the consummation by Acquiror of the transactions contemplated
hereby will conflict with or constitute a violation of or default under any
contract, commitment, agreement, arrangement or restriction of any kind to which
Acquiror is a party or by which Acquiror is bound.
5. NO TRANSFER. Except as provided in this Agreement or the
Merger Agreement, the Stockholder hereby agrees, without the prior written
consent of Acquiror, except pursuant to the terms hereof, not to (i) sell,
transfer, assign, pledge or otherwise dispose of or hypothecate any of his
Stockholder Shares; (ii) grant any proxies, deposit any Stockholder Shares
into a voting trust or enter into a voting agreement with respect to any
Stockholder Shares; or (iii) take any action that would make any representation
or warranty of the Stockholder contained herein untrue or incorrect or have
the effect of preventing or disabling the Stockholder from performing his
obligations under this Agreement. Any permitted transferee of Stockholder
Shares must become a party to this Agreement and any purported transfer of
Stockholder Shares to a person or entity that has not become a party hereto
shall be null and void. In furtherance of this Agreement, concurrently
herewith the Stockholder shall and hereby does authorize the Company's counsel
to notify the Company's transfer agent that there is a stop transfer order
with respect to all of the Stockholder Shares (and that this Agreement places
limits on the voting and transfer of such shares).
6. ENTIRE AGREEMENT. Other than the Merger Agreement
(including the exhibits, schedules and other documents and instruments referred
to therein), this
4
<PAGE>
Agreement (including the documents and instruments referred to
herein) (a) constitutes the entire agreement among the parties hereto with
respect to the subject matter hereof and supersedes all other prior agreements
and understandings, both written and oral, among the parties, or any of them,
with respect to the subject matter hereof; (b) shall not be assigned by
operation of law or otherwise without the prior written consent of the other
parties hereto, except that Acquiror may assign, in its sole discretion, all or
any of its rights, interests and obligations hereunder to any direct or indirect
wholly owned subsidiary of Acquiror; (c) shall not be amended, altered or
modified in any manner whatsoever, except by a written instrument executed by
the parties hereto; and (d) shall be governed in all respects, including
validity, interpretation and effect, by the laws of the State of Delaware
(without giving effect to the provisions thereof relating to conflicts of law).
7. REMEDIES. The parties acknowledge that it would be
impossible to fix money damages for violations of this Agreement and that such
violations will cause irreparable injury for which adequate remedy at law is not
available and, therefore, this Agreement must be enforced by specific
performance or injunctive relief. The parties hereto agree that any party may,
in its sole discretion, apply to any court of competent jurisdiction for
specific performance or injunctive or such other relief as such court may deem
just and proper in order to enforce this Agreement or prevent any violation
hereof and, to the extent permitted by applicable law, each party waives any
objection or defense to the imposition of such relief. Nothing herein shall be
construed to prohibit any party from bringing any action for damages in addition
to an action for specific performance or an injunction for a breach of this
Agreement.
8. LEGENDS ON CERTIFICATES. Until such time as this Agreement
shall terminate pursuant to Section 2 hereof, all certificates representing
Stockholder Shares shall bear the following legend:
THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS
OF A STOCKHOLDER VOTING AGREEMENT, DATED AS OF OCTOBER 17, 1996, BY AND
BETWEEN TENET HEALTHCARE CORPORATION AND THE STOCKHOLDER. ANY TRANSFEREE
OF THESE
5
<PAGE>
SHARES TAKES SUBJECT TO THE TERMS OF SUCH AGREEMENT, COPIES OF
WHICH ARE ON FILE AT THE OFFICES OF TENET HEALTHCARE CORPORATION.
9. PARTIES IN INTEREST. Subject to the provisions of Sections
5 and 6(b) hereof, this Agreement shall be binding upon and inure to the benefit
of and be enforceable by the parties hereto and their respective successors,
permitted assigns, heirs, executors, administrators and other legal
representatives, and nothing in this Agreement, express or implied, is intended
to confer upon any other person any rights or remedies of any nature whatsoever
under or by reason of this Agreement.
10. COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed to be an original, but all of which
shall constitute one and the same agreement.
11. DEFINITIONS. The following terms shall have the following
respective meanings:
a. "Beneficial Owner" has the meaning set forth in Rule 13d-3 of
the Rules and Regulations to the Exchange Act, and "Beneficially Owned" and
"Beneficially Owns" shall have correlative meanings; PROVIDED, HOWEVER, that
for purposes of this Agreement a person shall be deemed to be the Beneficial
Owner of Company Shares that may be acquired pursuant to the exercise of an
option or other right regardless of when such option is exercisable.
b. A "person" means a corporation, association, partnership,
joint venture, organization, business, individual, trust, estate or any other
entity or group (within the meaning of Section 13(d)(3) of the Exchange Act).
12. NOTICES. All notices and other communications hereunder
shall be in writing and shall be deemed given if delivered personally,
telecopied (which is confirmed) or mailed by registered or certified mail
(return receipt requested) to the parties at the following addresses (or at such
other address for a party as shall be specified by like notice):
6
<PAGE>
(a) If to Acquiror to:
Tenet Healthcare Corporation
3820 State Street
Santa Barbara, California 93105
Attention: General Counsel
with a copy to:
Skadden, Arps, Slate, Meagher & Flom
300 South Grand Avenue, Suite 3400
Los Angeles, California 90071
Telecopy No. (213) 687-5600
Attention: Brian J. McCarthy
(b) If to the Stockholder, to the address set forth on the
signature page, hereto.
13. INTERPRETATION. The headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.
14. SEVERABILITY. Any term or provision of this Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Agreement or affecting the validity or enforceability of any of the terms or
provisions of this Agreement in any other jurisdiction. If any provision of
this Agreement is so broad as to be unenforceable, the provision shall be
interpreted to be only so broad as is enforceable.
15. FURTHER ASSURANCES. The Stockholder further agrees to
execute all additional writings, consents and authorizations as may be
reasonably requested by Acquiror to evidence the agreements herein.
7
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.
TENET HEALTHCARE CORPORATION
By /s/ Jeffrey C. Barbakow
-----------------------------------
Name: Jeffrey C. Barbakow
Title: Chairman and Chief Executive Officer
JOSEPH, LITTLEJOHN & LEVY FUND, L.P.
By: JLL Associates, L.P., as general partner
By /s/ Paul S. Levy
-----------------------------------
Name: Paul S. Levy
Title: General Partner
No. of Shares Beneficially Owned:
7,096,774
-----------------------------------
Address for Notices:
50 Main Street, Suite 1000
White Plains, New York 10606
<PAGE>
[LETTERHEAD]
TENET TO MERGE WITH ORNDA IN TRANSACTION
VALUED AT $3.1 BILLION
Combination Creates Company with $8.5 Billion in Revenues
NEW YORK, N.Y. - OCTOBER 17, 1996 - Tenet Healthcare Corporation and OrNda
HealthCorp today jointly announced the signing of a definitive merger agreement
under which Tenet will acquire OrNda. The transaction values OrNda at more than
$3.1 billion. The resulting company will have pro forma revenues of
approximately $8.5 billion and operate 126 acute care hospitals in 22 states,
principally through the Sunbelt.
Under terms of the agreement, which was approved yesterday by the boards of
both companies, OrNda shareholders will receive 1.35 shares of Tenet common
stock for each share of OrNda stock in a tax-free exchange. Based on
approximately 60 million fully diluted OrNda shares and yesterday's closing
price of $22.1/8 per Tenet share. OrNda shareholders would receive $1.8 billion
in Tenet stock.
The pooling of interests transaction will create a consolidated company
with pro forma
-more-
<PAGE>
earnings before interest, taxes, depreciation and amortization (EBITDA) of
approximately $1.5 billion. The transaction will be accretive to earnings per
share.
"Joining these dynamic companies continues the momentum begun with the
creation of Tenet," said Jeffrey C. Barbakow, Tenet chairman and chief executive
officer. "Less than two years ago, we created a new force in healthcare with
the formation of Tenet. At that time, we committed ourselves to the delivery of
quality, community-based healthcare, unquestionable business integrity and the
enhancement of shareholder value. This combination with OrNda will further
these goals.
"The strategic and geographic match are perfect," Barbakow continued.
"Thirty-two of OrNda's 50 hospitals are a solid fit with existing Tenet
networks. Also, OrNda meshes very well with us culturally. During recent
months we have come to know OrNda well and we've been impressed with their
hospitals and their corporate and operating management. Their facilities and
their pool of talent will be of great benefit to Tenet. Together, we believe we
will be particularly attractive to other hospitals and health systems seeking
partners to enhance their strategic futures."
The combination of the two companies is expected to result in approximately
$70 million in annual cost savings, interest reductions and operating synergies
following the first full fiscal year of combined operations.
Barbakow, 52, will continue as chairman and chief executive officer of the
combined company and Michael H. Focht Sr., 54, will continue as president and
chief operating officer. Charles N. Martin Jr., 53, OrNda's chairman, president
and chief executive officer, will become Tenet's vice chairman and will be a
member of the executive committee of the company's board
-more-
<PAGE>
of directors. He will also serve as a member of the company's management
committee.
Tenet's board of directors will be expanded from 11 members to 14 to
welcome Martin and two OrNda board members, Paul S. Levy and Peter A. Joseph,
partners in the merchant banking firm of Joseph, Littlejohn & Levy, an affiliate
of which is OrNda's largest shareholder.
"Five years ago, OrNda was a collection of 11 hospitals with less than $500
million in revenue," said Martin. "Today, we have 50 hospitals with pro forma
revenues of approximately $2.7 billion. Just this year we have substantially
transformed this company in terms of the size and quality of our operations.
This merger creates a large, strong competitor with tremendous momentum and no
constraints on its ability to grow."
The acquisition will enhance Tenet's competitive presence in Southern
California, South Florida, Dallas and Houston. In addition, it will give the
company entry into other attractive regions such as the Northwest, New England,
Arizona and Nevada.
In sprawling Southern California, the transaction more than doubles Tenet's
holdings from 13 hospitals to 29. Pending transactions previously announced by
OrNda would increase the count to 31.
"We will be the largest integrated provider system in Southern California
and the only one with a full geographical representation," said Barbakow. "This
will allow us to work with payors of all types - both private and governmental -
across all of Southern California for the delivery of efficient healthcare
services."
In South Florida, the transaction further enhances Tenet's strong
integrated delivery system by increasing its acute care hospitals from seven to
11 and expanding the network's geographic reach south to Miami and into Coral
Gables. Tenet's pending transaction previously
-more-
<PAGE>
announced would increase the number of hospitals to 12.
Key OrNda shareholders representing approximately 14 percent of OrNda's
shares outstanding have agreed to vote in favor of the transaction.
The companies hope to close the transaction in early March 1997. It is
subject to approval of shareholders of both companies, review under the Hart-
Scott-Rodino Antitrust Improvements Act and other customary regulatory
approvals.
Under the terms of the agreement, Tenet or OrNda is each entitled, under
certain circumstances, to receive a termination fee of $50 million from the
other in the event the merger is not completed. In addition, Tenet has granted
OrNda an option to purchase approximately 10.5 percent of its common stock and
OrNda has granted Tenet an option to purchase 19.9 percent of its common stock
under certain circumstances.
Donaldson, Lufkin & Jenrette Securities Corporation is serving as financial
advisor to Tenet. Merrill Lynch & Co. is serving as financial advisor to OrNda.
OrNda HealthCorp, based in Nashville, Tenn., is the third largest investor-
owned hospital management company in the United States. It is a leading
provider of healthcare services, delivering a broad range of inpatient and
outpatient healthcare services principally through the operation of 50 acute
care hospitals located in urban and suburban communities in 15 states.
Tenet, based in Santa Barbara, Calif., is the second-largest investor-owned
healthcare company in the U.S., generating more than $5.5 billion in annual net
operating revenues. Through its subsidiaries, Tenet owns and operates 76 acute
care hospitals and related businesses in 13 states.
###
Listed: Tenet: NYSE, PSE(THC)
OrNda: NYSE(ORN)
<PAGE>
TENET & ORNDA ACUTE CARE PROPERTIES
STATE NAME LOCATION BEDS
- ----- ---- -------- ----
Alabama Brookwood Medical Center Birmingham 586
Lloyd Noland Hospital & Health System Fairfield 319
Arizona Community Hospital Medical Center Phoenix 59
Mesa General Hospital Medical Center Mesa 125
St. Luke's Behavioral Health Center Phoenix 86
St. Luke's Medical Center Phoenix 221
Tempe St. Luke's Hospital Tempe 110
Tucson General Hospital Tucson 146
Arkansas Central Arkansas Hospital Searcy 193
Methodist Hospital of Jonesboro Jonesboro 104
National Park Medical Center Hot Springs 166
Saint Mary's Regional Med. Center Russellville 170
California Alvarado Hospital Medical Center San Diego 231
Brotman Medical Center Culver City 495
Centinela Hospital Medical Center Inglewood 400
Century City Hospital Los Angeles 190
Chapman Medical Center Orange 104
Coastal Communities Hospital Santa Ana 177
Community Hospital of Huntington Park Huntington Park 99
Community Hospital of Los Gatos Los Gatos 164
Doctors Hospital of Manteca Manteca 73
Doctors Hospital of Pinole Pinole 137
Doctors Medical Center Hospital of
Modesto Modesto 433
Encino-Tarzana Reg. Medical Center Encino 151
Encino-Tarzana Reg. Medical Center Tarzana 231
Fountain Valley Regional Hospital
& Med. Ctr. Fountain Valley 413
French Hospital Medical Center San Luis Obispo 147
Garden Grove Hospital & Med. Ctr. Garden Grove 167
Garfield Medical Center Monterey Park 211
Greater El Monte Community Hospital South El Monte 113
Harbor View Medical Center San Diego 156
Irvine Medical Center Irvine 176
John F. Kennedy Memorial Hospital Indio 130
Lakewood Regional Medical Center Lakewood 175
Los Alamitos Medical Center Los Alamitos 173
Midway Hospital Medical Center Los Angeles 225
Mission Hospital of Huntington Park Huntington Park 127
Monterey Park Hospital Monterey Park 102
North Hollywood Medical Center North Hollywood 160
Placentia Linda Hospital Placentia 114
Redding Medical Center Redding 185
San Dimas Community Hospital San Dimas 99
San Ramon Regional Medical Center San Ramon 123
Santa Ana Hospital Medical Center Santa Ana 90
Sierra Vista Regional Medical Center San Luis Obispo 195
South Bay Medical Center Redondo Beach 201
St. Luke Medical Center Pasadena 172
Suburban Medical Center Paramount 184
Twin Cities Community Hospital Templeton 84
USC University Hospital Los Angeles 286
Valley Community Hospital Santa Maria 70
Westside Hospital Los Angeles 66
Whittier Hospital Medical Center Whittier 159
Woodruff Community Hospital Long Beach 96
Page 1, October 18, 1996
<PAGE>
Florida Coral Gables Hospital Coral Gables 285
Delray Community Hospital Delray Beach 211
Florida Medical Center Fort Lauderdale 459
Florida Medical Center, South Plantation 222
Hialeah Hospital Hialeah 378
Hollywood Medical Center Hollywood 334
Memorial Hospital of Tampa Tampa 174
North Bay Medical Center New Port Richey 122
North Ridge Medical Center Ft. Lauderdale 391
Palm Beach Gardens Medical Center Palm Beach Gardens 204
Palmetto General Hospital Hialeah 360
Palms of Pasadena Hospital St. Petersburg 310
Parkway Regional Medical Center North Miami 764
Seven Rivers Community Hospital Crystal River 128
Town & Country Hospital Tampa 201
West Boca Medical Center Boca Raton 185
Georgia North Fulton Regional Hospital Roswell 167
Spalding Regional Hospital Griffin 160
Indiana Culver Union Hospital Crawfordsville 120
Winona Memorial Hospital Indianapolis 365
Iowa Davenport Medical Center Davenport 150
Louisiana Doctors Hospital of Jefferson Metairie 138
Kenner Regional Medical Center Kenner 300
Meadowcrest Hospital Gretna 200
Memorial Medical Center Mercy Campus New Orleans 272
Memorial Medical Center Baptist Campus New Orleans 487
Minden Medical Center Minden 121
NorthShore Reg. Medical Center Slidell 174
St. Charles General Hospital New Orleans 173
Massachusetts Saint Vincent Hospital Worcester 432
Mississippi Gulf Coast Medical Center Biloxi 189
Missouri Columbia Regional Hospital Columbia 265
Kirksville Osteopathic Medical Center Kirksville 119
Lucy Lee Healthcare System Poplar Bluff 201
Lutheran Medical Center St. Louis 408
Twin Rivers Regional Medical Center Kennett 116
Nebraska Saint Joseph Hospital Omaha 374
Nevada Lake Meade Hospital Medical Center North Las Vegas 198
North Central Carolina Hospital Sanford 137
Carolina Frye Regional Medical Center Hickory 355
Oregon Eastmoreland Hospital Portland 100
Woodland Park Hospital Portland 209
South East Cooper Regional Medical Center Mt. Pleasant 100
Carolina Hilton Head Medical Center and Clinics Hilton Head 68
Piedmont Healthcare System Rock Hill 268
Tennessee Harton Regional Medical Center Tullahoma 137
Medical Center of Manchester Manchester 49
Saint Francis Hospital Memphis 890
University Medical Center Lebanon 260
Page 2, October 18, 1996
<PAGE>
Texas Brownsville Medical Center Brownsville 177
Cypress Fairbanks Medical Center Houston 143
Doctors Hospital of Dallas Dallas 268
Garland Community Hospital Garland 113
Houston Northwest Medical Center Houston 494
Lake Pointe Medical Center Rowlett 92
Mid-Jefferson Hospital Nederland 138
Nacogdoches Medical Center Nacogdoches 150
Odessa Regional Hospital Odessa 100
Park Place Medical Center Port Arthur 236
Park Plaza Hospital Houston 468
Providence Memorial Hospital El Paso 471
RHD Memorial Medical Center Dallas 190
Sharpstown General Hospital Houston 190
Sierra Medical Center El Paso 365
South Park Hospital & Medical Center Lubbock 101
Southwest General Hospital San Antonio 286
Trinity Medical Center Carrollton 149
Trinity Valley Medical Center Palestine 126
Twelve Oaks Hospital Houston 336
Washington Puget Sound Hospital Tacoma 160
West Virginia Plateau Medical Center Oak Hill 91
Wyoming Lander Valley Medical Center Lander 102
